

=> fil reg

FILE 'REGISTRY' ENTERED AT 11:09:14 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l30


L25 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 34

STEREO ATTRIBUTES: NONE
L27 5778 SEA FILE=REGISTRY SSS FUL L25
L28 STR



VAR G1=60/81
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 78

STEREO ATTRIBUTES: NONE
 L30 1776 SEA FILE=REGISTRY SUB=L27 SSS FUL L28

100.0% PROCESSED 3910 ITERATIONS
 SEARCH TIME: 00.00.01

1776 ANSWERS

=> d his

(FILE 'HOME' ENTERED AT 10:13:03 ON 07 OCT 2004)
 SET COST OFF

FILE 'HCAPLUS' ENTERED AT 10:15:11 ON 07 OCT 2004

L1 2 S (US20040121984 OR US20020049172 ORE US20020173483)/PN OR (WO9
 E KUO C/AU
 L2 204 S E3,E6,E7
 E KUO CHO/AU
 L3 71 S E4-E6,E9
 E SWANSON A/AU
 L4 12 S E3,E8
 L5 11 S E27
 E HAKOMORI S/AU

L6 220 S E3,E4,E7,E8
 L7 382 S E17-E19
 E TAKAHASHI N/AU
 L8 566 S E3-E6
 E TAKAHASHI NOR/AU
 L9 306 S E18,E10
 L10 74 S L2-L9 AND CHLAMYD?/CT,CW,BI
 L11 11 S L10 AND ?SACCHARIDE?
 L12 2 S L10 AND CARBOHYDRATE?/SC,SX,CW,CT
 L13 11 S L11,L12
 L14 8 S L13 AND ?MANNO?
 L15 3 S L13 NOT L14
 L16 6 S L14 AND (N LINK? OR ?ACETYLGLUCOSAMINE? OR CHITOBIOSE OR ASPA
 L17 4 S L16 AND HIGH
 L18 2 S L14 NOT L16
 L19 1 S L18 AND HIGH
 L20 5 S L17,L19,L1 AND L1-L19
 SEL RN

FILE 'REGISTRY' ENTERED AT 10:23:29 ON 07 OCT 2004

L21 16 S E1-E16
 L22 2 S L21 NOT OC5/ES
 L23 13 S L21 AND NR>=2
 L24 1 S L21 NOT L22,L23
 L25 STR
 L26 50 S L25
 L27 5778 S L25 FUL
 SAV L27 MAIER714/A
 L28 STR L25
 L29 50 S L28 SAM SUB=L27
 L30 1776 S L28 FUL SUB=L27
 SAV L30 MAIER714A/A
 L31 STR L28
 L32 20 S L31 CSS SAM SUB=L30
 L33 STR L28
 L34 42 S L33 CSS SAM SUB=L30
 L35 719 S L33 CSS FUL SUB=L30
 SAV L35 MAIER714B/A
 L36 STR L28
 L37 0 S L36 SAM SUB=L30
 L38 12 S L21 AND L30
 L39 1764 S L30 NOT L38

FILE 'HCAOLD' ENTERED AT 10:53:52 ON 07 OCT 2004

L40 0 S L38

FILE 'HCAPLUS' ENTERED AT 10:54:01 ON 07 OCT 2004

L41 504 S L38
 L42 1009 S L39
 L43 27 S L2-L9 AND L41
 L44 42 S L2-L9 AND L42
 L45 3 S L10 AND L43,L44
 L46 44 S L43,L44 NOT L45
 L47 33 S L46 AND (N LINK? OR ?ACETYLGLUCOSAMINE? OR ?CHITOBIOSE? OR ?AS
 L48 12 S L47 AND ?MANNO?
 L49 20 S L46 AND ?MANNO?
 L50 8 S L46 AND ASN
 L51 13 S L48,L49 AND L47,L50
 L52 13 S L51 AND ?MANNO?
 L53 7 S L52 AND HIGH MANNO?
 E CHLAMYDIA/CT
 E E3+ALL
 L54 4097 S E5,E4+NT

E E3+ALL
L55 4216 S E3+NT
E E2+ALL
L56 4227 S E2+NT
L57 3 S L41 AND L54-L56
L58 0 S L42 AND L54-L56
L59 3 S L41,L42 AND CHLAMYD?
L60 3 S L57,L59,L45
L61 352 S L41 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)
L62 683 S L42 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)

FILE 'REGISTRY' ENTERED AT 11:02:17 ON 07 OCT 2004

L63 1 S CHITOBIOSE/CN
L64 3 S (D-ASPARAGINE OR L-ASPARAGINE OR DL-ASPARAGINE OR ASPARAGINE)

FILE 'HCAPLUS' ENTERED AT 11:02:59 ON 07 OCT 2004

L65 68 S L63,L64 AND L41,L42
L66 354 S (CHITOBIOSE OR ASN OR ASPARAG?) AND L41,L42
L67 270 S L61,L62 AND L65,L66
L68 62 S L67 AND HIGH MANNO?
L69 18 S L65,L66 AND L43,L44
L70 18 S L65,L66 AND L45-L53
L71 2 S L65,L66 AND L60
L72 3 S L60,L71
L73 16 S L69-L70 NOT L72
L74 3 S L61,L62 AND L54-L56
L75 3 S L61,L62 AND CHLAMYD?
L76 3 S L72,L74,L75
L77 3 S L76 AND L1-L20,L41-62,L65-L76
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 07 OCT 2004

L78 14 S E1-E14
L79 2 S L78 NOT L38,L39
L80 12 S L78 NOT L79

FILE 'REGISTRY' ENTERED AT 11:09:14 ON 07 OCT 2004

=> d ide can tot l79

L79 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 577-76-4 REGISTRY

CN D-Glucose, 2-amino-4-O-(2-amino-2-deoxy- β -D-glucopyranosyl)-2-deoxy-
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Chitobiose (7CI)

OTHER NAMES:

CN 4-O-(2-Amino-2-deoxy- β -D-glucosyl)-D-glucosamine

FS STEREOSEARCH

DR 23327-39-1, 140849-41-8, 68232-34-8, 196503-39-6

MF C12 H24 N2 O9

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,
CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CSCHEM, MEDLINE, TOXCENTER,
USPATFULL

(*File contains numerically searchable property data)

DT.CA CAplus document type: Conference; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP

(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

210 REFERENCES IN FILE CA (1907 TO DATE)
 29 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 210 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 141:220857
 REFERENCE 2: 141:70359
 REFERENCE 3: 141:49529
 REFERENCE 4: 141:48369
 REFERENCE 5: 140:422448
 REFERENCE 6: 140:387761
 REFERENCE 7: 140:352510
 REFERENCE 8: 140:316890
 REFERENCE 9: 140:122384
 REFERENCE 10: 140:116605

L79 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 70-47-3 REGISTRY

CN L-Asparagine (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Asparagine, L- (8CI)

OTHER NAMES:

CN (-)-Asparagine


CN (S)-2,4-Diamino-4-oxobutanoic acid

CN (S)-Asparagine

CN α -Aminosuccinamic acid

CN Agedoite
 CN Altheine
 CN Asn
 CN Asparagine
 CN Asparagine acid
 CN Asparamide
 CN Aspartamic acid
 CN Aspartic acid β -amide
 CN Aspartic acid amide
 CN Butanoic acid, 2,4-diamino-4-oxo-, (S)-
 CN Crystal VI
 CN L- β -Asparagine
 CN L-2,4-Diamino-4-oxobutanoic acid
 CN l-Asparagine
 CN L-Aspartamine
 CN NSC 82391
 FS STEREOSEARCH
 DR 7006-34-0, 328-41-6, 32640-57-6
 MF C4 H8 N2 O3
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS,
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DETHERM*,
 DRUGU, EMBASE, GMELIN*, HODOC*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,
 MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, SPECINFO, TOXCENTER,
 USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent;
 Report
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC
 (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);
 PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role
 in record)
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical
 study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);
 PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES
 (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); CMBI (Combinatorial study); FORM (Formation, nonpreparative);
 MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC
 (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses);
 NORL (No role in record)
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
 study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
 (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14465 REFERENCES IN FILE CA (1907 TO DATE)

415 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

14497 REFERENCES IN FILE CAPLUS (1907 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


REFERENCE 1: 141:253204
REFERENCE 2: 141:247824
REFERENCE 3: 141:242593
REFERENCE 4: 141:242580
REFERENCE 5: 141:242571
REFERENCE 6: 141:242357
REFERENCE 7: 141:242251
REFERENCE 8: 141:239958
REFERENCE 9: 141:239112
REFERENCE 10: 141:238785

=> d ide can tot 180


L80 ANSWER 1 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 114154-07-3 REGISTRY
CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[2-
(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-
mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-
(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C64 H107 N5 O46
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PROC (Process); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:335216

REFERENCE 2: 133:204479

REFERENCE 3: 132:194576

REFERENCE 4: 128:188617

REFERENCE 5: 127:356647

REFERENCE 6: 119:176958

REFERENCE 7: 118:76442

REFERENCE 8: 114:223974

REFERENCE 9: 114:139267

REFERENCE 10: 114:120086

L80 ANSWER 2 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 114154-06-2 REGISTRY

CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
 O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O-
 β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 4)]- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-[O-
 α -D-mannopyranosyl-(1 \rightarrow 3)- α -D-mannopyranosyl-
 (1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-
 deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

FS STEREOSEARCH

DR 168330-64-1

MF C70 H117 N5 O51

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


DT.CA CAPLUS document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
 (Preparation); USES (Uses)


RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); OCCU (Occurrence); PROC (Process); PRP (Properties)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE	1:	136:335216
REFERENCE	2:	133:204479
REFERENCE	3:	133:1846
REFERENCE	4:	132:194576
REFERENCE	5:	128:188617
REFERENCE	6:	123:280123
REFERENCE	7:	119:176958
REFERENCE	8:	118:76442

REFERENCE 9: 114:139267

REFERENCE 10: 110:208671

L80 ANSWER 3 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 93445-86-4 REGISTRY

CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

DR 121930-54-9, 420839-30-1

MF C76 H127 N5 O56

CI COM

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAPLUS document type: Conference; Journal; Patent


RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process); PRP (Properties)



RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); OCCU (Occurrence); PRP (Properties)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

43 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
43 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:352937
REFERENCE 2: 136:335216
REFERENCE 3: 133:317669
REFERENCE 4: 133:292560
REFERENCE 5: 133:29458
REFERENCE 6: 132:319201
REFERENCE 7: 128:188617
REFERENCE 8: 126:275674
REFERENCE 9: 126:102397
REFERENCE 10: 124:336610

L80 ANSWER 4 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 85394-22-5 REGISTRY

CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[2-
(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]]- α -D-
mannopyranosyl-(1 \rightarrow 3)]-O-[O-2-(acetylamino)-2-deoxy- β -D-
glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O-
 β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-
glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
NAME)

FS STEREOSEARCH

DR 84825-28-5

MF C66 H110 N6 O46

CI COM

LC STN Files: CA, CAPLUS, USPATFULL


DT.CA CApus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); USES (Uses)


RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

19 REFERENCES IN FILE CA (1907 TO DATE)
 19 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:419439

REFERENCE 2: 139:258542

REFERENCE 3: 136:335216


REFERENCE 4: 134:1795
REFERENCE 5: 133:204479
REFERENCE 6: 128:188617
REFERENCE 7: 127:356647
REFERENCE 8: 127:79955
REFERENCE 9: 121:57821
REFERENCE 10: 119:264981

7 mannose


L80 ANSWER 5 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 84182-22-9 REGISTRY
CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
DR 161218-84-4, 110402-18-1, 200398-06-7
MF C58 H98 N2 O46
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
DT.CA Cplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

66 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 66 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE	1:	140:40774
REFERENCE	2:	139:226051
REFERENCE	3:	138:23131
REFERENCE	4:	137:276010
REFERENCE	5:	136:335216
REFERENCE	6:	136:164117
REFERENCE	7:	135:224291

REFERENCE 10: 134:162059


5 mannose

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

27 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
27 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:267456

REFERENCE 2: 136:335216

REFERENCE 3: 134:86469

REFERENCE 4: 133:204479

REFERENCE 5: 133:204465

REFERENCE 6: 133:190049

REFERENCE 7: 132:194576

REFERENCE 8: 128:305366

REFERENCE 9: 128:188617

REFERENCE 10: 127:356647

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

DR 161218-82-2, 133331-71-2, 108731-93-7, 183242-85-5, 200398-07-8, 422308-13-2

MF C58 H98 N2 O46

CI COM

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


DT.CA CAplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

53 REFERENCES IN FILE CA (1907 TO DATE)
53 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:136882
REFERENCE 2: 140:40774
REFERENCE 3: 138:184629
REFERENCE 4: 137:137536
REFERENCE 5: 136:335216
REFERENCE 6: 135:207321
REFERENCE 7: 133:317669
REFERENCE 8: 133:307885
REFERENCE 9: 133:42070
REFERENCE 10: 132:319202

6 mannose

L80 ANSWER 8 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
RN 77355-54-5 REGISTRY
CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-

mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→3)-O-
[α-D-mannopyranosyl-(1→6)]-α-D-mannopyranosyl-
(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-
deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN D-Glucose, O-α-D-mannopyranosyl-(1→3)-O-[α-D-
mannopyranosyl-(1→6)]-O-α-D-mannopyranosyl-(1→6)-O-[O-
α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-
(1→3)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-
deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-

FS STEREOSEARCH

DR 161218-81-1, 125699-05-0, 133309-40-7, 183242-83-3, 200398-09-0,
240126-93-6, 240129-84-4, 420839-17-4

MF C52 H88 N2 O41

CI COM

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP
(Preparation); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent)



RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); FORM (Formation, nonpreparative); PREP (Preparation)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

133 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 133 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:52833
 REFERENCE 2: 141:20543
 REFERENCE 3: 140:317606
 REFERENCE 4: 140:40774
 REFERENCE 5: 139:226051
 REFERENCE 6: 138:284074
 REFERENCE 7: 138:184629
 REFERENCE 8: 138:68631
 REFERENCE 9: 137:276010
 REFERENCE 10: 137:261579


8 mannose

L80 ANSWER 9 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN
 RN 77036-51-2 REGISTRY
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 DR 478635-26-6, 161218-85-5, 116883-23-9, 198492-50-1, 200398-05-6
 MF C64 H108 N2 O51
 LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL
 DT.CA Caplus document type: Conference; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological

study); FORM (Formation, nonpreparative)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

94 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 94 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:92263
 REFERENCE 2: 140:40774
 REFERENCE 3: 139:226051
 REFERENCE 4: 138:51916
 REFERENCE 5: 137:276010
 REFERENCE 6: 137:137536
 REFERENCE 7: 136:335216
 REFERENCE 8: 135:224291
 REFERENCE 9: 135:207321
 REFERENCE 10: 134:204126

L80 ANSWER 10 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 71496-53-2 REGISTRY

CN D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

FS STEREOSEARCH

DR 478695-78-2, 163351-16-4, 161478-66-6, 121940-81-6, 113788-95-7,
 152886-24-3, 155036-36-5, 175612-64-3, 221079-20-5, 227298-98-8,
 229326-64-1, 422308-11-0, 540534-32-5

MF C62 H104 N4 O46

CI COM

LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, CSCHM, TOXCENTER, USPATFULL

DT.CA Caplus document type: Conference; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
 RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: PREP (Preparation)


RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP

(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)


RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PRP (Properties); RACT (Reactant or reagent)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





—CHO

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

202 REFERENCES IN FILE CA (1907 TO DATE)
 16 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 202 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:152987

REFERENCE 2: 140:317606

REFERENCE 3: 140:317592

REFERENCE 4: 140:199731

REFERENCE 5: 139:319688

REFERENCE 6: 139:144583

REFERENCE 7: 139:131045

REFERENCE 8: 139:34952

REFERENCE 9: 138:61285

REFERENCE 10: 137:139008

9 mannose

L80 ANSWER 11 OF 12 REGISTRY COPYRIGHT 2004 ACS on STN

RN 71246-55-4 REGISTRY

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX

NAME)

FS STEREOSEARCH

DR 161218-88-8, 161564-50-7, 130583-21-0, 132853-97-5, 105071-71-4,
139501-29-4, 178249-77-9, 183242-87-7

MF C70 H118 N2 O56


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Conference; Journal; Patent


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
USES (Uses)RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PROC (Process); USES (Uses)RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent)RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

164 REFERENCES IN FILE CA (1907 TO DATE)
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 164 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE	1:	141:174462
REFERENCE	2:	140:402146
REFERENCE	3:	140:317403
REFERENCE	4:	140:158561
REFERENCE	5:	140:92263
REFERENCE	6:	140:40774
REFERENCE	7:	138:331180
REFERENCE	8:	138:284074
REFERENCE	9:	138:85301
REFERENCE	10:	138:68631

RN 66091-47-2 REGISTRY

5 mannose

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-

FS STEREOSEARCH

DR 503569-57-1, 161218-80-0, 126976-44-1, 133331-70-1, 139535-96-9, 152880-39-2, 183242-79-7, 341506-40-9, 364589-92-4, 420839-16-3

MF C46 H78 N2 O36

CI COM

LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Journal; Patent


RL.P Roles from patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)


RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

217 REFERENCES IN FILE CA (1907 TO DATE)
19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
217 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:102488

REFERENCE 2: 141:52833

REFERENCE 3: 141:20543

REFERENCE 4: 140:419439

REFERENCE 5: 140:161542

REFERENCE 6: 140:158561

REFERENCE 7: 140:92263

REFERENCE 8: 140:26737

REFERENCE 9: 139:359896

REFERENCE 10: 139:145535

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 11:09:38 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 177

L77 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:315462 HCAPLUS
 DN 136:335216
 ED Entered STN: 26 Apr 2002
 TI **Chlamydia oligosaccharides**
 IN Kuo, Cho-chou; Swanson, Albertina F.; Hakomori,
 Senitiroh; Takahashi, Noriko
 PA USA
 SO U.S. Pat. Appl. Publ., 18 pp., Cont. of U.S. Ser. No. 230,346.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-715
 NCL 514042000
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 10

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002049172	A1	20020425	US 2001-950684	20010913 <--
	US 2002173483	A1	20021121	US 1999-230346	19990219 <--
	US 2004121984	A1	20040624	US 2003-714842	20031118 <--
PRAI	US 1999-230346	A1	19990219	<--	
	US 1996-672849	B2	19960725	<--	
	WO 1997-US13037	W	19970725	<--	
	US 2001-950684	B1	20010913	<--	


CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	US 2002049172	ICM	A61K031-715
		NCL	514042000
US	2004121984	ECLA	A61K031/70J; A61K031/715; A61K031/715; C07H003/06 <--
AB	The carbohydrate moieties of the major outer membrane protein (MOMP) which are involved in the attachment of <i>C. trachomatis</i> and other chlamydiae to host mammalian cells can be used to block attachment and infectivity of chlamydiae . Thus, among the objects of the instant invention are the identification of the relevant oligosaccharides which mediate the binding of various chlamydiae to mammalian cells, which mediate the infectivity of various chlamydiae in mammalian cells, compns. comprising same and methods for using same to block binding of and infectivity of chlamydiae in a host. Those and other objects of the instant invention have been attained by the discovery of novel N-linked structures in chlamydia MOMP, of a "high mannose-type" which mediate binding of chlamydiae to mammalian host cells. Thus, the instant invention includes compns. and methods for precluding attachment of chlamydiae to host cells.		
ST	Chlamydia oligosaccharide attachment infectivity blockade		
IT	Infection (bacterial, inhibition; identification of Chlamydia oligosaccharides that block attachment and infectivity in host mammalian cells)		
IT	Mannooligosaccharides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (branched; identification of Chlamydia oligosaccharides that block attachment and infectivity in host mammalian cells)		


- IT Antibacterial agents
 Chlamydia
 Chlamydia pneumoniae
 Chlamydia psittaci
 Chlamydia trachomatis
 (identification of Chlamydia oligosaccharides that
 block attachment and infectivity in host mammalian cells)
- IT Oligosaccharides, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (identification of Chlamydia oligosaccharides that
 block attachment and infectivity in host mammalian cells)
- IT Ovalbumin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (oligosaccharides of; identification of Chlamydia
 oligosaccharides that block attachment and infectivity in host
 mammalian cells)
- IT 66091-47-2P 71246-55-4P 71496-53-2P
 77036-51-2P 77355-54-5P 83178-05-6P
 93445-86-4P
 RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR
 (Purification or recovery); THU (Therapeutic use); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
 (identification of Chlamydia oligosaccharides that
 block attachment and infectivity in host mammalian cells)
- IT 577-76-4D, Chitobiose, conjugates with
 trimannosyl core
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (identification of Chlamydia oligosaccharides that
 block attachment and infectivity in host mammalian cells)
- IT 84182-21-8P 84182-22-9P 85394-22-5P
 114154-06-2P 114154-07-3P
 RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR
 (Purification or recovery); THU (Therapeutic use); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
 (of hen egg ovalbumin; identification of Chlamydia
 oligosaccharides that block attachment and infectivity in host
 mammalian cells)
- IT 66091-47-2P 71246-55-4P 71496-53-2P
 77036-51-2P 77355-54-5P 83178-05-6P
 93445-86-4P
 RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR
 (Purification or recovery); THU (Therapeutic use); BIOL (Biological
 study); OCCU (Occurrence); PREP (Preparation); USES (Uses)
 (identification of Chlamydia oligosaccharides that
 block attachment and infectivity in host mammalian cells)
- RN 66091-47-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-
 mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-
 [α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 71496-53-2 HCAPLUS


CN D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-B


— CHO

RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 83178-05-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-A



PAGE 2-B

—OH

IT 577-76-4D, Chitobiose, conjugates with
trimannosyl core


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(identification of *Chlamydia oligosaccharides* that
block attachment and infectivity in host mammalian cells)

RN 577-76-4 HCAPLUS

CN D-Glucose, 2-amino-4-O-(2-amino-2-deoxy-β-D-glucopyranosyl)-2-deoxy-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 84182-21-8P 84182-22-9P 85394-22-5P
114154-06-2P 114154-07-3P


RL: NPO (Natural product occurrence); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses) (of hen egg ovalbumin; identification of **Chlamydia oligosaccharides** that block attachment and infectivity in host mammalian cells)

RN 84182-21-8 HCAPLUS


CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 84182-22-9 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 85394-22-5 HCAPLUS
 CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
 O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[2-
 (acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-
 mannopyranosyl-(1 \rightarrow 3)]-O-[O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O-
 β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 114154-06-2 HCAPLUS
 CN D-Glucose, O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-
 O-[O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[O-
 β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl-(1→4)]-α-D-mannopyranosyl-(1→3)]-O-[O-
 α-D-mannopyranosyl-(1→3)-α-D-mannopyranosyl-
 (1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-
 deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 114154-07-3 HCAPLUS


CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
 O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[2-
 (acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-
 mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L77 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:98333 HCAPLUS
 DN 128:188617
 ED Entered STN: 19 Feb 1998
 TI **Chlamydia mannose-containing oligosaccharides**
 , and use in inhibiting **chlamydial infectivity**
 IN Takahashi, Noriko; Kuo, Cho-Chou; Swanson,
 Albertina F.; Hakomori, Sen-Itiroh
 PA Biomembrane Institute, USA; University of Washington
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-715
 ICS C07H001-00
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 10, 63
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9804272	A1	19980205	WO 1997-US13037	19970725 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 2002173483	A1	20021121	US 1999-230346	19990219 <--
US 2003139375	A1	20030724	US 2002-287587	20021105 <--
US 2004121984	A1	20040624	US 2003-714842	20031118 <--
US 2004138173	A1	20040715	US 2003-732281	20031211 <--
PRAI US 1996-672849	A2	19960725	<--	
WO 1997-US13037	W	19970725	<--	
US 1999-230346	B1	19990219	<--	
US 2001-950684	B1	20010913	<--	
US 2002-287587	B1	20021105		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9804272	ICM	A61K031-715
	ICS	C07H001-00
US 2004121984	ECLA	A61K031/70J; A61K031/715; A61K031/715; C07H003/06 <--

AB **Mannose-containing, branched oligosaccharides** mediate binding of **chlamydia** to mammalian cells. The "high mannose-type" glycan was found to block adhesion of

chlamydiae to mammalian cells and thus to inhibit infectivity. The glycan and its mimetics, including multivalent derivs., can be used as agents for treatment or prevention of **chlamydia**-based human diseases.

- ST **Chlamydia inhibition mannose contg oligosaccharide**
- IT Antibacterial agents
 - Chlamydia**
 - Chlamydia pneumoniae**
 - Chlamydia psittaci**
 - Chlamydia trachomatis**
- Drug delivery systems
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT **Mannooligosaccharides**
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT **Carbohydrates, biological studies**
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT Glycoproteins, specific or class
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (MOMP (major outer membrane protein); **Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT Ovalbumin
 - Ovomucoids
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (glycopeptides from; **Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT 66091-47-2P 71246-55-4P 71496-53-2P
 77036-51-2P 77355-54-5P 83178-05-6P
 84182-21-8P 84182-22-9P 85394-22-5P
 93445-86-4P 114154-06-2P 114154-07-3P
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT 69401-47-4 77036-51-2D, isomer
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)
- IT 70-47-3D, Asparagine, trimannosyl core-chitobiose conjugates 577-76-4D, Chitobiose, trimannosyl core conjugates 3458-28-4, Mannose
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (**Chlamydia mannose-containing oligosaccharides**, and use in inhibiting **chlamydial** infectivity)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aizawa; US 5132413 A 1992 HCAPLUS
- (2) Genetics Institute Inc; WO 9305803 A1 1993 HCAPLUS
- (3) Kuo, C; The Journal of Clinical Investigation 1996, V98(12), P2813 HCAPLUS

- (4) Swanson, A; Infection and Immunity 1990, V58(2), P502 HCAPLUS
 (5) Swanson, A; Infection and Immunity 1994, V62(1), P24 HCAPLUS
 (6) Tonen Corporation; EP 0677295 A1 1995 HCAPLUS
 (7) Tonen Corporation; WO 9511704 A1 1995 HCAPLUS

IT 66091-47-2P 71246-55-4P 71496-53-2P
 77036-51-2P 77355-54-5P 83178-05-6P
 84182-21-8P 84182-22-9P 85394-22-5P
 93445-86-4P 114154-06-2P 114154-07-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(*Chlamydia* mannose-containing oligosaccharides
 , and use in inhibiting *chlamydial* infectivity)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 71496-53-2 HCAPLUS


CN D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 83178-05-6 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



CN D-Glucose, O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -
D-mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-
O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-
(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-
deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B

 OH

 OH

PAGE 2-A




RN 84182-22-9 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 85394-22-5 HCAPLUS


CN D-Glucose, O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-
O-[O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[2-
(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)]-α-D-
mannopyranosyl-(1→3)]-O-[O-2-(acetylamino)-2-deoxy-β-D-
glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-
β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 93445-86-4 HCAPLUS



CN D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→6)]-O-α-D-mannopyranosyl-(1→6)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

—OH


RN 114154-06-2 HCAPLUS

CN D-Glucose, O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-


O-[O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)]-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)]-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 114154-07-3 HCAPLUS


CN D-Glucose, O-2-(acetamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-
 O-[O-2-(acetamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)]-O-[2-
 (acetamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]- α -D-
 mannopyranosyl-(1 \rightarrow 3)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 77036-51-2D, isomer

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(*Chlamydia* mannose-containing oligosaccharides
, and use in inhibiting *chlamydial* infectivity)

RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




IT 70-47-3D, Asparagine, trimannosyl core-
 chitobiose conjugates 577-76-4D, Chitobiose,
 trimannosyl core conjugates
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Chlamydia mannose-containing oligosaccharides
 , and use in inhibiting chlamydial infectivity)
 RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 577-76-4 HCAPLUS
 CN D-Glucose, 2-amino-4-O-(2-amino-2-deoxy-β-D-glucopyranosyl)-2-deoxy-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:2750 HCAPLUS
 DN 126:102397
 ED Entered STN: 04 Jan 1997
 TI An N-linked high-mannose type
 oligosaccharide, expressed at the major outer membrane protein of
 Chlamydia trachomatis, mediates attachment and infectivity of the
 microorganism to HeLa cells
 AU Kuo, Cho-chou; Takahashi, Noriko; Swanson,
 Albertina F.; Ozeki, Yasuhiro; Hakomori, Sen-itiroh
 CS Dep. Pathobiol., Univ. Washington, Seattle, WA, 98195, USA
 SO Journal of Clinical Investigation (1996), 98(12), 2813-2818
 CODEN: JCINAO; ISSN: 0021-9738
 PB Rockefeller University Press
 DT Journal
 LA English
 CC 14-3 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 10
 AB The structure of the carbohydrate of the 40 kDa major outer membrane
 component of Chlamydia trachomatis and its role in defining
 infectivity of the organism were investigated. The
 oligosaccharides were released from the glycoprotein by
 N-glycanase digestion, coupled to a 2-aminopyridyl residue, and subjected


to two-dimensional sugar mapping technique. The major fractions consisted of "high-mannose type" oligosaccharides containing 8-9 mannose residues. Bi- and tri-antennary "complex type" oligosaccharides having terminal galactose were detected as minor components. These oligosaccharides were N-linked and contained no sialic acid. This structural profile is consistent with the authors' previous characterization based on lectin-binding and glycosidase digestion. Functional specificity of identified *Chlamydia* oligosaccharides was analyzed using glycopeptides fractionated from ovalbumin and structurally defined oligosaccharides from other sources. The glycopeptide fraction having high-mannose type oligosaccharide, as compared to those having complex or hybrid-type, showed a stronger inhibitory effect on attachment and infectivity of *Chlamydia* organisms to HeLa cells. Among high-mannose type oligosaccharides, the strongest inhibition was observed with mannose 8 as compared with mannose 6, 7, or 9. These results indicate that a specific high-mannose type oligosaccharide linked to the major outer membrane protein of *C. trachomatis* mediates attachment and infectivity of the organism to HeLa cells.

- ST *Chlamydia* oligosaccharide MOMP protein attachment infectivity; major outer membrane protein oligosaccharide
Chlamydia
- IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MOMP (major outer membrane protein), N-linked high-mannose oligosaccharide-containing; N-linked high-mannose type oligosaccharide, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT Cell adhesion
Chlamydia trachomatis
HeLa cell
Virulence (microbial)
(N-linked high-mannose type oligosaccharide, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT Mannooligosaccharides
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(N-linked high-mannose type oligosaccharide, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT Oligosaccharides, biological studies
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(N-linked; N-linked high-mannose type oligosaccharide, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT Infection
(bacterial; N-linked high-mannose type oligosaccharide, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)


- IT **Oligosaccharides**, biological studies
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (branched; **N-linked high-mannose** type **oligosaccharide**, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT **Animal cell**
 (infection; **N-linked high-mannose** type **oligosaccharide**, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT **Cell wall**
 (outer membrane; **N-linked high-mannose** type **oligosaccharide**, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT 66091-47-2 71246-55-4 71496-53-2
 77036-51-2 77355-54-5 83178-05-6
 93445-86-4
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**N-linked high-mannose** type **oligosaccharide**, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- IT 66091-47-2 71246-55-4 71496-53-2
 77036-51-2 77355-54-5 83178-05-6
 93445-86-4
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (**N-linked high-mannose** type **oligosaccharide**, expressed at major outer membrane protein of *Chlamydia trachomatis*, mediates attachment and infectivity of microorganism to human HeLa cells)
- RN 66091-47-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 71496-53-2 HCAPLUS


CN	D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-	(9CI)
	(CA INDEX NAME)	


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-B


CHO

RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 83178-05-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-A



PAGE 2-B

—OH

=> => d his

(FILE 'HOME' ENTERED AT 10:13:03 ON 07 OCT 2004)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 10:15:11 ON 07 OCT 2004

L1	2 S (US20040121984 OR US20020049172 ORE US20020173483)/PN OR (WO9
	E KUO C/AU
L2	204 S E3,E6,E7
	E KUO CHO/AU
L3	71 S E4-E6,E9
	E SWANSON A/AU
L4	12 S E3,E8
L5	11 S E27
	E HAKOMORI S/AU
L6	220 S E3,E4,E7,E8
L7	382 S E17-E19
	E TAKAHASHI N/AU
L8	566 S E3-E6
	E TAKAHASHI NOR/AU

L9 306 S E18,E10
 L10 74 S L2-L9 AND CHLAMYD?/CT,CW,BI
 L11 11 S L10 AND ?SACCHARIDE?
 L12 2 S L10 AND CARBOHYDRATE?/SC,SX,CW,CT
 L13 11 S L11,L12
 L14 8 S L13 AND ?MANNO?
 L15 3 S L13 NOT L14
 L16 6 S L14 AND (N LINK? OR ?ACETYLGLUCOSAMINE? OR CHITOBIOSE OR ASPA
 L17 4 S L16 AND HIGH
 L18 2 S L14 NOT L16
 L19 1 S L18 AND HIGH
 L20 5 S L17,L19,L1 AND L1-L19
 SEL RN

FILE 'REGISTRY' ENTERED AT 10:23:29 ON 07 OCT 2004

L21 16 S E1-E16
 L22 2 S L21 NOT OC5/ES
 L23 13 S L21 AND NR>=2
 L24 1 S L21 NOT L22,L23
 L25 STR
 L26 50 S L25
 L27 5778 S L25 FUL
 SAV L27 MAIER714/A
 L28 STR L25
 L29 50 S L28 SAM SUB=L27
 L30 1776 S L28 FUL SUB=L27
 SAV L30 MAIER714A/A
 L31 STR L28
 L32 20 S L31 CSS SAM SUB=L30
 L33 STR L28
 L34 42 S L33 CSS SAM SUB=L30
 L35 719 S L33 CSS FUL SUB=L30
 SAV L35 MAIER714B/A
 L36 STR L28
 L37 0 S L36 SAM SUB=L30
 L38 12 S L21 AND L30
 L39 1764 S L30 NOT L38

FILE 'HCAOLD' ENTERED AT 10:53:52 ON 07 OCT 2004

L40 0 S L38

FILE 'HCAPLUS' ENTERED AT 10:54:01 ON 07 OCT 2004

L41 504 S L38
 L42 1009 S L39
 L43 27 S L2-L9 AND L41
 L44 42 S L2-L9 AND L42
 L45 3 S L10 AND L43,L44
 L46 44 S L43,L44 NOT L45
 L47 33 S L46 AND (N LINK? OR ?ACETYLGLUCOSAMINE? OR ?CHITOBIOSE? OR ?AS
 L48 12 S L47 AND ?MANNO?
 L49 20 S L46 AND ?MANNO?
 L50 8 S L46 AND ASN
 L51 13 S L48,L49 AND L47,L50
 L52 13 S L51 AND ?MANNO?
 L53 7 S L52 AND HIGH MANNO?
 E CHLAMYDIA/CT
 E E3+ALL
 L54 4097 S E5,E4+NT
 E E3+ALL
 L55 4216 S E3+NT
 E E2+ALL
 L56 4227 S E2+NT
 L57 3 S L41 AND L54-L56

L58 0 S L42 AND L54-L56
L59 3 S L41,L42 AND CHLAMYD?
L60 3 S L57,L59,L45
L61 352 S L41 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)
L62 683 S L42 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)

FILE 'REGISTRY' ENTERED AT 11:02:17 ON 07 OCT 2004

L63 1 S CHITOBIOSE/CN
L64 3 S (D-ASPARAGINE OR L-ASPARAGINE OR DL-ASPARAGINE OR ASPARAGINE)

FILE 'HCAPLUS' ENTERED AT 11:02:59 ON 07 OCT 2004

L65 68 S L63,L64 AND L41,L42
L66 354 S (CHITOBIOSE OR ASN OR ASPARAG?) AND L41,L42
L67 270 S L61,L62 AND L65,L66
L68 62 S L67 AND HIGH MANNO?
L69 18 S L65,L66 AND L43,L44
L70 18 S L65,L66 AND L45-L53
L71 2 S L65,L66 AND L60
L72 3 S L60,L71
L73 16 S L69-L70 NOT L72
L74 3 S L61,L62 AND L54-L56
L75 3 S L61,L62 AND CHLAMYD?
L76 3 S L72,L74,L75
L77 3 S L76 AND L1-L20,L41-62,L65-L76
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 07 OCT 2004

L78 14 S E1-E14
L79 2 S L78 NOT L38,L39
L80 12 S L78 NOT L79

FILE 'REGISTRY' ENTERED AT 11:09:14 ON 07 OCT 2004

FILE 'HCAPLUS' ENTERED AT 11:09:38 ON 07 OCT 2004

FILE 'REGISTRY' ENTERED AT 11:35:39 ON 07 OCT 2004

L81 6 S L80 AND 2/N
L82 295 S L39 AND 2/N
L83 217 S L82 AND L35
L84 223 S L81,L83

FILE 'HCAPLUS' ENTERED AT 11:36:57 ON 07 OCT 2004

L85 525 S L84
L86 361 S L85 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)
L87 117 S L86 AND HIGH MANNO?
L88 23 S L86 AND L63,L64
L89 107 S L86 AND (CHIOBIOSE OR ASPARAGINE OR ASN)
L90 48 S L87 AND L88,L89
L91 46 S L90 NOT L77
L92 0 S L91 AND P/DT

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 11:38:22 ON 07 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d 191 all hitstr tot

L91 ANSWER 1 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:508107 HCAPLUS
DN 127:203168
ED Entered STN: 11 Aug 1997
TI Microheterogeneity of the oligosaccharides carried by the recombinant bovine lactoferrin expressed in Mamestra brassicae cells
AU Lopez, Michel; Coddeville, Bernadette; Langridge, James; Plancke, Yves; Sautiere, Pierre; Chaabihi, Hassan; Chirat, Frederic; Harduin-Lepers, Anne; Cerutti, Martine; Verbert, Andre; Delannoy, Philippe
CS Laboratoire de Chimie Biologique, Unite Mixte de Recherche du CNRS n° 111, Universite des Sciences et Technologies de Lille, Villeneuve d'Ascq, F-59655, Fr.
SO Glycobiology (1997), 7(5), 635-651
CODEN: GLYCE3; ISSN: 0959-6658
PB Oxford University Press
DT Journal
LA English
CC 12-2 (Nonmammalian Biochemistry)
AB The development of therapeutic glycoprotein production using the baculovirus expression system depends on the ability of insect cell lines to reproduce site specific mammalian-like N-glycans. A combination of 1H-NMR and mass spectrometry techniques (MALD-MS, ES-MS, and CID-MS-MS) allowed us to elucidate the N-linked oligosaccharides microheterogeneity on three different N-glycosylation sites, Asn233, Asn476, and Asn545, of a baculovirus-expressed recombinant bovine lactoferrin produced in Mamestra brassicae. Two families of N-glycan structures have been found: first, oligomannosidic glycans (Man9-5GlcNAc2) and secondly, short truncated partially fucosylated glycans (Man3-2[Fuc0-1]GlcNAc2). These results indicate that Mamestra brassicae cell line is not able to synthesize complex N-glycans, even if an α 1,6-linked fucose residue is frequently present on the asparagine-bound N-acetylglucosamine residue of short truncated structures. Nevertheless, we have shown that Mamestra brassicae ensures the same N-glycosylation pattern as found on natural bovine lactoferrin showing the same distribution between complex and high-mannose type glycans on the different glycosylation sites. Sites which are naturally occupied by high-mannose glycans (Asn233 and Asn545) are substituted essentially by the same type of N-glycans in the recombinant counterpart, and the site Asn476, which carries sialylated complex type chains in the natural glycoprotein, is substituted by short, truncated, partially fucosylated chains in Mamestra brassica-expressed bovine lactoferrin. These various results lead us to the conclusion that bovine lactoferrin is an interesting model to determine the potential of glycosylation of the baculovirus/insect cell expression systems.
ST glycosylation lactoferrin oligosaccharide insect cell
IT Oligosaccharides, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(N-linked; microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)

IT Glycosylation
Mamestra brassicae
(microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)

IT Glycoproteins, general, biological studies
Lactoferrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)

IT 70-47-3, L-Asparagine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)

IT 66091-47-2 70858-45-6 71246-55-4
77036-51-2 77355-54-5 78392-31-1
81046-85-7 83178-05-6 95041-21-7 110387-51-4
120448-61-5
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)


RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Altmann, F; Glycobiology 1993, V3, P619 HCAPLUS
- (2) Altmann, F; Glycoconjugate J 1995, V12, P150 HCAPLUS
- (3) Altmann, F; J Biol Chem 1995, V270, P17344 HCAPLUS
- (4) Blanc, S; Virology 1993, V192, P651 HCAPLUS
- (5) Branley, B; Cell 1990, V63, P861
- (6) Butters, T; Biochim Biophys Acta 1981, V640, P655 HCAPLUS
- (7) Chaabihi, H; J Virol 1993, V67, P2664 MEDLINE
- (8) Chen, W; J Biol Chem 1991, V266, P4081 HCAPLUS
- (9) Cheron, A; C R Acad Sci Hebd Seances Acad Sci 1977, V284, P585 HCAPLUS
- (10) Coddeville, B; Carbohydr Res 1992, V236, P145 HCAPLUS
- (11) Crestfield, A; J Biol Chem 1963, V238, P622 HCAPLUS
- (12) Davidson, D; Biochemistry 1990, V29, P5584 HCAPLUS
- (13) Davidson, D; Biochemistry 1991, V30, P6167 HCAPLUS
- (14) Davidson, D; Biochemistry 1991, V30, P6689 HCAPLUS
- (15) Elbein, A; Annu Rev Biochem 1987, V56, P497 HCAPLUS
- (16) Felgner, P; Nature 1989, V337, P387 MEDLINE
- (17) Furukawa, K; Curr Opin Biotechnol 1992, V3, P554 HCAPLUS
- (18) Goochee, C; Bio/Technology 1991, V9, P1347 HCAPLUS
- (19) Grabenhorst, E; Eur J Biochem 1993, V215, P189 HCAPLUS
- (20) Haeuw, J; Biochem J 1994, V294, P463
- (21) Hard, K; Biochemistry 1993, V32, P766 HCAPLUS
- (22) Hogeland, K; Biol Mass Spectrometry 1994, V23, P218 HCAPLUS
- (23) Houmard, J; Proc Natl Acad Sci USA 1972, V69, P3506 HCAPLUS
- (24) Hsieh, P; J Biol Chem 1984, V259, P2375 HCAPLUS
- (25) Jarvis, D; J Cell Biochem 1990, V42, P181 HCAPLUS
- (26) Jarvis, D; Mol Cell Biol 1989, V9, P214 HCAPLUS
- (27) Jenkins, N; Biochem Soc Trans 1995, V23, P171 HCAPLUS
- (28) Kamerling, J; Biochem J 1975, V151, P491 HCAPLUS
- (29) Kang, C; Adv Virus Res 1988, V35, P177 HCAPLUS
- (30) Klenk, H; Immunochemistry of Viruses II The Basis of Serodiagnosis and Vaccines 1990, P25 HCAPLUS
- (31) Kobata, A; Eur J Biochem 1992, V209, P483 HCAPLUS
- (32) Kornfeld, R; Annu Rev Biochem 1985, V54, P631 MEDLINE
- (33) Kubelka, V; Arch Biochem Biophys 1994, V308, P148 MEDLINE
- (34) Kubelka, V; Eur J Biochem 1993, V213, P1193 HCAPLUS

- (35) Kuroda, K; EMBO J 1986, V5, P1359 HCAPLUS
 (36) Kuroda, K; J Virol 1989, V63, P1677 HCAPLUS
 (37) Kuroda, K; Virology 1990, V174, P418 HCAPLUS
 (38) Kuroda, K; Virology 1991, V180, P159 HCAPLUS
 (39) Laemmli, U; Nature 1970, V227, P680 HCAPLUS
 (40) Licari, P; Biotechnol Prog 1993, V9, P146 HCAPLUS
 (41) Lis, H; Eur J Biochem 1993, V218, P1 HCAPLUS
 (42) Luckow, V; Bio/Technology 1988, V6, P47 HCAPLUS
 (43) Manneberg, M; Protein Sci 1994, V3, P30 HCAPLUS
 (44) Michalski, J; Glycoproteins and Disease 1996, P55 HCAPLUS
 (45) Miller, L; Annu Rev Microbiol 1988, V42, P177 HCAPLUS
 (46) Munk, K; Glycobiology 1992, V2, P233 HCAPLUS
 (47) Noteborn, M; Workshop on Baculovirus and Recombinant Protein Production Processes 1992, P92
 (48) Ogonah, W; Bio/Technology 1996, V14, P197
 (49) Olden, K; Biochim Biophys Acta 1982, V650, P209 HCAPLUS
 (50) O'Reilly, D; Baculovirus expression vectors: a laboratory manual 1994
 (51) Parekh, R; Glycoconjugate J 1990, V7, P382
 (52) Patel, T; Biochemistry 1993, V32, P679 HCAPLUS
 (53) Pierce, A; Eur J Biochem 1991, V196, P177 HCAPLUS
 (54) Ponimaskin, E; J Gen Virol 1994, V75, P1163 HCAPLUS
 (55) Rademacher, T; Annu Rev Biochem 1988, V57, P785 HCAPLUS
 (56) Schachter, H; Glycobiology 1991, V1, P453 HCAPLUS
 (57) Spik, G; Symposium Antwerp 1992 1993
 (58) Springer, T; Nature 1991, V349, P196 MEDLINE
 (59) Staudacher, E; Eur J Biochem 1992, V207, P987 HCAPLUS
 (60) Staudacher, E; Glycoconjugate J 1992, V9, P82 HCAPLUS
 (61) Summers, M; Tex Agric Exp Stn Bull 1987, V1555
 (62) Takeuchi, M; Glycobiology 1991, V349, P196
 (63) van Die, I; Glycobiology 1996, V6, P157 HCAPLUS
 (64) van Halbeek, H; Methods in Molecular Biology 1993, V17, P115 HCAPLUS
 (65) Varki, A; Glycobiology 1993, V3, P97 HCAPLUS
 (66) Veit, M; Arch Virol 1993, V133, P335 HCAPLUS
 (67) Velardo, M; J Biol Chem 1993, V268, P17902 HCAPLUS
 (68) Vliegthart, J; Adv Carbohydr Chem Biochem 1983, V41, P209 HCAPLUS
 (69) Voss, T; Eur J Biochem 1993, V217, P913 HCAPLUS
 (70) Wathen, M; Biochemistry 1991, V30, P2863 HCAPLUS
 (71) Williams, P; Biochim Biophys Acta 1991, V1075, P146 HCAPLUS
 (72) Wojczyk, B; Biochemistry 1995, V34, P2599 HCAPLUS
 (73) Yeh, J; Biochemistry 1993, V32, P11087 HCAPLUS
 (74) Zanetta, J; J Chromatogr 1972, V69, P291 HCAPLUS
- IT 70-47-3, L-Asparagine, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (microheterogeneity of the oligosaccharides carried by recombinant bovine lactoferrin expressed in Mamestra brassicae cells)
- RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- IT 66091-47-2 70858-45-6 71246-55-4
 77036-51-2 77355-54-5 78392-31-1
 81046-85-7 83178-05-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 78392-31-1 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 81046-85-7 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-


2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 83178-05-6 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH



PAGE 2-A




L91 ANSWER 2 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:238435 HCAPLUS
 DN 126:313764
 ED Entered STN: 12 Apr 1997
 TI Structure of Human Transferrin Receptor Oligosaccharides: Conservation of Site-Specific Processing
 AU Hayes, Gary R.; Williams, Anthony M.; Lucas, John J.; Enns, Caroline A.
 CS Department of Biochemistry and Molecular Biology, State University of New York Health Sciences Center, Syracuse, NY, 13201, USA
 SO Biochemistry (1997), 36(17), 5276-5284
 CODEN: BICHAW; ISSN: 0006-2960
 PB American Chemical Society
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB The human transferrin receptor (TfR) has three N-linked oligosaccharides. A combination of site-directed mutagenesis and carbohydrate and protein chemical was used to characterize the structures of the N-linked oligosaccharides and to map their locations. The authors find that the type of oligosaccharide at each position was unique for that particular site. Human TfR isolated from placentae was used to characterize the structure of the oligosaccharides found in the native TfR. Following digestion of purified TfR with trypsin, individual peptides were obtained via RP-HPLC and were assayed for monosaccharides by strong acid hydrolysis and HPAE-PAD. Peptides containing carbohydrate were subjected to amino acid sequencing to identify the specific Asn residue. The oligosaccharides at Asn 251 are of the complex type. HPAE-PAD and FACE anal. suggests that they are triantennary and trisialylated with

core fucosylation. The glycopeptide containing the site at Asn 317 was obtained after limited tryptic digestion and RP-HPLC. FACE anal. reveals predominantly a family of sialylated hybrid oligosaccharides. The consensus sequences for each N-linked site were mutated in various combinations and the resultant TfRs expressed in mouse 3T3 cells. Endoglycosidase H digestion of the mutated TfRs indicates that the pattern of oligosaccharides is consistent with the type of oligosaccharides found at each position in human tissue and the glycosylation of one site does not directly affect the glycosylation of other sites. Previous studies indicated that the oligosaccharide at Asn 727 was **high** **-mannose** type [Hayes, G. R., et al. (1995) Glycobiol. 5, 227-232]. These results indicate that the type of oligosaccharide found at each site is most dependent on the environment surrounding it.

- ST transferrin receptor oligosaccharide structure; glycosylation site
transferrin receptor
- IT Oligosaccharides, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(N-linked; characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT Glycosylation
(biol.; characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT Transferrin receptors
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT Protein motifs
(glycosylation site; characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT 70-47-3, L-Asparagine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT 83412-55-9D, sialylated 112822-58-9D, sialylated 189386-85-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- IT 70-47-3, L-Asparagine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- RN 70-47-3 HCAPLUS
- CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- IT 189386-85-4
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(characterization of oligosaccharide structure and identification of glycosylation sites of human transferrin receptor)
- RN 189386-85-4 HCAPLUS


CN D-Glucose, O- α -D-galactopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



- L91 ANSWER 3 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:22006 HCAPLUS
 DN 126:142395
 ED Entered STN: 15 Jan 1997
 TI Gender-specific glycosylation of human glycodelin affects its contraceptive activity
 AU Morris, Howard R.; Dell, Anne; Easton, Richard L.; Panico, Maria; Koistinen, Hannu; Koistinen, Riitta; Oehninger, Sergio; Patankar, Manish S.; Seppala, Markku; Clark, Gary F.
 CS Dep. Biochem., Imperial Coll., London, SW7 2AY, UK
 SO Journal of Biological Chemistry (1996), 271(50), 32159-32167
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 CC 13-3 (Mammalian Biochemistry)
 Section cross-reference(s): 6
 AB We have recently demonstrated that a human amniotic fluid-derived glycoprotein, glycodelin-A (GdA; previously known as PP14 or PAEP), potently inhibits gamete binding in an established sperm-egg binding system and expresses immunosuppressive activities directed against a variety of different immune cell types. GdA has **high mannose**-, hybrid-, and complex-type biantennary oligosaccharides including structures with fucosylated or sialylated N,N'-diacetyllactosamine (GalNAc β 1-4GlcNAc) sequences, which are rare in other human glycoproteins. We now report the characterization of glycodelin-S (GdS). This is a human seminal plasma glycoprotein that is immunol. indistinguishable from GdA, but unlike the latter, does not inhibit human sperm-zona pellucida binding under hemizona assay conditions. Anal. of the N-glycans of GdS by mass spectrometry revealed that all glycoforms of GdS are different from those of GdA. GdS glycans are unusually fucose-rich, and the major complex-type structures are biantennary glycans with Lewisx (Gal β 1-4(Fuca1-3)GlcNAc) and Lewisy (Fuca α 1-2Gal β 1-4(Fuca1-3)GlcNAc) antennae. It is probable that these highly fucosylated epitopes contribute to the immunosuppressive activity of human seminal plasma and to the low immunogenicity of sperm. This study provides the first evidence for gender-specific glycosylation that may serve to regulate key processes involved in human reproduction
 ST human glycodelin S N glycan structure; seminal plasma GdS carbohydrate structure contraceptive
 IT Oligosaccharides, biological studies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
 (N-linked; gender-specific glycosylation of human glycodelin affects its contraceptive (sperm-zona pellucida binding) activity)
 IT Sperm
 (binding to zona pellucida, as measure of glycodelin contraceptive activity; gender-specific glycosylation of human glycodelin affects its

- contraceptive (sperm-zona pellucida binding) activity)
- IT Glycosylation
Immunosuppression
Reproduction, animal
Sex
(gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(glycodeilin S; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT Protein motifs
(glycosylation site; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT Semen
(plasma, glycodeilin S (GdS) from; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT Egg
(zona pellucida, binding to sperm, as measure of glycodeilin contraceptive activity; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT 66091-47-2 78392-29-7 78392-30-0
83178-05-6
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(as N-glycan linked to glycodeilin S **asparagine** 28; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT 78334-44-8 78350-89-7 78392-81-1 186546-73-6 186546-74-7
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(as N-glycan linked to glycodeilin S **asparagine** 63; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT 70-47-3, L-Asparagine, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(in glycodeilin S, oligosaccharides attached to; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)
- IT 2438-80-4, Fucose 3458-28-4, Mannose
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(presence in glycodeilin S oligosaccharides; gender-specific glycosylation of human glycodeilin affects its contraceptive (sperm-zona pellucida binding) activity)

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Albersheim, P; Carbohydr Res 1967, V5, P340 HCAPLUS
- (2) Bohn, H; Placenta 1982, V4(suppl), P67
- (3) Bolton, A; Lancet 1987, V1, P593 MEDLINE
- (4) Burkman, L; Fertil Steril 1988, V49, P688 MEDLINE
- (5) Clark, G; Hum Reprod (Oxf) 1995, V10(suppl), P31
- (6) Dell, A; Glycobiology: A Practical Approach 1993, P187
- (7) Dell, A; J Biol Chem 1995, V270, P24116 HCAPLUS
- (8) Grinnell, B; Glycobiology 1994, V4, P221 HCAPLUS
- (9) Hanisch, F; Eur J Biochem 1985, V152, P343 MEDLINE
- (10) Hanisch, F; Eur J Biochem 1986, V155, P239 HCAPLUS
- (11) Hiraishi, K; Glycobiology 1993, V3, P381 HCAPLUS
- (12) Hunt, E; Biochem J 1973, V135, P833 HCAPLUS

- (13) Julkunen, M; Arch Androl 1984, V12(suppl), P59
- (14) Julkunen, M; Br J Obstet Gynaecol 1985, V92, P1145 HCAPLUS
- (15) Julkunen, M; Endocrinology 1986, V118, P1782 HCAPLUS
- (16) Julkunen, M; Hum Reprod (Oxf) 1986, V1, P7 HCAPLUS
- (17) Julkunen, M; Proc Natl Acad Sci U S A 1988, V85, P8845 HCAPLUS
- (18) Kamarainen, M; Blood 1994, V84, P467 HCAPLUS
- (19) Kashiwagi, N; Tohoku J Exp Med 1994, V173, P115 HCAPLUS
- (20) Koistinen, H; Mol Hum Reprod, in press 1996
- (21) Lasky, L; Annu Rev Biochem 1995, V64, P113 HCAPLUS
- (22) Lloyd, K; Biochemistry 1966, V5, P1489 HCAPLUS
- (23) Macek, M; Gamete Res 1988, V20, P93 MEDLINE
- (24) Miller, D; Mol Reprod Dev 1990, V26, P184 HCAPLUS
- (25) Minamide, S; Histochem Cell Biol 1995, V103, P339 HCAPLUS
- (26) Oehninger, S; Am Obstet Gynecol 1991, V164, P1210 MEDLINE
- (27) Oehninger, S; Fertil Steril 1995, V63, P377 MEDLINE
- (28) Oehninger, S; Mol Reprod Dev 1993, V35, P57 MEDLINE
- (29) Okamoto, N; Am J Reprod Immunol 1991, V26, P137 MEDLINE
- (30) Patankar, M; J Biol Chem 1993, V268, P21770 HCAPLUS
- (31) Pockley, A; Clin Exp Immunol 1989, V77, P252 HCAPLUS
- (32) Pockley, A; Immunology 1990, V69, P277 HCAPLUS
- (33) Pockley, A; J Reprod Immunol 1988, V13, P31 HCAPLUS
- (34) Powell, L; J Biol Chem 1995, V270, P7523 HCAPLUS
- (35) Reason, A; Glycobiology 1994, V4, P593 HCAPLUS
- (36) Riittinen, L; J Immunol Methods 1991, V136, P85 HCAPLUS
- (37) Saitoh, F; Anticancer Res 1995, V15, P2137 HCAPLUS
- (38) Stamenkovic, I; Cell 1991, V66, P1133 HCAPLUS
- (39) van Halbeek, H; Biochem Biophys Res Commun 1985, V131, P507 HCAPLUS
- (40) Velupillai, P; Proc Natl Acad Sci U S A 1994, V91, P18 HCAPLUS
- (41) Wasserman, P; Development (Camb) 1990, V108, P1

IT 66091-47-2 78392-29-7 78392-30-0

83178-05-6

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)


(as N-glycan linked to glycodelin S **asparagine** 28;
gender-specific glycosylation of human glycodelin affects its
contraceptive (sperm-zona pellucida binding) activity)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 78392-29-7 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, mono- α -D-mannopyranoside (9CI) (CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.



RN 78392-30-0 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-

mannopyranosyl-(1→3)-O-[α-D-mannopyranosyl-(1→6)]-
 α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-
 (1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-
 (1→4)-2-(acetylamino)-2-deoxy-, di-α-D-mannopyranoside (9CI)
 (CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.




RN 83178-05-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



IT 70-47-3, L-Asparagine, biological studies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (in glycodelin S, oligosaccharides attached to; gender-specific
 glycosylation of human glycodelin affects its contraceptive (sperm-zona
 pellucida binding) activity)
 RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L91 ANSWER 4 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:880357 HCAPLUS
 DN 124:139156
 ED Entered STN: 26 Oct 1995
 TI Structural analysis of the oligosaccharides derived from glycodelin, a
 human glycoprotein with potent immunosuppressive and contraceptive
 activities
 AU Dell, Anne; Morris, Howard R.; Easton, Richard L.; Panico, Maria;
 Patankar, Manish; Oehninger, Sergio; Koistinen, Riitta; Koistinen, Hannu;
 Seppala, Markku; Clark, Gary F.
 CS Dep. Biochem., Imperial Coll. Sci. Technol. Med., London, SW7 2AY, UK

- SO Journal of Biological Chemistry (1995), 270(41), 24116-26
CODEN: JBCHA3; ISSN: 0021-9258
- PB American Society for Biochemistry and Molecular Biology
- DT Journal
- LA English
- CC 6-4 (General Biochemistry)
Section cross-reference(s): 13, 15
- AB Glycodelin, also known as placental protein 14 (PP14) or progesterone-associated endometrial protein (PAEP), is a human glycoprotein with potent immunosuppressive and contraceptive activities. In this paper we report the first characterization of glycodelin-derived oligosaccharides. Using strategies based upon fast atom bombardment and electrospray mass spectrometry we have established that glycodelin is glycosylated at Asn-28 and Asn-63. The Asn-28 site carries high mannose, hybrid and complex-type structures, whereas the second site is exclusively occupied by complex-type glycans. The major non-reducing epitopes in the complex-type glycans are: Gal β 1 \rightarrow 4GlcNAc (lacNAc), GalNAc β 1-4GlcNAc (lacdiNAc), NeuAc α 2-6Gal β 1-4GlcNAc (sialylated lacNAc), NeuAc α 2-6GalNAc β 1-4GlcNAc (sialylated lacdiNAc), Gal β 1-4(Fuc α 1-3)GlcNAc (Lewisx), and GalNAc β 1-4(Fuc α 1-3)GlcNAc (lacdiNAc analog of Lewisx). It is possible that the oligosaccharides bearing sialylated lacNAc or lacdiNAc antennae may manifest immunosuppressive effects by specifically blocking adhesive and activation-related events mediated by CD22, the human B cell associated receptor. Oligosaccharides with fucosylated lacdiNAc antennae have previously been shown to potentially block selectin-mediated adhesions and may perform the same function in glycodelin. The potent inhibitory effect of glycodelin on initial human sperm-zona pellucida binding is consistent with our previous suggestion that this cell adhesion event requires a selectin-like adhesion process. This result also raises the possibility that a convergence between immune and gamete recognition processes may have occurred in the types of carbohydrate ligands recognized in the human.
- ST glycodelin oligosaccharide structure immunosuppression contraceptive
- IT Glycosidation
(sites; structural anal. of the oligosaccharides derived from glycodelin (PP14), a human glycoprotein with potent immunosuppressive and contraceptive activities)
- IT Contraceptives
Immunosuppressants
(structural anal. of the oligosaccharides derived from glycodelin (PP14), a human glycoprotein with potent immunosuppressive and contraceptive activities)
- IT Oligosaccharides
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(structural anal. of the oligosaccharides derived from glycodelin (PP14), a human glycoprotein with potent immunosuppressive and contraceptive activities)
- IT Globulins, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(α 2-PEG (α 2-pregnancy-associated endometrial globulin), structural anal. of the oligosaccharides derived from glycodelin (PP14), a human glycoprotein with potent immunosuppressive and contraceptive activities)
- IT 70-47-3, Asparagine, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(glycosylation site residues 28 and 63; structural anal. of the oligosaccharides derived from glycodelin (PP14), a human glycoprotein with potent immunosuppressive and contraceptive activities)

IT 66091-47-2 79295-70-8 82659-92-5 83800-28-6 84825-26-3
 118325-36-3 119534-74-6 146554-24-7 158167-31-8 169624-29-7
 169624-30-0 169624-31-1 169624-32-2 169624-33-3 169624-34-4
 173397-15-4 173397-16-5 173398-74-8 173398-75-9 173398-76-0
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); OCCU (Occurrence)
 (structural anal. of the oligosaccharides derived from glycodelin
 (PP14), a human glycoprotein with potent immunosuppressive and
 contraceptive activities)
 IT 70-47-3, **Asparagine**, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (glycosylation site residues 28 and 63; structural anal. of the
 oligosaccharides derived from glycodelin (PP14), a human glycoprotein
 with potent immunosuppressive and contraceptive activities)
 RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 66091-47-2
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); OCCU (Occurrence)
 (structural anal. of the oligosaccharides derived from glycodelin
 (PP14), a human glycoprotein with potent immunosuppressive and
 contraceptive activities)
 RN 66091-47-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-
 mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-
 [α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 5 OF 46 HCAPLUS · COPYRIGHT 2004 ACS on STN
 AN 1995:486453 HCAPLUS
 DN 123:106458
 ED Entered STN: 13 Apr 1995
 TI The **asparagine**-linked carbohydrate of honeybee venom
 hyaluronidase
 AU Kubelka, Viktoria; Altmann, Friedrich; Maerz, Leopold
 CS Institute fuer Chemie, Universitaet fuer Bodenkultur Wien, Vienna, A-1180,
 Austria
 SO Glycoconjugate Journal (1995), 12(1), 77-83
 CODEN: GLJOEW; ISSN: 0282-0080
 PB Chapman & Hall
 DT Journal
 LA English
 CC 7-5 (Enzymes)
 AB Hyaluronidase from honeybee venom was purified by gel permeation and
 cation-exchange chromatog. Its **asparagine**-linked carbohydrate
 chains were released from tryptic glycopeptides with N-glycosidase A and
 reductively aminated with 2-aminopyridine. Separation of the fluorescent
 derivs. by size-fractionation and reverse-phase HPLC afforded 18 fractions

which were analyzed by 2-dimensional HPLC mapping combined with exoglycosidase digestions. The bulk of the N-linked glycans of hyaluronidase consisted of small oligosaccharides (Man1-3GlcNAc2), most of which were either α 1,3-monofucosylated or α 1,3-(α 1,6)-difucosylated at the innermost GlcNAc residue. **High-mannose** type structures constituted the minor fractions, together making up .apprx.5% of the oligosaccharide pool from hyaluronidase. Four fractions, making up 8% of the N-linked glycans, contained the terminal trisaccharide GalNAc β 1-4[Fuc α 1-3]GlcNAc β 1- in β 1,2-linkage to the core α 1,3-mannosyl residue. No evidence for the presence of O-glycans or sialic acids could be found.

ST hyaluronidase oligosaccharide structure honeybee venom

IT Oligosaccharides

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

IT Venoms

(of honeybee; isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

IT Honeybee

(venom; isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

IT 61652-90-2P 66091-47-2P 70858-45-6P

71246-55-4P 88210-72-4P 95041-21-7P 110387-51-4P

119911-41-0P 119911-44-3P 119911-45-4P 147237-70-5P 150175-56-7P

150175-57-8P 150175-58-9P 150205-57-5P 165609-85-8P

166241-65-2P

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)

(isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

IT 9001-54-1, Hyaluronidase

RL: PRP (Properties)

(isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

IT 66091-47-2P 70858-45-6P 71246-55-4P

88210-72-4P 166241-65-2P

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)


(isolation and structure of oligosaccharides of hyaluronidase from honeybee venom)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 88210-72-4 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 166241-65-2 HCAPLUS


CN	D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[β -D-mannopyranosyl-(1 \rightarrow 3)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)
----	---

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 6 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:78555 HCAPLUS
 DN 122:31800
 ED Entered STN: 08 Nov 1994
 TI Molecular dynamics simulations of **high-mannose**
 oligosaccharides
 AU Balaji, Petety; Qasba, Pradman K.; Rao, V. S. R.
 CS Laboratory of Mathematical Biology, National Cancer Institute, Bethesda,
 MD, 20892, USA
 SO Glycobiology (1994), 4(4), 497-515
 CODEN: GLYCE3; ISSN: 0959-6658
 DT Journal
 LA English
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 22
 AB Conformations of several **high-mannose**-type
 oligosaccharides that are generated during the biosynthetic degradation of
 Man9GlcAc2 to Man5GlcNAc2 have been studied by mol. dynamics (MD). The
 conformations of the two α 1,3- and the two α 1,6-linkages in
 each oligomannose were different, suggesting that deriving oligosaccharide
 conformations based on the conformational preferences of the constituent

disaccharide fragments will not always yield correct results. Unlike other oligomannoses, Man9GlcNAc2 appears to take more than one distinct conformation around the core α 1,6-linkage. These various conformations may play an important role in determining the processing pathways.

Using the data on the preferred conformations of these oligomannoses and the available exptl. results, possible pathways for processing Mn9GlcNAc2 to Man5GlcNAc2 by α 1,2-linkage-specific mannosidases have been proposed. Conformational anal. of Man5GlcNAc2 indicates that the addition of β 1,2-GlcNAc to the α 1,3-linked core mannose, besides serving as a prerequisite for mannosidase II action as suggested earlier, may also prevent the removal of α 1,3-mannose. The MD simulations also suggest that the processing of the precursor oligosaccharide during Asn-linked complex and hybrid glycan biosynthesis proceeds in a well-defined pathway involving more than one α 1,2-linkage-specific mannosidase. Knowledge of the conformation of the processing intermediates obtained from the present study can be used to design highly specific substrate analogs to inhibit a particular mannosidase, thereby blocking one processing pathway without interfering with the others.

ST mol dynamics simulation mannose oligosaccharide; conformation mannose oligosaccharide

IT Conformation and Conformers
(mol. dynamics simulations of **high-mannose** oligosaccharides)

IT Oligosaccharides
RL: PRP (Properties)
(mol. dynamics simulations of **high-mannose** oligosaccharides)

IT Simulation and Modeling, physicochemical
(mol. dynamics, mol. dynamics simulations of **high-mannose** oligosaccharides)

IT 123062-75-9 123062-76-0 123062-77-1
153604-56-9 153604-57-0 159194-01-1
159530-20-8 159530-21-9 159530-22-0
159530-23-1 159627-19-7 159627-20-0
RL: PRP (Properties)
(mol. dynamics simulations of **high-mannose** oligosaccharides)


IT 123062-75-9 123062-76-0 123062-77-1
153604-56-9 153604-57-0 159194-01-1
159530-20-8 159530-21-9 159530-22-0
159530-23-1 159627-19-7 159627-20-0
RL: PRP (Properties)
(mol. dynamics simulations of **high-mannose** oligosaccharides)

RN 123062-75-9 HCAPLUS


CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 123062-76-0 HCAPLUS


CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -
D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-
[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-
(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-
deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 123062-77-1 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -
 D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-
 (1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-
 mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-
 β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 153604-56-9 HCAPLUS


CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 153604-57-0 HCAPLUS

CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 159194-01-1 HCAPLUS


CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 159530-20-8 HCAPLUS

CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-


mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)]-O-
 β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




PAGE 2-B




RN 159530-21-9 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A




PAGE 2-B




RN 159530-22-0 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A





RN 159530-23-1 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 159627-19-7 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-(2-acetyl-amino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetyl-amino)-2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—CH₂—OH

PAGE 2-A



RN 159627-20-0 HCAPLUS
 CN β -D-Glucopyranose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -
 D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O-
 α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-
 (1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-
 mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-
 (acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-
 2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—OH

PAGE 2-A




- TI Characterization of the oligosaccharide structures on a recombinant tissue-type plasminogen activator analog synthesized in Chinese hamster ovary cells
- AU Aeed, P. A.; Guido, D. M.; Mathews, W. R.; Leone, J. W.; Elhammer, A. P.
- CS Upjohn Co., Kalamazoo, MI, 49001, USA
- SO Fibrinolysis (1994), 8(1), 31-41
CODEN: FBRIE7; ISSN: 0268-9499
- DT Journal
- LA English
- CC 6-4 (General Biochemistry)
- AB The **asparagine**-linked oligosaccharides on a recombinant tissue-type plasminogen activator analog, lacking the epidermal growth factor-like and kringle 1 domains (FK2P), synthesized by Chinese hamster ovary cells, have been characterized. In vivo [3H]mannose labeled glycopeptides were extracted from SDS-PAGE gels of antibody precipitated FK2P and the major oligosaccharide structures were characterized by serial lectin affinity chromatog., size-exclusion chromatog. in combination with exoglycosidase digestions, ion exchange chromatog., HPLC and methylation anal. 44% Of the oligosaccharides on the mol. are triantennary (35% 2,4-branched, 9% 2,6-branched), 34% are biantennary and 20% are tetraantennary complex type, all of which are core-fucosylated. Approx. 1% of the structures are **high mannose** type, in the form of Man6GlcNAc2, Man7GlcNAc2 and Man8GlcNAc2. The remaining 1% of the structures appear to be hybrid type. The complex structures contain varying nos. of sialic acid residues ranging from non- to fully sialylated. No N-acetylgalactosamine was detected in acid hydrolyzates of FK2P, consistent with a lack of serine/threonine-linked oligosaccharides. Sequence anal. of tryptic peptides prepared from purified FK2P revealed that only one of the two consensus sites for N-linked glycosylation on the mol. is utilized.
- ST tissue type plasminogen activator oligosaccharide structure
- IT Carbohydrates and Sugars, biological studies
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(of recombinant tissue-type plasminogen activator analog expressed in Chinese hamster ovary cells)
- IT Oligosaccharides
RL: PRP (Properties)
(N-linked, of recombinant tissue-type plasminogen activator analog expressed in Chinese hamster ovary cells, structure of)
- IT 66091-47-2D, mannosylated 78392-81-1D, sialylated 83412-55-9D, sialylated 84813-89-8D, sialylated 107688-07-3D, sialylated 112822-58-9D, sialylated
RL: BIOL (Biological study)
(of recombinant tissue-type plasminogen activator analog expressed in Chinese hamster ovary cells)
- IT 70-47-3, **Asparagine**, biological studies
RL: BIOL (Biological study)
(of recombinant tissue-type plasminogen activator analog position 320, expressed in Chinese hamster ovary cells, glycosylation of)
- IT 139639-23-9D, Tissue-type plasminogen activator, analog
RL: BIOL (Biological study)
(oligosaccharide of recombinant, expressed in Chinese hamster ovary cells, structure and attachment site of)
- IT 66091-47-2D, mannosylated
RL: BIOL (Biological study)
(of recombinant tissue-type plasminogen activator analog expressed in Chinese hamster ovary cells)
- RN 66091-47-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-


(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-
 (1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



IT 70-47-3, **Asparagine**, biological studies
 RL: BIOL (Biological study)
 (of recombinant tissue-type plasminogen activator analog position 320,
 expressed in Chinese hamster ovary cells, glycosylation of)
 RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1994:455685 HCAPLUS
 DN 121:55685
 ED Entered STN: 06 Aug 1994
 TI Interaction of Immobilized Recombinant Mouse C-Type Macrophage Lectin with Glycopeptides and Oligosaccharides
 AU Yamamoto, Kazuo; Ishida, Chizu; Shinohara, Yasuro; Hasegawa, Yukio; Konami, Yukiko; Osawa, Toshiaki; Irimura, Tatsuro
 CS Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo, 113, Japan
 SO Biochemistry (1994), 33(26), 8159-66
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English
 CC 15-6 (Immunochemistry)
 AB Inflammatory and tumoricidal macrophages express galactose- and N-acetylgalactosamine-specific Ca²⁺-dependent lectins on their surfaces. This lectin is a family member of membrane-bound C-type animal lectins and consists of 304 amino acid residues (mol. weight 34,595). Expression vectors containing a nucleotide sequence corresponding to the carbohydrate-binding domain of mouse macrophage lectin cDNA have been prepared. The carbohydrate-binding specificity of the recombinant macrophage lectin expressed in Escherichia coli was investigated by comparing elution profiles of various glycopeptides having defined carbohydrate structures on immobilized lectins. When elution profiles of **high mannose**-type and complex-type **Asn**-linked carbohydrate chains were compared, the degree of retardation from immobilized macrophage lectin column was in the order tetraantennary complex-type with terminal galactosyl residues > triantennary complex-type with terminal galactosyl residues > biantennary complex-type with terminal galactosyl residues > **high mannose**-type glycopeptides. N-Terminal octapeptides from human glycophorin A that bore three NeuAc α 2-3Gal β 1-3(NeuAc α 2-6)GalNAc serine/threonine-linked tetrasaccharide chains and their sequentially deglycosylated derivs. were also applied to this column. Glycopeptides carrying three constitutive GalNAc-Ser/Thr(Tn-antigen) had the strongest affinity, whereas those with fully sialylated carbohydrate tetrasaccharide chains showed weak interaction. The association kinetics of **Asn**-linked glycopeptides from bovine fetuin to recombinant macrophage lectin was determined by surface plasmon resonance spectroscopy. The results indicated a *k*_{assoc} value of 1.63 \times 10⁴ M⁻¹ s⁻¹. The calculated value for *K*_a was 6.20 \times 10⁷ M.
 ST macrophage lectin glycopeptide oligosaccharide
 IT Glycopeptides
 Oligosaccharides
 RL: BIOL (Biological study)
 (C-type lectins of macrophage interaction with)
 IT Macrophage
 (C-type lectins of, glycopeptides and oligosaccharides interaction with)
 IT Agglutinins and Lectins
 RL: BIOL (Biological study)
 (C-type, of macrophage, glycopeptides and oligosaccharides interaction with)
 IT Fetuins
 RL: BIOL (Biological study)
 (asialo-, conjugates, with glycopeptides, C-type lectins of macrophage interaction with)
 IT 71496-53-2 78392-81-1 82867-73-0 82867-74-1 107691-47-4
 110402-16-9 111945-05-2 156097-18-6 156097-19-7 **156097-20-0**
 156257-73-7
 RL: BIOL (Biological study)
 (C-type lectins of macrophage interaction with)
 IT **156097-20-0**
 RL: BIOL (Biological study)


(C-type lectins of macrophage interaction with)

RN 156097-20-0 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L91 ANSWER 9 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:99742 HCAPLUS
 DN 120:99742
 ED Entered STN: 05 Mar 1994
 TI Role of intramolecular **high-mannose** chains in the folding and assembly of soybean (Glycine max) lectin polypeptides: Studies by the combined use of spectroscopy and gel-filtration size analysis
 AU Nagai, Kaoru; Shibata, Keiichi; Yamaguchi, Haruki
 CS Coll. Agric., Univ. Osaka Prefect., Sakai, 593, Japan
 SO Journal of Biochemistry (Tokyo, Japan) (1993), 114(6), 830-4
 CODEN: JOBIAO; ISSN: 0021-924X
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB It was previously reported [Nagai, K. & Yamaguchi, H. (1993) J. Biochem. 113, 123-125] that intramol. **high-mannose** chains are essential for reconstitution of soybean lectin from denatured subunits. To obtain more detailed information on the role of the intramol. **high-mannose** chains in the folding and assembly of soybean lectin polypeptides, the effects of **asparagine**-linked oligosaccharides, Man9GlcNAc2Asn (M9-Asn) and Glc1-3Man9GlcNAc2Asn (GM9-Asn), on the reconstitution of soybean lectin from denatured subunits were examined by comparison with a denaturation features of the lectin with varying concns. of guanidine hydrochloride. The combined use of spectroscopy and size-anal. by gel filtration revealed that both the folding and assembly of denatured subunit anal. polypeptides were completely prevented in the presence of 300 μ M M9-Asn, whereas the same concentration of GM9-Asn only interfered with the polypeptide assembly, exhibiting no significant effect on the polypeptide folding. These results, considered together with those in the previous report, indicate that the sugar branch Man α 1-2Man- α 1-2Man linked to the 3 position of the β -mannosyl residue of the **high-mannose** chains functions in the folding of the subunit polypeptides, and that other branches participate in the subunit assembly.
 ST lectin mannose oligosaccharide requirement structure soybean; conformation
 lectin mannose oligosaccharide requirement soybean; subunit assembly
 lectin mannose oligosaccharide soybean
 IT Agglutinins and Lectins
 RL: BIOL (Biological study)
 (high-mannose **asparagine**-linked oligosaccharides requirement for folding and assembly of subunits of,

of soybean)

IT Soybean
(lectin of, folding and subunits assembly)

IT Conformation and Conformers
(of lectin, of soybean, **asparagine**-linked **high-mannose** oligosaccharides requirement for folding of)

IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, **asparagine**-linked, soybean lectin folding and subunits assembly requirement for)

IT Molecular association
(self-, of lectin subunits, of soybean, **asparagine**-linked **high-mannose** oligosaccharides requirement for assembly of)

IT **71246-55-4**
RL: BIOL (Biological study)
(**asparagine**-linked, soybean lectin folding and subunits assembly requirement for)

IT **71246-55-4D**, glucosylated
RL: BIOL (Biological study)
(**asparagine**-linked, soybean lectin folding and subunits assembly requirement for, of soybean)


IT **71246-55-4**
RL: BIOL (Biological study)
(**asparagine**-linked, soybean lectin folding and subunits assembly requirement for)

RN **71246-55-4** HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




IT 71246-55-4D, glucosylated
 RL: BIOL (Biological study)
 (asparagine-linked, soybean lectin folding and subunits
 assembly requirement for, of soybean)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-
 mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-
 (1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-
 mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-
 β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 10 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:52320 HCAPLUS
 DN 120:52320
 ED Entered STN: 05 Feb 1994
 TI Development of neoglycoproteins conjugated with natural oligosaccharides through carboxyl residues of proteins and its application to recombinant human interleukin 1
 AU Ishihara, Hideko; Chiba, Taku; Takeuchi, Akihiko; Hayashi, Hidetoshi; Takei, Yutaka; Takii, Takemasa; Onozaki, Kikuo
 CS Coll. Nursing, Mizuho, Nagoya City Univ., Nagoya, 467, Japan
 SO Biochemistry and Molecular Biology International (1993), 31(3), 527-35
 CODEN: BMBIES; ISSN: 1039-9712
 DT Journal
 LA English
 CC 15-5 (Immunochemistry)
 AB In order to develop glycosylated cytokines, neoglycoproteins were synthesized utilizing naturally occurring oligosaccharides. **High mannose type oligosaccharide-asparagine (Asn)** s, containing Man8GN2-Asn, Man7GN2-Asn and Man6GN2-Asn, were obtained from quail ovalbumin and were coupled to bovine serum albumin (BSA) by carbodiimide-mediated coupling. Major reaction occurred between amino residues of oligosaccharide-**Asns** and carboxyl residues of BSA. Approx. one mol. of oligosaccharides-**Asns** was coupled to each mol. of BSA with 50% yield of glycosylation. Among the oligosaccharides, Man6GN2-Asn appeared to be conjugated predominantly. While this strategy was applied to

recombinant human interleukin 1 α (IL-1 α), three mols. of oligosaccharide-Asns were introduced into each mol. of IL-1 with 10% yield of glycosylation.

- ST synthetic neoglycoprotein prepn interleukin 1 glycosylation
- IT Acetylation
(of oligosaccharide-asparagine conjugates)
- IT Glycosidation
(of recombinant interleukin-1 α , by reaction with oligosaccharides)
- IT Lymphokines and Cytokines
RL: PREP (Preparation)
(interleukin 1 α , preparation of glycosylated, from recombinant mol., by reaction with oligosaccharides)
- IT Oligosaccharides
RL: RCT (Reactant); RACT (Reactant or reagent)
(mannose-containing, reaction of, in glycosylation of recombinant interleukin-1 α and other proteins)
- IT Glycoproteins, specific or class
RL: PREP (Preparation)
(neo-, preparation of, glycosylated recombinant interleukin 1 and other proteins as)
- IT 25952-53-8, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
RL: BIOL (Biological study)
(in glycosylation of interleukin-1 and other proteins with oligosaccharides)
- IT 77036-51-2 77355-54-5 84182-22-9
RL: BIOL (Biological study)
(interleukin-1 and other proteins glycosylation with)
- IT 77036-51-2 77355-54-5 84182-22-9
RL: BIOL (Biological study)
(interleukin-1 and other proteins glycosylation with)
- RN 77036-51-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 84182-22-9 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L91 ANSWER 11 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:48469 HCAPLUS
 DN 120:48469
 ED Entered STN: 05 Feb 1994
 TI The carbohydrate structures of *Trypanosoma brucei* brucei MITat 1.6 variant surface glycoprotein. A re-investigation of the C-terminal glycan
 AU Strang, Anne Marie; Allen, Anthony K.; Holder, Anthony A.; van Halbeek, Herman
 CS Complex Carbohydr. Res. Cent., Univ. Georgia, Athens, GA, 30602-4712, USA
 SO Biochemical and Biophysical Research Communications (1993), 196(3), 1430-9
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal
 LA English
 CC 6-4 (General Biochemistry)
 AB The authors have studied the oligosaccharide chains of the variant surface glycoprotein (VSG) of *Trypanosoma brucei* brucei MITat 1.6. Glycopeptides were generated by Pronase digestion, purified by gel permeation and ion-exchange chromatog., and structurally characterized by ¹H and ³¹P NMR spectroscopy in combination with chemical composition anal. The two glycopeptide

fractions obtained each proved to be homogeneous in their peptide and heterogeneous in their carbohydrate structures. The fraction representing the "internal" N-glycosylation site of the BSG was found to contain **high-mannose** type oligosaccharides with structures Man7-9GlcNAc2 linked to Asn-Ala-Thr. The other glycopeptide fraction contained the membrane-anchoring C-terminal glycan of the VSG attached to Asp. Its oligosaccharide structures are of the glycosylphosphatidylinositol (GPI) type.


- ST Trypanosoma surface glycoprotein carbohydrate structure
 IT Trypanosoma brucei brucei
 (carbohydrate structures of MITat 1.6 variant surface glycoprotein of)
 IT Carbohydrates and Sugars, biological studies
 RL: BIOL (Biological study)
 (of MITat 1.6 variant surface glycoprotein of Trypanosoma brucei
 brucei, structure of)
 IT Glycolipoproteins
 RL: BIOL (Biological study)
 (VSG, of Trypanosoma brucei brucei, structure of carbohydrate of)
 IT **84182-22-9D**, mannosylated 152159-09-6D, galactosylated
 RL: BIOL (Biological study)
 (of MITat 1.6 variant surface glycoprotein of Trypanosoma brucei
 brucei, structure of)
 IT **84182-22-9D**, mannosylated
 RL: BIOL (Biological study)
 (of MITat 1.6 variant surface glycoprotein of Trypanosoma brucei
 brucei, structure of)
 RN 84182-22-9 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 12 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:598059 HCAPLUS
 DN 119:198059
 ED Entered STN: 13 Nov 1993
 TI Site-specific N-glycosylation and oligosaccharide structures of
 recombinant HIV-1 gp120 derived from a baculovirus expression system
 AU Yeh, Jiunn-Chern; Seals, Jonathan R.; Murphy, Cheryl I.; van Halbeek,
 Herman; Cummings, Richard D.
 CS Health Sci. Cent., Univ. Oklahoma, Oklahoma City, OK, 73190, USA
 SO Biochemistry (1993), 32(41), 11087-99
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English
 CC 6-4 (General Biochemistry)
 Section cross-reference(s): 33
 AB The authors report the complete structures of the N-linked
 oligosaccharides and the site-specificity of the N-glycosylation of
 recombinant gp120 (rgp120) of the HIV-1 BH8 isolate produced by a
 baculovirus expression system. Glycopeptides derived from the tryptic
 digests of intact rgp 120 or of cyanogen bromide-generated fragments of
 rgp120 were isolated by their binding to Con A-Sepharose and were purified
 by reversed-phase HPLC. The isolated glycopeptides were treated with
 PNGase F, releasing the carbohydrate moiety while converting **Asn**
 to Asp, and identified by amino acid anal. and/or peptide sequencing. The
 authors' results indicate that all 22 potential N-glycosylation sites in
 the rgp120 sequence are utilized. The authors did not detect
 N-acetylgalactosamine in rgp120, indicating that the glycoprotein lacks
 typical O-linked oligosaccharides. To investigate the oligosaccharide
 structures at the sites of glycosylation, the authors determined the
 carbohydrate composition for each site and characterized the oligosaccharides
 by 1H-NMR spectroscopy and by oligosaccharide mapping using high pH
 anion-exchange chromatog. Mannose and N-acetylglucosamine were the only
 sugars observed in the intact rgp120 and likewise in individual
 glycopeptides. All glycopeptides derived from rgp120 contained
high mannose-type N-linked oligosaccharides, ranging
 from GlcNAc2Man5 to GlcNAc2Man9. However, different glycosylation sites
 showed varied degrees of processing of the **high mannose**
 -type oligosaccharides, as characterized by the ratio of GlcNAc2Man8-9 to
 GlcNAc2Man5-7. These results demonstrate that N-glycosylation of rgp120
 in the baculovirus expression system occurs at all potential sites and is
 site specific in terms of oligosaccharide structures.
 ST HIV1 gp120 glycoprotein recombinant mannose oligosaccharide; glycosylation
 gp120 glycoprotein recombinant HIV1
 IT Glycosidation
 (of gp120 glycoprotein recombinant form of HIV-1 virus,
 site-specificity of)

IT Carbohydrates and Sugars, biological studies
 RL: BIOL (Biological study)
 (of gp120 glycoproteins recombinant form, of HIV-1 virus)

IT Sialoglycoproteins
 RL: BIOL (Biological study)
 (gp120env, oligosaccharides structure and site-specific glycosylation
 of recombinant, of HIV-1 virus)

IT Virus, animal
 (human immunodeficiency 1, gp120 glycoprotein recombinant form of,
 oligosaccharide structure and site-specific glycosylation of)

IT Oligosaccharides
 RL: BIOL (Biological study)
 (mannose-containing, of gp120 glycoprotein recombinant form, of HIV-1
 virus, structure and site-specific processing of)

IT 71246-55-4
 RL: PROC (Process)
 (of gp120 glycoprotein recombinant form, of HIV-1 virus, site-specific
 processing of)


IT 71246-55-4
 RL: PROC (Process)
 (of gp120 glycoprotein recombinant form, of HIV-1 virus, site-specific
 processing of)

RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-
 mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-
 α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-
 (1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-
 mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-
 β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-
 glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 13 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:466091 HCAPLUS
 DN 119:66091
 ED Entered STN: 21 Aug 1993
 TI Structural study of the sugar chains of CD36 purified from bovine mammary epithelial cells: Occurrence of novel hybrid-type sugar chains containing the Neu5Ac α 2 \rightarrow 6GalNAc β 1 \rightarrow 4GlcNAc and the Man α 1 \rightarrow 2Man α 1 \rightarrow 3Man α 1 \rightarrow 6Man groups
 AU Nakata, Noboru; Furukawa, Kiyoshi; Greenwalt, Dale E.; Sato, Takeshi; Kobata, Akira
 CS Inst. Med. Sci., Univ. Tokyo, Tokyo, 108, Japan
 SO Biochemistry (1993), 32(16), 4369-83
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English
 CC 6-4 (General Biochemistry)
 Section cross-reference(s): 13
 AB CD36 is a glycoprotein included in the bovine milk fat globule membrane derived from mammary secretory epithelial cells during lactation. Asparagine-linked sugar chains were quant. released from CD36 as oligosaccharides by hydrazinolysis. These sugar chains were converted to radioactive oligosaccharides by reduction with NaB₃H₄ and separated into neutral and acidic fractions by paper electrophoresis. Most of the acidic oligosaccharides were converted to neutral ones by sialidase digestion, indicating that they are sialyl derivs. The neutral and sialidase-treated acidic oligosaccharides were fractionated by Bio-Gel P-4 column chromatog. in combination with serial chromatog. on immobilized lectin columns

including a Wistaria floribunda agglutinin (WFA)-agarose column. WFA is known to bind oligosaccharides terminating with either an α - or β -N-acetylgalactosamine residue. Structural studies of oligosaccharides in each fraction by sequential exoglycosidase digestion as well as methylation anal. revealed that CD36 contains **high mannose**-type, hybrid-type, and bi-, tri-, and tetraantennary complex-type sugar chains. A portion of the hybrid-type and the complex-type sugar chains which bound to a WFA-agarose column (28% of all oligosaccharides) contained the GalNAc β 1 \rightarrow 4GlcNAc group(s) instead of the GalNAc group(s) in their outer chain moieties. Like oligosaccharides found in human LH (Weisshaar, G., et al., 1991), some of the GalNAc β 1 \rightarrow 4GlcNAc groups found in the CD36 oligosaccharides were sialylated as the Neu5Ac α 2 \rightarrow 6GalNAc group. Furthermore, most of the hybrid-type sugar chains of CD36 with the Gal/GalNAc β 1 \rightarrow 4GlcNAc β 1 \rightarrow 2 outer chain on their Man α 1 \rightarrow 3 arm contained an unusual Man α 1 \rightarrow 2Man α 1 \rightarrow 3 group on their Man α 1 \rightarrow 6 arm.


- ST oligosaccharide glycoprotein CD36 mammary epithelium; glycoprotein IIIB
oligosaccharide mammary epithelium
- IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(IIIB, oligosaccharides of, of milk fat globule membrane, structure of)
- IT Oligosaccharides
RL: BIOL (Biological study)
(N-linked, of glycoprotein CD36 of mammary epithelium, structure of)
- IT Mammary gland
(epithelium, glycoprotein CD36 of, oligosaccharides of, structure of)
- IT Oligosaccharides
RL: BIOL (Biological study)
(sialo-, N-linked, of glycoprotein CD36 of mammary epithelium, structure of)
- IT **66091-47-2D**, mannosylated 71496-53-2 78392-81-1 111929-14-7
111937-74-7 111945-05-2 111962-72-2 112822-58-9 121123-35-1
121123-39-5 132908-01-1 148556-13-2 148556-14-3 148614-73-7
148615-17-2 148615-18-3 148615-21-8 148615-22-9 148682-81-9
148682-82-0 148682-83-1 148682-84-2 148682-85-3 148892-76-6
148892-77-7 148892-78-8 148892-94-8 148913-52-4 148913-53-5
RL: BIOL (Biological study)
(of glycoprotein CD36, of mammary epithelium)
- IT **66091-47-2D**, mannosylated
RL: BIOL (Biological study)
(of glycoprotein CD36, of mammary epithelium)
- RN 66091-47-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L91 ANSWER 14 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:403677 HCAPLUS
 DN 119:3677
 ED Entered STN: 10 Jul 1993
 TI Effect of substrate structure on the activity of Man9-mannosidase from pig liver involved in N-linked oligosaccharide processing
 AU Bause, Ernst; Breuer, Wilhelm; Schweden, Juergen; Roeser, Rainer; Geyer, Rudolf
 CS Inst. Physiol. Chem., Bonn, W-5300/1, Germany
 SO European Journal of Biochemistry (1992), 208(2), 451-7
 CODEN: EJBICAI; ISSN: 0014-2956
 DT Journal
 LA English
 CC 7-3 (Enzymes)
 AB Man9-mannosidase, an α 1,2-specific enzyme located in the endoplasmic reticulum and involved in N-linked-oligosaccharide processing, has been isolated from crude pig-liver microsomes and its substrate specificity studied using a variety of free and peptide-bound **high-mannose** oligosaccharide derivs. The purified enzyme displays no activity toward synthetic α -mannosides, but removes three

α 1,2-mannose residues from the natural Man9-(GlcNAc)₂ substrate (M9). The α 1,2-mannosidic linkage remaining in the M6 intermediate is cleaved about 40-fold more slowly. Similar kinetics of hydrolysis were determined with Man9-(GlcNAc)₂ N-glycosidically attached to the hexapeptide Tyr-Asn-Lys-Thr-Ser-Val (GP-M9), indicating that the specificity of the enzyme is not influenced by the peptide moiety of the substrate. The α 1,2-mannose residue which is largely resistant to hydrolysis, was found to be attached in both the M6 and GP-M6 intermediate to the α 1,3-mannose of the peripheral α 1,3/ α 1,6-branch of the glycan chain. Studies with glycopeptides varying in the size and branching pattern of the sugar chains, revealed that the relative rates at which the various α 1,2-mannosidic linkages were cleaved, differed depending on their structural complexity. This suggests that distinct sugar residues in the aglycon moiety may be functional in substrate recognition and binding. Reduction or removal of the terminal GlcNAc residue of the chitobiose unit in M9 increased the hydrolytic susceptibility of the fourth (previously resistant) α 1,2-mannosidic linkage significantly. It was concluded from this observation that, in addition to peripheral mannose residues, the intact chitobiose core represents a structural element affecting Man9-mannosidase specificity. A possible biol. role of the enzyme during N-linked-oligosaccharide processing is discussed.


- ST liver mannosidase specificity oligosaccharide chitobiose core
 IT Liver, composition
 (mannosidase of endoplasmic reticulum of, substrate specificity of, chitobiose core in)
 IT Endoplasmic reticulum
 (mannosidase of, of liver, substrate specificity of, chitobiose core in)
 IT Kinetics, enzymic
 (of mannosidase, of liver for mannooligosaccharides and glycopeptides)
 IT Glycopeptides
 Oligosaccharides
 RL: BIOL (Biological study)
 (mannose-containing, mannosidase of liver endoplasmic reticulum specificity for, chitobiose core in)
 IT Molecular structure-biological activity relationship
 (mannosidase substrate, of mannose-containing oligosaccharides and glycopeptides)
 IT 69775-84-4 71246-55-4 83562-97-4 144644-29-1 144644-30-4
 144644-31-5 144671-62-5 144671-63-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with mannosidase of liver endoplasmic reticulum, kinetics of, structure in relation to)
 IT 9068-25-1, α -1,2-Mannosidase
 RL: BIOL (Biological study)
 (substrate specificity of, of liver endoplasmic reticulum, chitobiose core in)
 IT 71246-55-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with mannosidase of liver endoplasmic reticulum, kinetics of, structure in relation to)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 15 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:228517 HCAPLUS
 DN 118:228517
 ED Entered STN: 12 Jun 1993
 TI Direct demonstration of the essential role of the intramolecular
high-mannose oligosaccharide chains in the folding and
 assembly of soybean (Glycine max) lectin polypeptides
 AU Nagai, Kaoru; Yamaguchi, Haruki
 CS Coll. Agric., Univ. Osaka Prefect., Sakai, 593, Japan
 SO Journal of Biochemistry (Tokyo, Japan) (1993), 113(2), 123-5
 CODEN: JOBIAO; ISSN: 0021-924X
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB The role of the intramol. **high-mannose** oligosaccharide
 chains in the folding and assembly of soybean lectin polypeptides was
 investigated. Soybean lectin, dissociated into subunits and completely
 denatured in 6M guanidine hydrochloride, was quant. reconstituted to the
 active tetrameric structure by simple dilution. However, neither the activity
 nor the tetrameric structure was regained in the presence of 100 µM of
 an **asparagine**-linked oligosaccharide, ManGlcNAc2Asn, having the
 same structure as that of the sugar chains of soybean lectin. Besides,
 the same concentration of this glycopeptide even dissociated, although only
 gradually, the native lectin into subunits. On the other hand, the
 deglycosylated subunits had no ability to regain the activity or the
 tetrameric structure. The present study provided for the first time
 direct evidence of the essential role of the intramol. **high-**
mannose oligosaccharide chains in the proper folding and assembly
 of glycopolypeptides.
 ST soybean lectin folding assembly oligosaccharide
 IT Soybean
 (lectin of, folding and subunit assembly of, **high-**
mannose oligosaccharide chains role in)
 IT Quaternary structure
 (of soybean lectin, assembly of, **high-mannose**
 oligosaccharide chains role in)
 IT Conformation and Conformers
 (of soybean lectin, folding of, **high-mannose**
 oligosaccharide chains role in)
 IT Agglutinins and Lectins
 RL: BIOL (Biological study)
 (of soybean, folding and subunit assembly of, **high-**
mannose oligosaccharide chains role in)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (mannose-containing, of soybean lectin, folding and subunit assembly
 requirement for)
 IT 71246-55-4
 RL: BIOL (Biological study)
 (of soybean lectin, folding and subunit assembly requirement for)
 IT 71246-55-4
 RL: BIOL (Biological study)
 (of soybean lectin, folding and subunit assembly requirement for)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O-α-D-mannopyranosyl-(1→2)-O-α-D-
 mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→2)-
 α-D-mannopyranosyl-(1→6)]-O-α-D-mannopyranosyl-
 (1→6)-O-[O-α-D-mannopyranosyl-(1→2)-O-α-D-
 mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)]-O-
 β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX


NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



L91 ANSWER 16 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:167052 HCAPLUS
 DN 118:167052
 ED Entered STN: 01 May 1993
 TI Characterization of recombinant murine interleukin 5 expressed in Chinese hamster ovary cells
 AU Kodama, Shiho; Endo, Tamao; Tsujimoto, Masafumi; Kobata, Akira
 CS Suntory Inst. Biomed. Res., Osaka, 618, Japan
 SO Glycobiology (1992), 2(5), 419-27
 CODEN: GLYCE3; ISSN: 0959-6658
 DT Journal
 LA English
 CC 15-5 (Immunochemistry)
 AB The authors purified recombinant murine interleukin 5 (rmIL-5) from the supernatant of Chinese hamster ovary cells. Each peptide fragment of the purified rmIL-5 generated by Achromobacter protease I digestion was characterized and glycosylation sites were determined. Although rmIL-5 contains 3 potential sites of N-linked glycosylation (**Asn**-26, **Asn**-55, and **Asn**-69), **Asn**-69 is not glycosylated. The oligosaccharides released from the protein by hydrazinolysis were fractionated by paper electrophoresis, lectin column chromatog., and gel permeation chromatog., and their structures were analyzed by sequential exoglycosidase digestion in combination with methylation anal. The results indicated that they are a mixture of bi-, tri-, and tetraantennary complex-type sugar chains with and without a fucose at the C-6 position of the proximal N-acetylglucosamine residue and **high-mannose**-type sugar chains. Although >80% of the sugar chains are neutral oligosaccharides similar to recombinant human IL-5, rmIL-5 has more tetraantennary oligosaccharides than rhIL-5. A site differential study revealed that **Asn**-55 has more tetraantennary oligosaccharides than **Asn**-26.
 ST mouse interleukin 5 oligosaccharide
 IT Mouse
 (interleukin-5 of, recombinant, from Chinese hamster ovary cells, oligosaccharides of)
 IT Glycosidation
 (of recombinant interleukin-5 of mouse from CHO cell line, sites for)
 IT Protein sequences
 (of recombinant interleukin-5 of mouse, glycosylation sites and oligosaccharides in relation to)
 IT Animal cell line
 (CHO, interleukin-5 of mouse from, oligosaccharides of, characterization of)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (branched, **high-mannose**, N-linked, of recombinant interleukin-5 of mouse, from Chinese hamster ovary cells)
 IT Oligosaccharides
 RL: BIOL (Biological study)

- (fucose-containing, of recombinant interleukin-5 of mouse, from Chinese hamster ovary cells)
- IT Oligosaccharides
 RL: BIOL (Biological study)
 (galactosyl-terminated, branched, of recombinant interleukin-5 of mouse, from Chinese hamster ovary cells)
- IT Lymphokines and Cytokines
 RL: BIOL (Biological study)
 (interleukin 5, oligosaccharides of recombinant mouse, from Chinese hamster ovary cells)
- IT 70-47-3, **Asparagine**, biological studies
 RL: BIOL (Biological study)
 (as residue 26 and 55 of recombinant interleukin-5 of mouse, oligosaccharide linked to, from CHO cell line)
- IT 71496-53-2 77355-54-5 77449-92-4 78392-81-1
 83412-55-9 84813-89-8 93445-86-4 107688-07-3
 RL: BIOL (Biological study)
 (of recombinant interleukin-5 of mouse from CHO cell line)
- IT 70-47-3, **Asparagine**, biological studies
 RL: BIOL (Biological study)
 (as residue 26 and 55 of recombinant interleukin-5 of mouse, oligosaccharide linked to, from CHO cell line)
- RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)


Absolute stereochemistry.




- IT 77355-54-5 77449-92-4
 RL: BIOL (Biological study)
 (of recombinant interleukin-5 of mouse from CHO cell line)
- RN 77355-54-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 77449-92-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, mono- α -D-mannopyranoside (9CI) (CA INDEX NAME)

CM 1



CRN 77355-54-5
 CMF C52 H88 N2 O41

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 7296-15-3
CMF C6 H12 O6

Absolute stereochemistry.



AN 1993:37452 HCAPLUS
DN 118:37452
ED Entered STN: 03 Feb 1993
TI Role of target cell glycoproteins in sensitivity to natural killer cell lysis
AU Ahrens, Patricia B.
CS Dep. Biochem., Med. Coll. Wisconsin, Milwaukee, WI, 53226, USA
SO Journal of Biological Chemistry (1993), 268(1), 385-91
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA English
CC 15-10 (Immunochemistry)
AB Natural killer cells select targets for lysis based on target cell glycoproteins. Compared to controls, K-562 cells treated with kifunensine, an inhibitor of Golgi mannosidase I, accumulate more **high mannose**-type **asparagine**-linked oligosaccharide, Man9GlcNAc2, and bind more Con A, and oligomannosyl binding lectin. In addition, natural killer cell lysis of kifunensine-treated cells increases 34% over that of controls. Increased sensitivity to lysis occurs after treatment with other N-glycan processing inhibitors that promote accumulation of **high mannose**-type glycosides (deoxymannojirimycin and swainsonine). In addition, kifunensine-treated cells form more effector:target conjugates. Monoclonal antibodies to the adhesion mol. LFA-1 and its ligand ICAM-1 reduce lysis of control targets but are less effective in blocking lysis of kifunensine-treated cells. K-562 cells bind anti-ICAM-1 but not anti-LFA-1, and this binding does not change after kifunensine treatment. These data demonstrate conclusively a role for **asparagine**-linked oligosaccharides in the human natural killer cell:target interaction. The presence of **high mannose**-type glycans on K-562 cells correlates with increased binding of effectors and a greater susceptibility to lysis. Thus, target cell N-glycosides influence the NK-target interaction mediated by adhesion mols. such as ICAM-1.
ST target glycoprotein natural killer cytotoxicity
IT Cytotoxicity
(natural killer cell-mediated, sensitivity to, target cell glycoproteins role in)
IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(ICAM-1 (intercellular adhesion mol. 1), target cell glycoproteins role in sensitivity to natural killer cell-mediated cytotoxicity in relation to)
IT Integrins
RL: BIOL (Biological study)
(antigens LFA-1, target cell glycoproteins role in sensitivity to natural killer cell-mediated cytotoxicity in relation to)
IT Glycoproteins, specific or class
RL: BIOL (Biological study)
(mannose-containing, in target cell sensitivity to natural killer cell-mediated cytotoxicity)
IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, N-linked, in target cell sensitivity to natural killer cell-mediated cytotoxicity)
IT Lymphocyte
(natural killer cell, cytotoxicity by, sensitivity to, target cell glycoproteins role in)
IT 71246-55-4
RL: BIOL (Biological study)
(in target cell sensitivity to natural killer cell-mediated cytotoxicity)
IT 70-47-3, **Asparagine**, biological studies
RL: BIOL (Biological study)
(mannose-rich oligosaccharides linked to, in target cell sensitivity to

natural killer cell-mediated cytotoxicity)

IT 71246-55-4

RL: BIOL (Biological study)


(in target cell sensitivity to natural killer cell-mediated cytotoxicity)

RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A

IT 70-47-3, **Asparagine**, biological studies


RL: BIOL (Biological study)

(mannose-rich oligosaccharides linked to, in target cell sensitivity to natural killer cell-mediated cytotoxicity)

RN 70-47-3 HCAPLUS

CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L91 ANSWER 18 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:566202 HCAPLUS

DN 117:166202

ED Entered STN: 01 Nov 1992

TI Detailed structural analysis of **asparagine**-linked oligosaccharides of the nicotinic acetylcholine receptor from *Torpedo californica*

AU Shoji, Hiroki; Takahashi, Noriko; Nomoto, Hiroshi; Ishikawa, Masami; Shimada, Ichio; Arata, Yoji; Hayashi, Kyoza

CS Dep. Mol. Biol., Gifu Pharm. Univ., Gifu, 502, Japan

SO European Journal of Biochemistry (1992), 207(2), 631-41

CODEN: EJBCAI; ISSN: 0014-2956


DT Journal
 LA English
 CC 6-4 (General Biochemistry)
 Section cross-reference(s): 33
 AB The structures of the major oligosaccharide moieties of the nicotinic acetylcholine receptor (AcChoR) protein from *T. californica* have been reported (Nomoto, H. et al., 1986) to be **high-mannose** types. Here detailed analyses of the structures of the remaining oligosaccharides in this receptor are reported. The sialylated oligosaccharides released by glycopeptidase (almond) digestion were separated according to the number of sialic acid residues using high-performance anion-exchange chromatog. with pulsed amperometric detection. After removal of sialic acid from each fraction, the resulting neutral oligosaccharides were sep. pyridylaminated and were analyzed by a combination of sequential exoglycosidase digestion and HPLC, then identified on a two-dimensional sugar map. The structures of two desialylated pyridylamino-oligosaccharides were further analyzed by high-resolution proton NMR. Each oligosaccharide was composed of species containing varying nos. of sialic acids. The desialylated complex-type oligosaccharides of AcChoR consisted of ten, eight and one different biantennary, triantennary and tetraantennary oligosaccharide, resp. The biantennary oligosaccharides were divided into two groups; oligosaccharides with fucose at the proximal N-acetylglucosamine (six varieties) and oligosaccharides without fucose (four varieties). Each group consisted of species differing in the number of terminal galactose residues. The major component of the biantennary oligosaccharides had two galactose residues at the non-reducing termini. The terminal α -galactose residue(s) linked to C3 of β -galactose were found in the fucose-containing biantennary oligosaccharides (two varieties). The triantennary oligosaccharides were also divided into two groups; oligosaccharides with (four varieties) and without (four varieties) bisecting N-acetylglucosamine. These groups were composed of species differing in the number of terminal galactose residues. The major component of the triantennary oligosaccharides was fully galactosylated with three galactose residues. An unusual group, Gal β 1-3GlcNAc, was present in low levels in the triantennary oligosaccharides. In contrast, the tetraantennary oligosaccharide was composed of only one species, which is fully galactosylated with four galactose residues.

ST Torpedo nicotinic acetylcholine receptor oligosaccharide
 IT Torpedo californica
 (nicotinic acetylcholine receptor of, **asparagine**-linked oligosaccharides of, structure of)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of nicotinic acetylcholine receptor, of Torpedo californica, structure of **asparagine**-linked)
 IT Receptors
 RL: BIOL (Biological study)
 (nicotinic, **asparagine**-linked oligosaccharides of, of Torpedo californica, structure of)
 IT 66091-47-2 71246-55-4 71496-53-2 77036-51-2
 77355-54-5 78392-81-1 82867-73-0 82867-74-1 83419-14-1
 84807-99-8 84808-02-6 84825-26-3 84825-29-6 85394-22-5
 85394-27-0 92344-08-6 103584-68-5 107676-46-0 109050-95-5
 110402-12-5 111059-47-3 143501-93-3 143516-20-5
 RL: BIOL (Biological study)
 (of nicotinic acetylcholine receptor, of Torpedo californica, structure of)
 IT 66091-47-2 71246-55-4 77036-51-2
 77355-54-5
 RL: BIOL (Biological study)
 (of nicotinic acetylcholine receptor, of Torpedo californica, structure of)


RN 66091-47-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 19 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:465340 HCAPLUS
 DN 117:65340
 ED Entered STN: 23 Aug 1992
 TI Structures of sugar chains of the subunits of an α -amylase inhibitor
 from Phaseolus vulgaris white kidney beans
 AU Yamaguchi, Haruki; Funaoka, Hiroyuki; Iwamoto, Hiroyuki
 CS Coll. Agric., Univ. Osaka Prefect., Sakai; 591, Japan
 SO Journal of Biochemistry (Tokyo, Japan) (1992), 111(3), 388-95
 CODEN: JOBIAO; ISSN: 0021-924X
 DT Journal
 LA English
 CC 7-3 (Enzymes)
 Section cross-reference(s): 33
 AB The structures of asparagine-linked oligosaccharides in the
 subunits of an α -amylase inhibitor from the white kidney bean (*P.*
vulgaris) were determined. Glycopeptides obtained from each subunit were
 treated with hydrazine, then N-acetylated. The oligosaccharides thus
 liberated were labeled with 2-aminopyridine at their reducing ends and
 purified by gel-permeation, reverse-phase, and size-fractionation HPLC.
 The structures of seven oligosaccharides from the α -subunit and
 eight oligosaccharides from the β -subunit were determined by a combination
 of composition and mol. size analyses, exo- and endoglycosidase digestions,
 partial acetolysis, and ¹H NMR spectroscopy. The major glycan chains in
 the α -subunit were Man α 1-6(Man α 1-3)Man α 1-
 6(Man α 1-2Man α 1-3)-Man β 1-4GlcNAc β 1-4GlcNAc and
 (Man α 1-2)Man α 1-6(Man α 1-2Man α 1-3)Man α 1-6(Man-
 α 1-2Man α 1-2Man α 1-3)Man β 1-4GlcNAc β 1-4GlcNAc,
 while a glycan chain Man α 1-6(Man- α 1-3)(Xyl β 1-2)Man β 1-
 4GlcNAc β 1-4GlcNAc comprised more than 70% of the sugar moiety of the
 β -subunit.
 ST amylase inhibitor subunit oligosaccharide structure Phaseolus; white
 kidney bean amylase inhibitor oligosaccharide; kidney bean amylase
 inhibitor oligosaccharide structure
 IT Bean
 (amylase inhibitor of, oligosaccharide structure of subunits of)
 IT Carbohydrates and Sugars, biological studies
 RL: BIOL (Biological study)
 (of amylase inhibitor subunits of white kidney bean)
 IT Glycoproteins, specific or class
 RL: BIOL (Biological study)
 (amylase-inhibiting, PHA-I, oligosaccharides of α and β
 subunits, of white kidney bean, structure of N-linked)
 IT Oligosaccharides
 RL: PRP (Properties)
 (branched, **high-mannose**, N-linked, structure of, of
 amylase inhibitor α and β subunits of white kidney bean)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (branched, **high-mannose**, xylose-containing, N-linked,
 structure of, of amylase inhibitor α and β subunits of white
 kidney bean)
 IT 9000-90-2, α -Amylase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, oligosaccharide structure of, of white kidney bean)
 IT 66091-47-2 71246-55-4 77036-51-2
 77355-54-5 83178-05-6 110037-52-0 116173-22-9
 RL: BIOL (Biological study)
 (of amylase inhibitor α and β subunits of white kidney bean)
 IT 70858-45-6
 RL: BIOL (Biological study)
 (of amylase inhibitor β subunit of white kidney bean)

IT 66091-47-2 71246-55-4 77036-51-2

77355-54-5 83178-05-6

RL: BIOL (Biological study)


(of amylase inhibitor α and β subunits of white kidney bean)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 77036-51-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 77355-54-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 83178-05-6 HCAPLUS
 CN D-Glucose, . O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 70858-45-6


RL: BIOL (Biological study)

(of amylase inhibitor β subunit of white kidney bean)

RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L91 ANSWER 20 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:56946 HCAPLUS

DN 116:56946

ED Entered STN: 21 Feb 1992

TI Structural study of the sugar moieties of monoclonal antibodies secreted by human-mouse hybridoma

AU Tandai, Megumi; Endo, Tamao; Sasaki, Satoshi; Masuho, Yasuhiko; Kochibe, Naohisa; Kobata, Akira

CS Inst. Med. Sci., Univ. Tokyo, Tokyo, 108, Japan

SO Archives of Biochemistry and Biophysics (1991), 291(2), 339-48

CODEN: ABBIA4; ISSN: 0003-9861

DT Journal

LA English

CC 15-3 (Immunochemistry)

AB Six monoclonal antibodies, 3 each of human IgG1 and IgG2 subclasses, were obtained from human-mouse hybridomas. Structural study of their **asparagine**-linked sugar chains was performed to elucidate the regulatory mechanism of secreted monoclonal IgG glycosylation. The sugar moieties were quant. released as oligosaccharides from the polypeptide backbone by hydrazinolysis. They were converted into radioactive oligosaccharides by NaB³H₄ reduction after N-acetylation. Structural study of each oligosaccharide by lectin affinity column chromatog., sequential exoglycosidase digestion, and methylation anal. indicated that almost all of them were biantennary complex-type sugar chains containing Man α 1 \rightarrow 6(Man α 1 \rightarrow 3)Man β 1 \rightarrow 4GlcNAc β 1 \rightarrow 4 (\pm Fucal \rightarrow 6)GlcNAc as core structures.


Bisecting N-acetylglucosamine residue, which is present in human IgG but not in mouse IgG, could not be detected at all. The molar ratio of each oligosaccharide from the 6 IgG samples was different. However, no subclass specificity was detected except that all IgG1 contained neutral,

mono-, and disialylated sugar chains, whereas IgG2 did not contain disialylated ones. The molar ratio of N-acetylneuraminic acid to N-glycolylneuraminic acid was also different for each IgG. All 6 IgGs contained monoantennary complex-type and **high mannose** -type oligosaccharides which had never been detected in serum IgGs of various mammals so far investigated. Thus, the processing of **asparagine**-linked sugar chains of IgG is less complete in human-mouse hybridoma than in human or mouse B cells, and the glycosylation machinery of the mouse cells is dominant in the hybrid cells.


ST sugar monoclonal antibody human mouse hybridoma
 IT Glycosidation
 (of monoclonal antibodies in human-mouse hybridomas, mouse cell genetic dominance in)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of monoclonal antibodies, from human-mouse hybridomas, structure of)
 IT Hybridoma
 (B-cell, monoclonal antibodies from human-mouse, sugar moieties of, structure of)
 IT Antibodies
 RL: BIOL (Biological study)
 (monoclonal, of human-mouse hybridoma, sugar moieties of, structure of)
 IT 66091-47-2 71369-21-6 71496-53-2 78334-43-7 78392-81-1
 84808-02-6 84825-26-3 98969-42-7 101971-14-6 103584-68-5
 109050-95-5 110387-54-7 110402-12-5 111059-47-3 115973-44-9
 RL: PRP (Properties)
 (**asparagine**-linked, of monoclonal antibodies from human-mouse hybridomas)
 IT 66091-47-2
 RL: PRP (Properties)
 (**asparagine**-linked, of monoclonal antibodies from human-mouse hybridomas)
 RN 66091-47-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 21 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:677032 HCAPLUS
 DN 115:277032
 ED Entered STN: 27 Dec 1991
 TI The substrate-specificity of human lysosomal α -D-mannosidase in
 relation to genetic α -mannosidosis
 AU Al Daher, Samer; De Gasperi, Rita; Daniel, Peter; Hall, Nicholas; Warren,
 Christopher D.; Winchester, Bryan
 CS Inst. Child Health, Univ. London, London, WC1N 1EH, UK
 SO Biochemical Journal (1991), 277(3), 743-51
 CODEN: BIJOAK; ISSN: 0306-3275
 DT Journal
 LA English
 CC 14-14 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 7
 AB The specificity of human liver lysosomal α -mannosidase (EC 3.2.1.24)
 towards a series of oligosaccharide substrates derived from **high**
-mannose, complex and hybrid **asparagine**-linked glycans
 and from the storage products in α -mannosidosis was investigated.
 The enzyme hydrolyzes all $\alpha(1-2)$ -, $\alpha(1-3)$ - and

α (1-6)-mannosidic linkages in these glycans without a requirement for added Zn^{2+} , albeit at different rates. A major finding of this study is that all the substrates are hydrolyzed by non-random pathways. These pathways were established by determining the structures of intermediates in the digestion mixts. by a combination of HPTLC and HPLC before and after acetolysis. The catabolic pathway for a particular substrate appears to be determined by its structure, raising the possibility that degradation

occurs by

an uninterrupted sequence of steps within one active site. The structures of the digestion intermediates are compared with the published structures of the storage products in mannosidosis and of intact **asparagine**-linked glycans. Most but not all of the digestion intermediates derived from **high-mannose** glycans have structures found in intact **asparagine**-linked glycans of human glycoproteins or among the storage products in the urine of patients with mannosidosis. However, the relative abundances of these structures suggest that the catabolic pathway is not the same as the processing pathway. In contrast, the intermediates formed from the digestion of oligosaccharides derived from hybrid and complex N-glycans are completely different from any processing intermediates and also from the oligosaccharides of composition Man2-4GlcNAc that account for 80-90% of the storage products in α -mannosidosis. It is postulated that the structures of these major storage products arise from the action of an exo/endo- α (1-6)-mannosidase on the partially catabolized oligomannosides that accumulate in the absence of the main lysosomal α -mannosidase.

ST mannosidase oligosaccharide substrate specificity mannosidosis

IT Oligosaccharides

RL: BIOL (Biological study)

(mannose-containing and **asparagine**-linked, α -mannosidase reactions with, specificity of, in humans, mannosidosis in relation to)

IT Liver, composition

(α -mannosidase of lysosomes of, oligosaccharide substrate-specificity of, in humans, mannosidosis in relation to)

IT 9025-42-7, α -D-Mannosidase

RL: BIOL (Biological study)

(deficiency of, α -mannosidosis from, α -mannosidase reaction specificity with various mannose-containing **asparagine**-linked oligosaccharide substrates in humans in relation to)

IT 50722-98-0 52134-33-5 52134-34-6 60177-38-0 **66091-47-2**

70158-31-5 70158-32-6 70158-33-7 **70858-45-6** 74385-50-5

74399-85-2 76260-38-3 83259-19-2 95041-21-7 100634-95-5

100634-96-6 106788-52-7 126673-15-2 126673-17-4

RL: BIOL (Biological study)

(α -mannosidase reaction with, specificity of, in humans, mannosidosis in relation to)

IT **66091-47-2 70858-45-6**

RL: BIOL (Biological study)


(α -mannosidase reaction with, specificity of, in humans, mannosidosis in relation to)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L91 ANSWER 22 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN

AN . 1991:601288 HCAPLUS

DN 115:201288

ED Entered STN: 15 Nov 1991

TI α -Mannosidase-catalyzed trimming of **high-mannose** glycans in noninfected and baculovirus-infected *Spodoptera frugiperda* cells (IPLB-SF-21AE). A possible contributing regulatory mechanism for assembly of complex-type oligosaccharides in infected cells

AU Davidson, Donald J.; Bretthauer, Roger K.; Castellino, Francis J.

CS Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA

SO Biochemistry (1991), 30(41), 9811-15

CODEN: BICHAW; ISSN: 0006-2960

DT Journal

LA English

CC 6-1 (General Biochemistry)

Section cross-reference(s): 7, 14


AB Incubation of a *S. frugiperda* (IPLB-SF-2 AE) cell extract with the oligosaccharide Man9GlcNAc2, the aglucoyl derivative of the glycan that is normally transferred from the dolichol carrier to the relevant **Asn** residue in the nascent protein, results in its trimming to Man6GlcNAc2, an intermediate that is relatively stable to further α -D-mannosidase action in these cells. On the other hand, incubation of a similar extract from cells that had been infected for various times with a wild-type baculovirus (*Autographa californica* nuclear polyhedrosis virus) or a recombinant baculovirus (r-BAC)/human plasminogen (HPg) construct employed for expression of HPg led to rapid trimming of Man6GlcNAc2 to Man5GlcNAc2 and Man3GlcNAc2. These latter reactions displayed temporal effects, in that an enhancement of this latter trimming process occurred as a function of the time of infection of the cells with the wild-type and recombinant viral constructs. It was previously demonstrated that the nature of the oligosaccharide assembled on Asn289 of HPg expressed in several lepidopteran insect cell lines was dependent on the time of infection of the cells with r-BAC/HPg and that the amount of complex glycan found on this recombinant protein increased with an increase in infection times. The present study provides a significant contributing explanation for these findings, in that the infective process lead to an enhancement of an α -D-mannosidase activity that catalyzes trimming of the Man6GlcNAc2 that accumulates in noninfected cells, to Man5GlcNAc2, the preferred substrate for GlcNAc transferase I. This latter process is requisite for further processing of **high-mannose** oligosaccharide to

complex and hybrid glycans. The control of Man6GlcNAc2 trimming is one potentially important determinant as to whether complex and/or hybrid glycans will be assembled on glycoproteins.


- ST mannosidase glycan trimming infected insect cell; baculovirus infected insect cell mannosidase
- IT Animal cell line
(IPLB-SF-21AE, mannosidase from, **high-mannose** glycans trimming by, baculovirus infection effect on, complex-type oligosaccharide assembly in relation to)
- IT Glycoproteins, biological studies
RL: BIOL (Biological study)
(glycans assembly on, **high-mannose** glycans trimming by mannosidase from baculovirus-infected lepidopteran insect cells in relation to)
- IT Spodoptera frugiperda
(mannosidase from cell line of, **high-mannose** glycans trimming by, baculovirus infection effect on)
- IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, trimming of, by mannosidase from lepidopteran insect cells, baculovirus infection effect on, complex-type oligosaccharide assembly in relation to)
- IT Virus, animal
(Autographa californica nuclear polyhedrosis, infection with, of lepidopteran insect cells, mannosidase trimming of **high-mannose** glycans in, complex-type oligosaccharide assembly in relation to)
- IT 9001-91-6, Plasminogen
RL: BIOL (Biological study)
(glycans assembly on recombinant human, **high-mannose** glycans trimming by mannosidase from baculovirus-infected lepidopteran insect cells in relation to)
- IT 9025-42-7, α -D-Mannosidase
RL: BIOL (Biological study)
(**high-mannose** glycans trimming by, in baculovirus-infected lepidopteran insect cells, complex-type oligosaccharide assembly in relation to)
- IT 71246-55-4 77355-54-5
RL: BIOL (Biological study)
(trimming of, by α -mannosidase from baculovirus-infected lepidopteran insect cells, complex-type oligosaccharide assembly in relation to)
- IT 71246-55-4 77355-54-5
RL: BIOL (Biological study)
(trimming of, by α -mannosidase from baculovirus-infected lepidopteran insect cells, complex-type oligosaccharide assembly in relation to)
- RN 71246-55-4 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 23 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:579860 HCAPLUS

DN 115:179860

ED Entered STN: 01 Nov 1991

TI Structures of the **asparagine-289-linked oligosaccharides** assembled on recombinant human plasminogen expressed in a Mamestra brassicae cell line (IZD-MB0503)

AU Davidson, Donald J.; Castellino, Francis J.

CS Dep. Chem. Biochem., Univ. Notre Dame, Notre Dame, IN, 46556, USA

SO Biochemistry (1991), 30(27), 6689-96

CODEN: BICHAW; ISSN: 0006-2960

DT Journal

LA English

CC 12-6 (Nonmammalian Biochemistry)

Section cross-reference(s): 7

- AB In this report, a previous investigation was extended in which it was demonstrated for the first time that lepidopteran insect (*Spodoptera frugiperda*) cells (IPLB-SF-21AE) were capable of assembling N-linked complex oligosaccharide on a human protein (plasminogen), the cDNA of which had been inserted into these cells via recombinant DNA technol. with a baculovirus vector. To investigate whether a more general capability of lepidopteran insect cells to produce complex oligosaccharide existed, and to identify the chemical nature of the types of oligosaccharides that such insect cells were able to assemble, the authors infected *M. brassicae* (IZD-MB0503) cells for 48 h with a recombinant (r) baculovirus containing the [R561E]human plasminogen (HPg) cDNA and characterized the nature of the glycopeptidase F (GF) released N-linked oligosaccharides contained on **asparagine**-289 of the r-HPg expressed by these cells. Approx. 63% of the total N-linked oligosaccharides were of the complex type, with bisialo-biantennary (28%), asialo-biantennary (7%), fucosylated bisialo-biantennary (25%), and fucosylated asialo-biantennary (3%) oligosaccharides representing the major complex-type carbohydrate species. The remainder of the oligosaccharides were of the **high-mannose** type, with (mannose)₉(N-acetylglucosamine)₂ (22%), (mannose)₅(N-acetylglucosamine)₂ (13%), and (mannose)₃(N-acetylglucosamine)₂ (2%) representing the major oligosaccharides observed. Investigations with r-HPg expression in another lepidopteran insect cell line, *Manduca sexta* (CM-1), also clearly demonstrated that (α 2,6)-linked sialic acid was present on the purified protein, suggesting that the ability of insect cells to assemble complex-type oligosaccharide on r-HPg is general in nature. These studies demonstrate that despite the observations that endogenous insect cell proteins apparently do not contain N-linked complex oligosaccharide, the glycosyltransferase genes required for assembly of such structures are present in these cells and are capable of being utilized under proper conditions. The resulting alteration of oligosaccharide processing appears to be a general property of lepidopteran insect cells, which is effected in this case by infection with a recombinant baculovirus containing the cDNA for HPg. This system may serve as a general probe for elucidation of some of the regulatory factors governing protein glycosylation.
- ST Mamestra **asparagine** oligosaccharide recombinant plasminogen; insect **asparagine** oligosaccharide recombinant plasminogen; IZD MB0503 oligosaccharide recombinant plasminogen; baculovirus infection insect cell oligosaccharide processing
- IT Animal cell line
(IZD-MB0503, **asparagine**-linked complex oligosaccharide assembly on human recombinant plasminogen by cells of, with baculovirus vector)
- IT Insect
Mamestra brassicae
(**asparagine**-linked complex oligosaccharide assembly on human recombinant plasminogen by cells of, with baculovirus vector)
- IT Oligosaccharides
RL: BIOL (Biological study)
(assembly of, on human recombinant plasminogen by insect cells with baculovirus vector)
- IT Glycosidation
(by insect cells, with baculovirus vector, mechanism of)
- IT *Manduca sexta*
(complex oligosaccharide assembly by cells of, with baculovirus vector)
- IT Glycoproteins, biological studies
RL: FORM (Formation, nonpreparative)

(formation of, in insect cells with baculovirus vector)

IT Virus, animal
(baculo-, **asparagine**-linked complex oligosaccharide assembly
by insect cells infected with human plasminogen cDNA in, in culture)

IT 9001-91-6, Plasminogen **66091-47-2 71246-55-4**
71496-53-2 71496-55-4 78392-81-1 79295-70-8
RL: FORM (Formation, nonpreparative)
(formation of, by insect cells with baculovirus vector containing human
plasminogen cDNA)

IT **70858-45-6**
RL: FORM (Formation, nonpreparative)
(formation of, in insect cells expressing recombinant plasminogen)


IT **66091-47-2 71246-55-4**
RL: FORM (Formation, nonpreparative)
(formation of, by insect cells with baculovirus vector containing human
plasminogen cDNA)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



IT 70858-45-6


RL: FORM (Formation, nonpreparative)

(formation of, in insect cells expressing recombinant plasminogen)

RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L91 ANSWER 24 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:444523 HCAPLUS
 DN 115:44523
 ED Entered STN: 10 Aug 1991
 TI Heterogeneity of the complex N-linked oligosaccharides at specific glycosylation sites of two secreted carrot glycoproteins
 AU Sturm, Arnd
 CS Friedrich Miescher Inst., Basel, CH-4002, Switz.
 SO European Journal of Biochemistry (1991), 199(1), 169-79
 CODEN: EJBCAI; ISSN: 0014-2956
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 Section cross-reference(s): 7, 11, 34
 AB The N-linked glycans from the 52/54-kDa medium protein and cell wall β -fructosidase, two glycoproteins secreted by carrot suspension culture cells, were characterized. Carrot wells were labeled with $[3H]$ glucosamine or $[3H]$ fucose. The 52/54-kDa medium protein was isolated from the culture medium and β -fructosidase from cell walls. The purified proteins were digested with trypsin and glycopeptides were isolated and sequenced. Glycans obtained from individual glycopeptides were separated by gel filtration chromatog. and characterized by Con A chromatog. by treatments with exoglycosidases and by sugar composition anal. The 52/54-kDa medium protein and cell wall β -fructosidase have one **high-mannose**-type glycan similar to those from yeast and animal glycoproteins. In addition, the 52/54-kDa medium protein has three complex-type and cell wall β -fructosidase two complex-type glycans per polypeptide. The complex-type glycans isolated from individual glycosylation sites are fairly large and very heterogeneous. The smallest of these glycans has the structure $[Xyl](Man)_3[Fuc](GlcNAc)_2Asn$ (square brackets indicating branching) whereas the larger ones carry addnl. sugars like terminal N-acetylglucosamine and possibly rhamnose and arabinose in the case of the 52/54-kDa medium protein and only arabinose in the case of cell wall β -fructosidase. These terminal sugars are linked to the α -mannose residues of the glycan cores. The 52/54-kDa medium protein is secreted with large and homogeneous complex glycans, their heterogeneity originates from slow processing after secretion. The complex glycans from cell wall β -fructosidase are processed before the enzyme is integrated into the cell wall.
 ST glycoprotein oligosaccharide heterogeneity secretion carrot; protein 52

- 54kDa oligosaccharide carrot; fructosidase beta oligosaccharide carrot
- IT Glycoproteins, specific or class
 RL: BIOL (Biological study)
 (52,000-54,000-mol.-weight, oligosaccharides linked to **asparagine**
 of, structural heterogeneity of, of carrot cells)
- IT Oligosaccharides
 RL: BIOL (Biological study)
 (complex-type, of fructosidase and 52,000/54,000-mol.-weight glycoprotein,
 of carrot cell, structures of)
- IT Carrot
 (fructosidase and 52,000/54,000-mol.-weight glycoprotein of, structural
 heterogeneity of oligosaccharides of)
- IT Cell wall
 (fructosidase of, of carrot, structural heterogeneity of
 oligosaccharides of)
- IT Carbohydrates and Sugars, biological studies
 RL: BIOL (Biological study)
 (of fructosidase and 52,000/54,000-mol.-weight glycoprotein, of carrot
 cell)
- IT Oligosaccharides
 RL: BIOL (Biological study)
 (mannose-containing, of fructosidase and 52,000/54,000-mol.-weight
 glycoprotein, of carrot cell, structures of)
- IT Biological transport
 (secretion, of 52,000/54,000-mol.-weight glycoprotein, by carrot cell,
 oligosaccharide moiety processing after)
- IT 58-86-6, Xylose, biological studies 147-81-9, Arabinose 2438-80-4,
 Fucose 3458-28-4, Mannose 7512-17-6, N-Acetylglucosamine
 134886-83-2 134886-84-3
 RL: BIOL (Biological study)
 (of fructosidase and 52,000/54,000-mol.-weight glycoprotein, of carrot
 cell)
- IT 9001-57-4, β -Fructosidase
 RL: BIOL (Biological study)
 (oligosaccharides linked by **asparagines** of, of carrot cell
 wall, structural heterogeneity of)
- IT 134886-83-2
 RL: BIOL (Biological study)
 (of fructosidase and 52,000/54,000-mol.-weight glycoprotein, of carrot
 cell)
- RN 134886-83-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-
 mannopyranosyl-(1 \rightarrow 4)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O-
 α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-
 (1 \rightarrow 4)-O- α -D-mannopyranosyl-(1 \rightarrow 4)- α -D-
 mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-
 (acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-
 2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 25 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:162076 HCAPLUS
 DN 114:162076
 ED Entered STN: 03 May 1991
 TI Structural analysis of the glycoprotein allergen Art v II from the pollen of mugwort (*Artemisia vulgaris* L.)
 AU Nilsen, Bente M.; Sletten, Knut; Smestad Paulsen, Berit; O'Neill, Malcolm; Van Halbeek, Herman
 CS Dep. Pharm., Univ. Oslo, Oslo, Norway
 SO Journal of Biological Chemistry (1991), 266(4), 2660-8
 CODEN: JBCHA3; ISSN: 0021-9258
 DT Journal
 LA English
 CC 15-2 (Immunochimistry)
 AB The glycoprotein allergen Art v II, from the pollen of mugwort (*A. vulgaris* L.) was treated with peptide:N-glycosidase F (PNGase F) to release **asparagine**-linked oligosaccharides. The oligosaccharides were isolated by gel permeation chromatog. and their structures determined by 500-MHz ¹H NMR spectroscopy, fast atom bombardment-mass spectrometry, and high-pH anion-exchange chromatog. The **high-mannose** oligosaccharides Man5GlcNAc2, Man6GlcNAc2, Man7GlcNAc2, Man8GlcNAc2, and Man9GlcNAc2 were present in the ratios 2:49:19:24:6 and accounted for all the **asparagine**-linked oligosaccharides released from Art v II by PNGase F. The N-terminal amino acid sequences of Art v II and of four peptides generated by cyanogen bromide cleavage of deglycosylated Art v II were determined. The first 30 amino acid residues of Art v II did not contain any potential N-glycosylation sites. One potential N-glycosylation site was identified in one of the CNBr fragments. The native protein conformation was shown by ELISA inhibition assays to be essential for the binding of rabbit IgG to Art v II and for the binding of human IgE to the major IgE-binding epitope(s) in this allergen. At least one minor IgE-binding epitope still bound IgE after denaturation of the allergen. Removal of the **high-mannose** chains from denatured Art v II had no effect on the binding of human IgE to the minor IgE-binding epitope(s).
 ST mugwort allergen carbohydrate structure; *Artemisia* allergen carbohydrate structure
 IT *Artemisia vulgaris*
 (allergen Art v II of pollen of, structure of carbohydrate chains of)
 IT Pollen
 (allergen Art v II of, structure of carbohydrate chains of, of mugwort)
 IT Protein sequences

Absolute stereochemistry.

The diagram shows a complex branched oligosaccharide structure. It consists of five pyranose rings connected by glycosidic bonds. The structure includes several substituents: an NHAc group, an AcNH group, a CHO group, and several R groups. Stereochemistry is indicated with wedges and dashes. The rings are connected by glycosidic bonds, with some branches indicated by dashed lines.

PAGE 2-A




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



RN 77036-51-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 83178-05-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 26 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:547445 HCAPLUS
 DN 113:147445
 ED Entered STN: 27 Oct 1990
 TI Structures of the **asparagine**-linked sugar chain of glucose transporter from human erythrocytes
 AU Endo, Tamao; Kasahara, Michihiro; Kobata, Akira
 CS Inst. Med. Sci., Univ. Tokyo, Tokyo, 108, Japan
 SO Biochemistry (1990), 29(39), 9126-34
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB The **asparagine**-linked sugar chain of glucose transporter from human erythrocytes was quant. released as oligosaccharides from the polypeptide backbone by hydrazinolysis. They were converted to radioactive oligosaccharides by NaB₃H₄ reduction after N-acetylation and fractionated by anion-exchange column chromatog. and Bio-Gel P-4 column chromatog. after sialidase treatment. Structural study of each oligosaccharide by exo- and endoglycosidase digestion and methylation anal. indicated that the glycoprotein contains a **high-mannose**-type oligosaccharide, Man₉·GlcNAc·GlcNAc, and biantennary complex-type oligosaccharides with Man α 1 \rightarrow 6(\pm GlcNAc β 1 \rightarrow 4)(Man α 1 \rightarrow 3)Man β 1 \rightarrow 4GlcNAc β 1 \rightarrow 4(\pm Fuc α 1 \rightarrow 6)GlcNAc as their cores and the poly-N-acetyllactosamine composed of about 16 N-acetyllactosaminyl units as their outer chains. These structural features of the sugar moiety of glucose transporter are quite different from those of two major intrinsic glycoproteins of human erythrocytes, glycophorin A and band 3.

ST glucose transporter glycoprotein oligosaccharide structure erythrocyte
 IT Erythrocyte
 (glucose-transporter glycoprotein of, of human, structure of oligosaccharides of)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of glucose-transporter protein of human erythrocyte, structure of)
 IT Glycophorins
 RL: BIOL (Biological study)
 (A, glucose-transporter glycoprotein of human erythrocyte oligosaccharide structure in relation to)
 IT Glycolipoproteins
 RL: BIOL (Biological study)
 (band 3, glucose-transporter glycoprotein of human erythrocyte oligosaccharide structure in relation to)
 IT Glycoproteins, specific or class
 RL: BIOL (Biological study)
 (glucose-transporting, oligosaccharides of, of human erythrocytes, structure of)
 IT 38711-46-5 39024-56-1 70858-45-6 71246-55-4
 81415-06-7 102038-83-5 110387-51-4 110402-13-6 129176-14-3
 RL: BIOL (Biological study)
 (of glucose-transporter protein of human erythrocyte, structure of)
 IT 70-47-3, **Asparagine**, biological studies
 RL: BIOL (Biological study)
 (of glucose-transporter protein of human erythrocytes, oligosaccharides attached to)
 IT 70858-45-6 71246-55-4
 RL: BIOL (Biological study)
 (of glucose-transporter protein of human erythrocyte, structure of)
 RN 70858-45-6 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-

2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl- (1 \rightarrow 2) -O- α -D-mannopyranosyl- (1 \rightarrow 3) -O- [O- α -D-mannopyranosyl- (1 \rightarrow 2) - α -D-mannopyranosyl- (1 \rightarrow 6)] -O- α -D-mannopyranosyl- (1 \rightarrow 6) -O- [O- α -D-mannopyranosyl- (1 \rightarrow 2) -O- α -D-mannopyranosyl- (1 \rightarrow 2) - α -D-mannopyranosyl- (1 \rightarrow 3)] -O- β -D-mannopyranosyl- (1 \rightarrow 4) -O-2- (acetylamino) -2-deoxy- β -D-glucopyranosyl- (1 \rightarrow 4) -2- (acetylamino) -2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



IT 70-47-3, **Asparagine**, biological studies
 RL: BIOL (Biological study)
 (of glucose-transporter protein of human erythrocytes, oligosaccharides
 attached to)
 RN 70-47-3 HCAPLUS
 CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L91 ANSWER 27 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:437007 HCAPLUS
 DN 113:37007
 ED Entered STN: 03 Aug 1990
 TI Structural analysis of **Asn**-linked oligosaccharides of porcine
 pancreatic kallikrein
 AU Tomiya, Noboru; Yamaguchi, Tadashi; Awaya, Juichi; Kurono, Masayasu; Endo,
 Satoshi; Arata, Yoji; Ishihara, Hideko; Mori, Masami; Tejima, Setsuzo;
 Takahashi, Noriko
 CS Mie Res. Lab., Sanwa Kagaku Kenkyusho Co. Ltd., Mie, 511-04, Japan


- SO Advances in Experimental Medicine and Biology (1989),
247A(Kinins 5, Pt. A), 527-32
CODEN: AEMBAP; ISSN: 0065-2598
- DT Journal
- LA English
- CC 7-5 (Enzymes)
Section cross-reference(s): 34
- AB The oligosaccharide side chains of pancreatic β -kallikrein B were
separated and their structures were determined The oligosaccharides eluted in
the **high-mannose** type region and the complex-type region.
- ST kallikrein oligosaccharide structure pancreas
- IT Oligosaccharides
RL: BIOL (Biological study)
(branched; of kallikrein, of pancreas, structure of)
- IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, of kallikrein, of pancreas, structure of)
- IT 66091-47-2 71246-55-4 77036-51-2
77355-54-5 83178-05-6 84813-89-8 107688-07-3
110387-64-9 110387-65-0 115796-96-8 115796-97-9 115796-98-0
115796-99-1 115797-00-7 115797-01-8 115797-02-9 115797-03-0
115826-53-4 115826-54-5 115826-55-6 115826-56-7 115826-57-8
RL: BIOL (Biological study)
(of kallikrein, of pancreas)
- IT 9001-01-8, Kallikrein
RL: BIOL (Biological study)
(β -, B, oligosaccharide structure of, of pancreas)
- IT 66091-47-2 71246-55-4 77036-51-2
77355-54-5 83178-05-6
RL: BIOL (Biological study)
(of kallikrein, of pancreas)
- RN 66091-47-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 77355-54-5 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 83178-05-6 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

\triangleleft OH

\cdots OH

PAGE 2-A



L91 ANSWER 28 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:627434 HCAPLUS
 DN 111:227434
 ED Entered STN: 23 Dec 1989
 TI Structure, oligosaccharide structures, and posttranslationally modified sites of the nicotinic acetylcholine receptor
 AU Poulter, L.; Earnest, J. P.; Stroud, R. M.; Burlingame, A. L.
 CS Dep. Pharm. Chem., Univ. California, San Francisco, CA, 94143, USA
 SO Proceedings of the National Academy of Sciences of the United States of America (1989), 86(17), 6645-9
 CODEN: PNASA6; ISSN: 0027-8424
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 Section cross-reference(s): 9
 AB Using mass spectrometry the transmembrane topog. of the nicotinic acetylcholine receptor, a 5-subunit glycosylated protein complex that forms a gated ion channel in the neuromuscular junction was examined. The primary sequences of the 4 polypeptide chains making up the acetylcholine receptor from *Torpedo californica* contain many possible sites for glycosylation or phosphorylation. Liquid secondary ion mass spectrometry was used to identify post-translationally modified residues and to determine the intact oligosaccharide structures of the carbohydrate present on the acetylcholine receptor. **Asparagine-143** of the α subunit (in consensus numbering) is shown to be glycosylated with **high-mannose** oligosaccharide. **Asparagine-453** of the γ -subunit is not glycosylated, a fact that bears on the question of the orientations of putative transmembrane helices M3, M4, and M5. The structures of the 6 major acetylcholine receptor oligosaccharides were determined; the major components (70%) are of the **high-mannose** type, with bi-, tri-, and tetraantennary complex oligosaccharides making up approx. 22 mol% of the total carbohydrate. This application of a multichannel array detector mass spectrometer provided a breakthrough in sensitivity that allowed identification of the site of attachment of, and the sequence of, oligosaccharides on a 300-kDa membrane protein from only 5 pmol of the isolated oligosaccharide.
 ST nicotinic acetylcholine receptor structure oligosaccharide; membrane topog nicotinic acetylcholine receptor; mass spectrometry glycoprotein oligosaccharide structure
 IT Cell membrane
 (nicotinic acetylcholine receptor topog. in, protein oligosaccharide structures in relation to)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of nicotinic acetylcholine receptor, structure of)
 IT Mass spectroscopy
 (oligosaccharide structure of glycoproteins determination by, multi-channel array detection in)
 IT Receptors
 RL: BIOL (Biological study)

(nicotinic, membrane topog. and oligosaccharide structures of)


IT 123739-48-0
RL: BIOL (Biological study)
(of nicotinic acetylcholine receptor)

IT 123739-48-0
RL: BIOL (Biological study)
(of nicotinic acetylcholine receptor)


RN 123739-48-0 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 6)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L91 ANSWER 30 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1988:563655 HCAPLUS
 DN 109:163655
 ED Entered STN: 12 Nov 1988
 TI Rates of processing of the **high mannose**
 oligosaccharide units at the three glycosylation sites of mouse
 thyrotropin and the two sites of free α -subunits
 AU Miura, Yoshitaka; Perkel, Victor S.; Magner, James A.
 CS Michael Reese Hosp., Univ. Chicago, Chicago, IL, 60616, USA
 SO Endocrinology (1988), 123(3), 1296-302
 CODEN: ENDOAO; ISSN: 0013-7227
 DT Journal
 LA English
 CC 2-2 (Mammalian Hormones)
 AB The structures of **high mannose** (Man) oligosaccharide

units were determined at individual glycosylation sites of mouse TSH. Mouse thyrotropic tumor tissue was incubated with D-[2-3H]Man with or without [14C]tyrosine ([14C]Tyr) for 2, 3, or 6 h, and for a 3-h pulse followed by a 2-h chase. TSH heterodimers or free α -subunits were obtained from homogenates using specific antisera. After reduction and alkylation, subunits were treated with trypsin. The tryptic fragments were then loaded on a reverse phase HPLC column to sep. tryptic fragments bearing labeled oligosaccharides. The N-linked oligosaccharides were released with endoglycosidase-H and analyzed by paper chromatog. Man9GlcNac2 and Man8GlcNac2 units predominated at each time point and at each specific glycosylation site, but the processing of high Man oligosaccharides differed at each glycosylation site. The processing at Asn23 of TSH β -subunits was slower than that at Asn56 or Asn82 of α -subunits. The processing at Asn82 was slightly faster than that at Asn56 for both α -subunits of TSH heterodimers and free α -subunits. Evidently, the early processing of oligosaccharides differs at the individual glycosylation sites of TSH and free α -subunits, perhaps, because of local conformational differences.

ST TSH glycosylation site oligosaccharide processing; **asparagine**
TSH subunit processing
IT Glycosidation
(TSH and its α -subunits sites for, oligosaccharide processing at)
IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, at TSH glycosylation sites)
IT 9002-71-5, Thyrotropin
RL: BIOL (Biological study)
(and its α -subunits, oligosaccharide mannose-high units
processing at glycosylation sites of)
IT **70-47-3, Asparagine**, biological studies
RL: BIOL (Biological study)
(as glycosylation sites for TSH and its α -subunits,
oligosaccharide differential processing in)
IT **71246-55-4**
RL: BIOL (Biological study)
(at TSH glycosylation sites)
IT **70-47-3, Asparagine**, biological studies
RL: BIOL (Biological study)
(as glycosylation sites for TSH and its α -subunits,
oligosaccharide differential processing in)
RN 70-47-3 HCAPLUS
CN L-Asparagine (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT **71246-55-4**
RL: BIOL (Biological study)
(at TSH glycosylation sites)
RN 71246-55-4 HCAPLUS
CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A



L91 ANSWER 31 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1988:3428 HCAPLUS
 DN 108:3428
 ED Entered STN: 09 Jan 1988
 TI Structure, position, and biosynthesis of the **high mannose** and the complex oligosaccharide side chains of the bean storage protein phaseolin
 AU Sturm, Arnd; Van Kuik, J. Albert; Vliegenthart, J. F. G.; Chrispeels, Maarten J.
 CS Dep. Biol., Univ. California, La Jolla, CA, 92093, USA
 SO Journal of Biological Chemistry (1987), 262(28), 13392-403
 CODEN: JBCHA3; ISSN: 0021-9258
 DT Journal
 LA English
 CC 11-1 (Plant Biochemistry)
 Section cross-reference(s): 6, 33
 AB Phaseolin, the major storage protein of the common bean (*Phaseolus vulgaris*), is a glycoprotein which is synthesized during seed development and accumulates in protein storage vacuoles or protein bodies. The protein has 3 different N-linked oligosaccharide side chains: Man9(GlcNAc)2, Man7(GlcNAc)2, and Xyl-Man3(GlcNAc)2 (where Xyl represents xylose). The structures of these glycans were determined by 1H NMR spectroscopy. The Man9(GlcNAc)2 glycan has the typical structure found in plant and animal glycoproteins. The structures of the 2 other glycans are given. Phaseolin was separated by electrophoresis on denaturing gels into 4 size classes of polypeptides. The 2 abundant ones have 2 oligosaccharides each, whereas the less abundant ones have only 1 oligosaccharide each. Polypeptides with 2 glycans have Man7(GlcNAc)2 attached to **asparagine (Asn)**252 and Man9(GlcNAc)2 attached to Asn341. Polypeptides with only 1 glycan have Xyl-Man3(GlcNAc)2 attached to Asn252. Both these **Asn** residues are in canonical glycosylation sites; the numbering starts with the N-terminal methionine of the signal peptide of phaseolin. The presence of Man7(GlcNAc)2 and of Xyl-Man3(GlcNAc)2 at the same **Asn** residue (position 252) of different polypeptides seems to be controlled by the glycosylation status of Asn341. When Asp341 is unoccupied, the glycan at Asn252 is complex. When Asn341 is occupied, the glycan at Asn252 is only modified to the extent that 2 mannosyl residues are removed. The processing of the glycans, after the removal of the glucose residues, involves enzymes in the Golgi apparatus as well as in the protein bodies. Formation of the Xyl-Man3(GlcNAc)2 glycan is a multistep process that involves the Golgi apparatus-mediated removal of 6 mannose residues and the addition of 2 N-acetylglucosamine residues and 1 xylose. The terminal N-acetylglucosamine residues are later removed in the protein bodies. The conversion of Man9(GlcNAc)2 to Man7(GlcNAc)2 is a late processing event which occurs in the protein bodies. Expts. in which [3H]glucosamine-labeled phaseolin obtained from the endoplasmic reticulum (i.e. precursor phaseolin) is incubated with jack bean α -mannosidase show that the **high-mannose** glycan on Asn252, but not the one on

- Asn341, is susceptible to enzyme degradation Incubation of [3H]glucosamine-labeled phaseolin obtained from the Golgi apparatus with jack bean β -N-acetylglucosaminidase results in the removal of the terminal N-acetylglucosamine residues from the complex chain. These observations are discussed in relation to the hypothesis that the control of glycan modification is determined largely by the accessibility of the glycan chains to the glycosidases and glycosyltransferases in the Golgi apparatus
- ST Phaseolus phaseolin oligosaccharide structure position formation; bean phaseolin oligosaccharide structure position formation
- IT Oligosaccharides
RL: BIOL (Biological study)
(complex, of phaseolin of bean, structure and position and biosynthesis of)
- IT Protein sequences
(of phaseolin glycosylated regions, of bean)
- IT Bean
(phaseolin of, **high-mannose** and complex oligosaccharides of, structure and position and biosynthesis of)
- IT Golgi apparatus
(phaseolin oligosaccharide processing in, of bean)
- IT Oligosaccharides
RL: BIOL (Biological study)
(mannose-containing, of phaseolin of bean, structure and position and biosynthesis of)
- IT Globulins, biological studies
RL: BIOL (Biological study)
(phaseolins, **high-mannose** and complex oligosaccharides of, of bean, structure and position and biosynthesis of)
- IT Organelle
(protein body, phaseolin oligosaccharide processing in, of bean)
- IT 70-47-3, **Asparagine**, biological studies
RL: BIOL (Biological study)
(of phaseolin positions 252 and 341, as glycosylation sites)
- IT 71246-55-4 78630-21-4 111589-63-0
RL: BIOL (Biological study)
(of phaseolin, of bean, structure and position and biosynthesis of)
- IT 70-47-3, **Asparagine**, biological studies
RL: BIOL (Biological study)
(of phaseolin positions 252 and 341, as glycosylation sites)
- RN 70-47-3 HCAPLUS
- CN L-Asparagine (9CI) (CA INDEX NAME)


Absolute stereochemistry.




- IT 71246-55-4
RL: BIOL (Biological study)
(of phaseolin, of bean, structure and position and biosynthesis of)
- RN 71246-55-4 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L91 ANSWER 32 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:437847 HCAPLUS
 DN 107:37847
 ED Entered STN: 08 Aug 1987
 TI Carbohydrates of influenza virus. Structure of the oligosaccharides linked to **asparagines** 406 and 478 in the hemagglutinin of fowl plague virus, strain Dutch
 AU Geyer, Rudolf; Diabate, Silvia; Geyer, Hildegard; Klenk, Hans Dieter; Niemann, Heiner; Stirm, Stephan
 CS Biochem. Inst. Klin., Univ. Giessen, Giessen, D-6300, Fed. Rep. Ger.
 SO Glycoconjugate Journal (1987), 4(1), 17-32
 CODEN: GLJOEW; ISSN: 0282-0080
 DT Journal
 LA English
 CC 15-6 (Immunochimistry)
 Section cross-reference(s): 10
 AB Fowl plague virus, strain Dutch, was metabolically labeled with D-[2-3H]mannose, or with D-[6-3H]glucosamine, and the small subunit (HA2; 0.8 mg in total) of the viral hemagglutinin was isolated by preparative SDS-PAGE. After proteolytic digestion, the radioactive oligosaccharides were sequentially liberated from the glycopeptides by treatment with different endo- β -N-acetylglucosaminidases and with peptide: N-glycosidase or, finally, by hydrazinolysis. In this manner, 4 groups of glycans were obtained by consecutive gel filtrations and were subfractionated by HPLC. The structures of the individual oligosaccharides were analyzed by micromethylation, by acetolysis, or by digestion with exoglycosidases. The major species among the **high mannose** glycans at **asparagine** (Asn)-406 of the viral glycopolypeptide were found to be Man α 1-2Man α 1-3(Man α 1-2Man α 1-6)Man α 1-6(Man α 1-2Man α 1-2Man α 1-3)Man β 1-4GlcNAc β 1-4GlcNAc and Man α 1-3(Man α 1-2Man α 1-6)Man α 1-6(Man α 1-2Man α 1-2Man α 1-3)Man β 1-4GlcNAc β 1-4GlcNAc, while the complex glycans at **Asn**-478 are predominantly GlcNAc β 1-2Man α 1-3(GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc (lacking, in part, one of the outer N-acetylglucosamine residues) and GlcNAc β 1-2Man α 1-3(Gal β 1-4GlcNAc β 1-2Man α 1-6)Man β 1-4GlcNAc β 1-4GlcNAc.
 ST fowl plague virus hemagglutinin oligosaccharide
 IT Glycoproteins, biological studies
 RL: BIOL (Biological study)
 (carbohydrates of, of fowl plague virus hemagglutinin, characterization of)
 IT Carbohydrates and Sugars, biological studies
 RL: BIOL (Biological study)
 (of hemagglutinin, of fowl plague virus, characterization of)
 IT Virus, animal
 (fowl plague, hemagglutinin of, carbohydrates of, characterization of)
 IT Agglutinins and Lectins

RL: BIOL (Biological study)
(hemagglutinins, carbohydrates of, of fowl plague virus,
characterization of)

IT 71246-55-4 77036-51-2 84808-02-6 109050-95-5

RL: BIOL (Biological study)
(of fowl plague virus hemagglutinin)

IT 71246-55-4 77036-51-2


RL: BIOL (Biological study)
(of fowl plague virus hemagglutinin)

RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 33 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1987:3453 HCAPLUS
DN 106:3453
ED Entered STN: 11 Jan 1987
TI **Asn-linked oligosaccharides in lectin-resistant tumor-cell mutants with varying metastatic potential**
AU Dennis, James W.; Laferte, S.; Fukuda, M.; Dell, A.; Carver, J. P.
CS Cancer Res. Div., Mt. Sinai Hosp., Toronto, ON, M5G 1X5, Can.
SO European Journal of Biochemistry (1986), 161(2), 359-73
CODEN: EJBCAI; ISSN: 0014-2956
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
AB MDW4, a what germ agglutinin-resistant mutant of the metastatic murine tumor MDAY-D2 has previously been shown to be poorly metastatic when injected i.v. and nonmetastatic when injected s.c. into syngeneic mice. W4EB8, a Bandeiraea simplicifolia (BSII) lectin-selected subline of MDW4 has previously been shown to be intermediate between that of MDAY-D2 and MDW4 cell for sensitivity to lectin and metastatic phenotype when injected i.v. into mice. Wild-type mutant cells processed **high-mannose-type asparagine (Asn)-linked** oligosaccharides to biantennary (GlcNAc)2(Man)3(GlcNAc)2. In MDAY-2 cells this structure was processed further to sialylated tetra-antennary complex with polylactosamine-containing antennae terminating in either sialic acid or α 1-3-linked galactose. MDW4 cells had 4-5 times more (GlcNAc)2(Man)3(GlcNAc)2 than MDAY-D2 cells and a major component of triantennary structure (GlcNAc)3(Man)3(GlcNAc)2 (i.e. 2,2,6-substituted trimannosyl core) that was not found in wild-type cells. The partial revertant, W4EB8, had intermediate levels of mutant (GlcNAc)3(Man)3(GlcNAc)2 and sialylated complex-type carbohydrates. A shift in expression from incomplete complex type to sialylated tri/tetra-antennary complex-type carbohydrates in tumor cells may enhance metastatic potential of tumor cells in the exptl. metastasis assay. In addition, somatic cell hybridization anal. indicated that the defect in MDW4 cells was identical to that of the Chinese hamster ovary mutant Lec8; a deficiency in UDP-galactose transport into the golgi.
ST oligosaccharide structure tumor metastasis
IT Golgi apparatus
(UDP-galactose transport by, in oligosaccharide processing in tumors, metastasis in relation to)
IT Biological transport
(of UDP-galactose, by Golgi apparatus, in oligosaccharide processing by tumors, metastasis in relation to)
IT Oligosaccharides
RL: BIOL (Biological study)
(of neoplasm, metastasis in relation to)
IT Neoplasm, composition
(oligosaccharides of, metastasis in relation to)
IT 131-48-6 71246-55-4 77036-51-2 77355-54-5
84808-02-6 105165-37-5
RL: BIOL (Biological study)
(of neoplasm, metastasis in relation to)
IT 2956-16-3, UDP-galactose
RL: PROC (Process)
(transport of, by Golgi apparatus, in oligosaccharide processing by tumors, metastasis in relation to)
IT 71246-55-4 77036-51-2 77355-54-5
RL: BIOL (Biological study)
(of neoplasm, metastasis in relation to)
RN 71246-55-4 HCAPLUS
CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-


mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→2)-
 α-D-mannopyranosyl-(1→6)]-O-α-D-mannopyranosyl-
 (1→6)-O-[O-α-D-mannopyranosyl-(1→2)-O-α-D-
 mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)]-O-
 β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
 glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 77355-54-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




L91 ANSWER 34 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:2656 HCAPLUS
 DN 106:2656
 ED Entered STN: 11 Jan 1987
 TI Characterization of the mechanism of protein glycosylation and the structure of glycoconjugates in tissue culture trypomastigotes and intracellular amastigotes of *Trypanosoma cruzi*
 AU Doyle, Patricia; De la Canal, Laura; Engel, Juan C.; Parodi, Armando J.
 CS Inst. Nac. Diagn. Invest. Enfermedad Chagas "Dr. Mario Fatala Chaben", Buenos Aires, 1063, Argent.
 SO Molecular and Biochemical Parasitology (1986), 21(1), 93-101
 CODEN: MBIPDP; ISSN: 0166-6851
 DT Journal
 LA English
 CC 10-2 (Microbial Biochemistry)
 AB Trypomastigote cells of *T. cruzi* incubated with [U-14C]glucose accumulated dolichol-P-P-linked Man7GlcNAc2 and Man9GlcNAc2. Both oligosaccharides were transferred to asparagine residues in proteins. On the other hand, intracellular amastigotes behaved as epimastigotes, i.e., only Man9GlcNAc2 accumulated and was transferred to proteins under similar

incubation conditions. Intracellular amastigotes differed, therefore, from amastigotes obtained from an axenic culture, which behaved as trypomastigotes. A similar processing of protein-linked Man9GlcNAc2 and Man8GlcNAc2 occurred in epimastigotes and trypomastigotes but the structure of the main Man7GlcNAc2 isomer produced by demannosylation of the above mentioned oligosaccharides differed from that of the Man7GlcNAc2 transferred in trypomastigotes and amastigotes from axenic cultures. The infective trypomastigote stage of the parasite showed, therefore, an alteration in the mechanism of protein N-glycosylation when compared to the other stages, namely epimastigote (insect vector stage) and amastigote (mammalian intracellular stage). Complex-type, **asparagine**-bound oligosaccharides were synthesized in both epimastigotes and trypomastigotes but the amts. of those compds. were extremely low when compared to those of **high mannose**-type oligosaccharides.


ST Trypanosoma developmental stage protein glycosylation
 IT Trypanosoma cruzi
 (glycoproteins and protein glycosylation in, development in relation to)
 IT Glycosidation
 (of proteins by Trypanosoma cruzi, development in relation to)
 IT Glycoproteins
 Oligosaccharides
 RL: BIOL (Biological study)
 (of Trypanosoma cruzi, development in relation to)
 IT Microorganism development
 (parasitic stages, glycoproteins and protein glycosylation of Trypanosoma cruzi in)
 IT 71246-55-4 81034-79-9 81046-85-7
 RL: BIOL (Biological study)
 (of Trypanosoma cruzi, development in relation to)
 IT 71246-55-4 81034-79-9 81046-85-7
 RL: BIOL (Biological study)
 (of Trypanosoma cruzi, development in relation to)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 81034-79-9 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 81046-85-7 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




L91 ANSWER 35 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1986:609380 HCAPLUS
 DN 105:209380
 ED Entered STN: 13 Dec 1986
 TI Hydrazinolysis-N-reacetylation of glycopeptides and glycoproteins. II.
 Purification of oligosaccharides having a free reducing end from
 glycopeptide sources
 AU Bendiak, Brad; Cumming, Dale A.
 CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
 SO Carbohydrate Research (1986), 151, 89-103
 CODEN: CRBRAT; ISSN: 0008-6215
 DT Journal
 LA English
 CC 34-4 (Amino Acids, Peptides, and Proteins)
 Section cross-reference(s): 22, 33
 AB A hydrazinolysis-N-reacetylation procedure, modified by the inclusion of a
 mild acid hydrolysis step after N-acetylation, was used to prepare, in
 overall yields of 60-70%, pure oligosaccharides containing a reducing D-GlcNAc
 residue from glycopeptide sources. Three types of asparagine
 -linked glycopeptides were treated: a high-mannose
 type, a complex-type containing sialic acid, and a complex-type containing
 sialic
 acid, linked both α -(2 \rightarrow 3) and α -(2 \rightarrow 6) to
 β -D-Galp residues. After the hydrazinolysis-N-reacetylation
 procedure, there was often contamination of the reducing oligosaccharides
 with glycopeptide that remained intact through the procedure, as well as
 minor oligosaccharide products, altered in the nature of the residue at
 the reducing end. Oligosaccharides having a reducing D-GlcNAc residue

were purified by standard liquid chromatog. and HPLC. NMR (360-MHz) was valuable in establishing common structural reporter signals which enabled major products to be identified at stages during the production of free reducing oligosaccharides, and their purity to be assessed.


ST hydrazinolysis reacetylation glycopeptide oligosaccharide
 IT Hydrazinolysis
 (-reacetylation, of glycopeptides, in oligosaccharide purification)
 IT Acetylation
 (hydrazinolysis-, of glycopeptides, in oligosaccharides purification)
 IT Hydrolysis
 (of glycopeptide acetylated hydrazine derivs., in oligosaccharide purification)
 IT Glycopeptides
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oligosaccharides of, hydrazinolysis-reacetylation in purification of)
 IT Oligosaccharides
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (purification of free reducing, from glycopeptide sources, hydrazinolysis-reacetylation in)
 IT 2776-93-4 67299-24-5 78836-79-0 105092-58-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (hydrazinolysis-N-reacetylation of)
 IT 97055-07-7P 105071-69-0P 105071-70-3P 105092-59-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acidic hydrolysis of)
 IT 35061-50-8P 71246-55-4P 71496-53-2P 83411-82-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 IT 71246-55-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




L91 ANSWER 36 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:574622 HCAPLUS
 DN 103:174622
 ED Entered STN: 30 Nov 1985
 TI Characterization by nuclear magnetic resonance of the concanavalin A
 binding oligosaccharide on the β b chain of placental
 β -hexosaminidase B: lectin binding to the separated polypeptide
 chains of hexosaminidases A and B
 AU O'Dowd, Brian F.; Mahuran, Don; Cumming, Dale; Lowden, J. Alexander
 CS Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.
 SO Canadian Journal of Biochemistry and Cell Biology (1985), 63(7),
 723-9
 CODEN: CJBBDU; ISSN: 0714-7511
 DT Journal
 LA English
 CC 7-5 (Enzymes)
 AB The type and distribution of the oligosaccharides on each polypeptide of
 human placental β -hexosaminidases A [subunit and chain structure,
 $\alpha(\beta\alpha\beta\beta)$] and B [2($\beta\alpha\beta\beta$)] were examined The
 denatured polypeptides were separated by isoelec. focusing in a polyacrylamide
 slab gel and each gel was then overlaid with 125I-labeled lectins. The
 $\beta\alpha$ chain contains negligible carbohydrate, the $\beta\beta$ chain contains
 both the **high-mannose**- and a complex-type
 oligosaccharide, and the α chain contains predominantly **high**
-mannose- or hybrid-type moieties. Two **asparagine**
 -linked **high-mannose**-type oligosaccharides present on
 the $\beta\beta$ polypeptide of β -hexosaminidase B were isolated by Con A
 chromatog. and by reverse-phase HPLC. 1H NMR characterization of the
 oligosaccharides revealed an equimolar glycan mixture of the **high-**
mannose (Man)-type structure Man5 and Man6.
 ST oligosaccharide structure beta hexosaminidase placenta
 IT Molecular structure, natural product
 (of **asparagine**-linked oligosaccharides, of
 β -hexosaminidases of human placenta)
 IT Placenta
 (β -hexosaminidases of, of human, structure of **asparagine**
 -linked oligosaccharides of)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (B, of β -hexosaminidase, of human placenta)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (mannose-containing, of β -hexosaminidase B, of human placenta)
 IT 9012-33-3
 RL: BIOL (Biological study)
 (A and B, **asparagine**-linked oligosaccharides of, of human
 placenta, structure of)
 IT 66091-47-2 77355-54-5
 RL: BIOL (Biological study)
 (of β -hexosaminidase B, of human placenta)
 IT 66091-47-2 77355-54-5
 RL: BIOL (Biological study)
 (of β -hexosaminidase B, of human placenta)
 RN 66091-47-2 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-
 mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-
 [α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-
 (1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-
 (1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 77355-54-5 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 37 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:521078 HCAPLUS
 DN 103:121078
 ED Entered STN: 19 Oct 1985
 TI Comparative study of the oligosaccharides of human thyroglobulins obtained from normal subjects and patients with various diseases
 AU Hotta, Taeko; Ishii, Ikuko; Ishihara, Hideko; Tejima, Setsuzo; Tarutani, Osamu; Takahashi, Noriko
 CS Med. Sch., Nagoya City Univ., Nagoya, 467, Japan
 SO Journal of Applied Biochemistry (1985), 7(2), 98-103
 CODEN: JABIDV; ISSN: 0161-7354
 DT Journal
 LA English
 CC 14-8 (Mammalian Pathological Biochemistry)
 AB **Asparagine**-linked oligosaccharides were released quant. by N-oligosaccharide glycopeptidase (almond) digestion from human thyroglobulins prepared from thyroid glands of normal subjects and patients with several pathol. conditions. The pyridylamino derivs. of the oligosaccharides were prepared and analyzed by HPLC. The content of **high-mannose**-type oligosaccharides was comparable to

that of the complex type in normal thyroglobulins. Man9GlcNAc2 was the predominant component in the **high-mannose**-type region, while biantennary oligosaccharides with fucose were the major components in the complex-type region. **High-mannose**-type oligosaccharides were markedly decreased in thyroglobulins prepared from patients with various disorders, such as Basedow's disease, papillary carcinoma, and adenomatous goiter, whereas they were appreciably increased in thyroglobulin from diffuse goiter.

ST oligosaccharide thyroglobulin thyroid disease

IT Oligosaccharides

RL: BIOL (Biological study)

(of thyroglobulins, in thyroid diseases, in humans)

IT Goiter

(oligosaccharides of thyroglobulins in subtypes of, in humans)

IT Graves' disease

Thyroid gland, disease or disorder

(oligosaccharides of thyroglobulins in, in humans)

IT Thyroglobulins

RL: BIOL (Biological study)

(oligosaccharides of, in thyroid diseases in humans)

IT Carcinoma

(papillary, oligosaccharides of thyroglobulins in, of thyroid gland of humans)

IT 66091-47-2 71246-55-4 77036-51-2

77355-54-5 84182-22-9

RL: BIOL (Biological study)

(of thyroglobulins, in thyroid diseases, in humans)

IT 66091-47-2 71246-55-4 77036-51-2

77355-54-5 84182-22-9

RL: BIOL (Biological study)


(of thyroglobulins, in thyroid diseases, in humans)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 77355-54-5 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 84182-22-9 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 38 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:2563 HCAPLUS
 DN 102:2563
 ED Entered STN: 12 Jan 1985
 TI Structure of the N-asparagine-linked oligosaccharide units of human placental β -glucocerebrosidase
 AU Takasaki, Seiichi; Murray, Gary J.; Furbish, F. Scott; Brady, Roscoe O.; Barranger, John A.; Kobata, Akira
 CS Sch. Med., Kobe Univ., Kobe, Japan

SO Journal of Biological Chemistry (1984), 259(16), 10112-17
CODEN: JBCHA3; ISSN: 0021-9258

DT Journal
LA English
CC 7-5 (Enzymes)
Section cross-reference(s): 6

AB The N-**asparagine**-linked oligosaccharide chains of homogeneous human placental β -glucocerebrosidase were released by hydrazinolysis, and their structures were analyzed. The sequence of sugars, linkage, and anomeric configuration of the glycosidic bonds were determined. Approx. 20% of the released sugar chain was of the typical **high-mannose** type. The balance was of complex type with biantennary and triantennary structures. Trisialylated oligosaccharide was detected as a major component.

ST glucocerebrosidase beta oligosaccharide structure placenta
IT Oligosaccharides
RL: BIOL (Biological study)
(**asparagine**-linked, of β -glucocerebrosidase of human placenta, structure of)

IT Placenta
(β -glucocerebrosidase of, of human, structure of oligosaccharides of)

IT 66091-47-2 78392-29-7 78392-30-0. 93375-82-7
93375-83-8 93375-84-9 93382-88-8 93382-89-9 93382-90-2
93382-91-3 93395-37-0 93395-38-1 93451-60-6 93451-61-7
RL: BIOL (Biological study)
(of β -glucocerebrosidase, of human placenta)


IT 37228-64-1
RL: BIOL (Biological study)
(oligosaccharides of, of human placenta, structure of)

IT 66091-47-2 78392-29-7 78392-30-0
RL: BIOL (Biological study)
(of β -glucocerebrosidase, of human placenta)


RN 66091-47-2 HCAPLUS
CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 78392-29-7 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, mono- α -D-mannopyranoside (9CI) (CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.



RN 78392-30-0 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-

mannopyranosyl-(1→3)-O-[α-D-mannopyranosyl-(1→6)]-
 α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-
 (1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-
 (1→4)-2-(acetylamino)-2-deoxy-, di-α-D-mannopyranoside (9CI)
 (CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.




L91 ANSWER 39 OF 46 HCAPLUS' COPYRIGHT 2004 ACS on STN
 AN 1984:119088 HCAPLUS
 DN 100:119088
 ED Entered STN: 12 May 1984
 TI Processing of MOPC 315 immunoglobulin A oligosaccharides: evidence for endoplasmic reticulum and trans Golgi α 1,2-mannosidase activity
 AU Hickman, Scot; Theodorakis, Janice L.; Greco, Jeanne M.; Brown, Peter H.
 CS Div. Hematol. Oncol., Jew. Hosp. St. Louis, St. Louis, MO, 63110, USA
 SO Journal of Cell Biology (1984), 98(2), 407-16
 CODEN: JCLBA3; ISSN: 0021-9525
 DT Journal
 LA English
 CC 15-3 (Immunochemistry)
 AB The processing of **asparagine**-linked oligosaccharides on the α -chains of an IgA was investigated using MOPC 315 murine plasmacytoma cells. These cells secrete IgA containing complex-type oligosaccharides that were not sensitive to endo- β -N-acetylglucosaminidase H. In contrast, oligosaccharides present on the intracellular α -chain precursor were of the **high mannose**-type, remaining sensitive to endo- β -N-acetylglucosaminidase H despite a long intracellular half-life of 2-3 h. The major [3H]mannose-labeled α -chain oligosaccharides identified after a 20-min pulse were Man8GlcNAc2 and Man9GlcNAc2. Following chase incubations, the major oligosaccharide accumulating intracellularly was Man6GlcNAc2, which contained a single α 1,2-linked mannose residue. Conversion of Man6GlcNAc2 to complex-type oligosaccharides occurred at the time of secretion since appreciable amts. of Man5GlcNAc2 or further processed structures could not be detected intracellularly. The subcellular locations of the α 1,2-mannosidase activities were studied using carbonyl cyanide m-chlorophenylhydrazone and monensin. Despite inhibiting the secretion of IgA, these inhibitors of protein migration did not affect the initial processing of Man9GlcNAc2 to Man6GlcNAc2. Furthermore, no large accumulation of Man5GlcNAc2 occurred, indicating the presence of 2 subcellular locations of α 1,2-mannosidase activity involved in oligosaccharide processing in MOPC 315 cells. Thus, the first 3 α 1,2-linked mannose residues were removed shortly after the α -chain was glycosylated, most likely in rough endoplasmic reticulum, since this processing occurred in the presence of carbonyl cyanide m-chlorophenylhydrazone. However, the removal of the final α 1,2-linked mannose residue as well as subsequent carbohydrate processing occurred just before IgA secretion, most likely in the trans Golgi complex since processing of Man6GlcNAc2 to Man5GlcNAc2 was greatly inhibited in the presence of monensin.
 ST IgA oligosaccharide processing mannosidase; endoplasmic reticulum IgA oligosaccharide processing; Golgi body IgA oligosaccharide processing
 IT Endoplasmic reticulum
 Golgi apparatus
 (mannosidase of, IgA heavy chain oligosaccharides processing by)
 IT Immunoglobulins
 RL: BIOL (Biological study)


- (A, oligosaccharides of heavy chain of, processing of, mannosidase of endoplasmic reticulum and Golgi body in)
- IT Oligosaccharides
RL: BIOL (Biological study)
(asparagine-linked, processing of, of IgA heavy chain, mannosidase of endoplasmic reticulum and Golgi body in)
- IT 66091-47-2 71246-55-4 77355-54-5
RL: BIOL (Biological study)
(IgA heavy chain oligosaccharides processing in relation to)
- IT 77036-51-2
RL: BIOL (Biological study)
(IgA oligosaccharides processing in relation to)
- IT 9068-25-1
RL: BIOL (Biological study)
(of endoplasmic reticulum and Golgi body, IgA oligosaccharides processing by)
- IT 66091-47-2 71246-55-4 77355-54-5
RL: BIOL (Biological study)
(IgA heavy chain oligosaccharides processing in relation to)
- RN 66091-47-2 HCAPLUS
- CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 77355-54-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 77036-51-2

RL: BIOL (Biological study)


(IgA oligosaccharides processing in relation to)

RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L91 ANSWER 40 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:63704 HCAPLUS
DN 100:63704
ED Entered STN: 12 May 1984
TI Structural studies on glycoprotein oligosaccharides of chromaffin granule membranes and dopamine β -hydroxylase
AU Margolis, Renee K.; Finne, Jukka; Krusius, Tom; Margolis, Richard U.
CS Downstate Med. Cent., State Univ. New York, Brooklyn, NY, 11203, USA
SO Archives of Biochemistry and Biophysics (1984), 228(2), 443-9
CODEN: ABBIA4; ISSN: 0003-9861
DT Journal
LA English
CC 6-3 (General Biochemistry)
Section cross-reference(s): 7
AB Dopamine β -hydroxylase (I) present in the soluble matrix of bovine adrenal medullary chromaffin granules contains biantennary complex oligosaccharides and **high-mannose** oligosaccharides in a molar ratio of .apprx.2:1. The **high-mannose** oligosaccharides contain an average of 6 mannose residues. The largest biantennary oligosaccharides (40% of the total) have 2 complete peripheral branches consisting of sialic acid-galactose-N-acetylglucosamine, but an equal proportion lack sialic acid on 1 branch and the remainder lack N-acetylglucosamine and(or) galactose. Affinity chromatog. on lentil lectin-agarose demonstrated that 84% of the I biantennary oligosaccharides are substituted by fucose on the core N-acetylglucosamine, which is linked to **asparagine**. Based on carbohydrate concentration and the proportions of biantennary and **high-mannose** oligosaccharides, the 4 I subunits of 75,000 mol. weight apparently are not identical with respect to their oligosaccharide moieties. In chromaffin granule membranes, **high-mannose** and biantennary oligosaccharides comprise 20 and 35%, resp., of the glycoprotein carbohydrate. Almost 40% is present in the form of large complex oligosaccharides with ≥ 3 antennas, <3% of which have both a core fucose residue and a 2,6-substituted α -linked mannose residue. Chromaffin granule membranes also contain a small proportion (.apprx.6%) of O-glycosidically linked glycoprotein oligosaccharides which are predominantly monosialyl derivs. of galactosyl-N-acetylglucosamine. The ratio of N-acetyl- to N-glycolylneuraminic acid in I and the glycoproteins of chromaffin granule membranes is .apprx.1.5:1, which is within the same range as that previously found in membrane gangliosides and in the chromogranins isolated from the soluble granule matrix.
ST oligosaccharide structure glycoprotein chromaffin granule; dopamine hydroxylase oligosaccharide structure
IT Adrenal medulla
(dopamine β -hydroxylase and membranes of chromaffin granules of, structure of glycoprotein oligosaccharides of)
IT Oligosaccharides
RL: BIOL (Biological study)
(of chromaffin granule membranes and dopamine β -hydroxylase, structure of)
IT Sialoglycoproteins
RL: BIOL (Biological study)
(of chromaffin granule membranes, of adrenal medulla, structure of oligosaccharides of)
IT Molecular structure, natural product
(of oligosaccharides of dopamine β -hydroxylase and membranes of chromaffin granule)
IT Organelle
(chromaffin granule, glycoprotein oligosaccharides of dopamine β -hydroxylase and membranes of, of adrenal medulla, structure of)
IT Oligosaccharides

RL: BIOL (Biological study)
(mannose-containing, of dopamine β -hydroxylase, of chromaffin granule, structure of)

IT 9013-38-1

RL: BIOL (Biological study)
(of adrenal medulla chromaffin granules, oligosaccharides of, structure of)

IT 77355-54-5

RL: BIOL (Biological study)
(of dopamine β -hydroxylase, of adrenal medulla chromaffin granules)

IT 77355-54-5


RL: BIOL (Biological study)
(of dopamine β -hydroxylase, of adrenal medulla chromaffin granules)

RN 77355-54-5 HCAPLUS



CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



L91 ANSWER 41 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:18999 HCAPLUS
 DN 100:18999
 ED Entered STN: 12 May 1984
 TI Swainsonine affects the processing of glycoproteins in vivo
 AU Abraham, David J.; Sidebotham, Ramon; Winchester, Bryan G.; Dorling, Peter R.; Dell, Anne
 CS Queen Elizabeth Coll., Univ. London, London, W8 7AH, UK
 SO FEBS Letters (1983), 163(1), 110-13
 CODEN: FEBLAL; ISSN: 0014-5793
 DT Journal
 LA English
 CC 4-5 (Toxicology)
 AB Rats, sheep and guinea pigs treated with swainsonine [72741-87-8] excrete **high mannose** oligosaccharides in the urine. The major rat and guinea pig oligosaccharide is (Man)5GlcNAc [74385-50-5], whereas sheep excrete a mixture of oligosaccharides of composition (Man)2-5GlcNAc2 and (Man)3-5GlcNAc. The presence of these oligosaccharides suggests that Golgi α -D-mannosidase II as well as lysosomal α -D-mannosidase is inhibited by swainsonine resulting in storage of abnormally processed **asparagine**-linked glycans from glycoproteins. Altered glycoprotein processing appears to have little effect on the health of the intoxicated animal, but the accompanying lysosomal storage produces a disease state.
 ST swainsonine poisoning oligosaccharide urine; glycoprotein metab
 swainsonine poisoning
 IT Poisoning
 (by swainsonine, oligosaccharides of urine response to, glycoprotein metabolism in relation to)
 IT Glycoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism of, swainsonine effect on, oligosaccharides of urine in relation to)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of urine, during swainsonine poisoning, glycoprotein metabolism in relation to)
 IT Urine
 (oligosaccharides of, during swainsonine poisoning, glycoprotein metabolism in relation to)
 IT 60177-38-0 66091-47-2 70858-45-6 74385-49-2
 74385-50-5 81034-76-6
 RL: BIOL (Biological study)
 (of urine, during swainsonine poisoning, glycoprotein metabolism in relation to)
 IT 72741-87-8
 RL: BIOL (Biological study)
 (poisoning by, glycoprotein metabolism response to)
 IT 66091-47-2 70858-45-6

RL: BIOL (Biological study)


(of urine, during swainsonine poisoning, glycoprotein metabolism in relation to)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L91 ANSWER 42 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1984:4518 HCAPLUS

DN 100:4518

ED Entered STN: 12 May 1984

TI Structures of the oligosaccharides present at the three **asparagine**-linked glycosylation sites of human IgD

AU Mellis, Scott J.; Baenziger, Jacques U.

CS Sch. Med., Washington Univ., St. Louis, MO, 63110, USA

SO Journal of Biological Chemistry (1983), 258(19), 11546-56

CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

CC 15-3 (Immunochemistry)

AB The complete amino acid sequence of the human myeloma IgD WAH has been determined and the sites of **asparagine** glycosylation identified as residues 354, 445, and 496 (Takahashi, N., et al., 1982). The structures of the oligosaccharides at each of these positions were determined. **Asparagine** (Asn 354) bears oligosaccharides exclusively of the **high mannose** type containing from 5-9 mannose residues. Twenty per cent of the oligosaccharides at this site contain 1 glucose residue at the terminus of the branch emanating from the α 1-3-linked core mannose which is believed to reflect incomplete processing of the triglucosyl-**high mannose** oligosaccharide intermediate following transfer from dolichol to nascent peptide. **Asn** 445 and **Asn** 496 bear exclusively dibranched complex oligosaccharide structures; 30-40% of these mols. contain a bisecting GlcNAc-linked β 1-4 to the innermost core mannose residue. At **Asn** 445, 40% of both the bisected and nonbisected oligosaccharides contain 1 residue of fucose on the **Asn**-linked GlcNAc and 50% bear a single N-acetylneuraminic acid residue. The oligosaccharides at **Asn** 496 are devoid of sialic acid and fucose. Thus, IgD WAH is notable for the presence of virtually unprocessed oligosaccharide structures (glucosylated **high mannose**) on the same peptide backbone as extensively processed complex type mols. The finding that each of the 3 **Asn** glycosylation sites of IgD WAH bears either exclusively a complex or a **high mannose** type oligosaccharide indicates that there is considerable specificity in the glycosylation process. These oligosaccharides, nonetheless, display extensive microheterogeneity at each location.

ST **asparagine** linked glycosylation IgD WAH; oligosaccharide structure IgD WAH

IT Glycosidation
(**asparagine**-linked sites for, of human IgD WAH, oligosaccharide structure at)

IT Oligosaccharides
RL: BIOL (Biological study)
(at **asparagine**-linked glycosylation sites, of human IgD WAH, structure of)

IT Protein sequences
(of IgD WAH, **asparagine**-linked oligosaccharide structures at glycosidation sites of, of human)

IT Immunoglobulins
(D WAH, **asparagine**-linked glycosylation sites of human, oligosaccharide structures at)

IT 70-47-3, biological studies
RL: BIOL (Biological study)
(-linked glycosylation sites, of human IgD WAH, oligosaccharide structure determination of)


IT 66091-47-2 68329-65-7 68329-66-8 71246-55-4
71799-82-1 75898-93-0 75898-94-1 76392-62-6 76397-74-5
77036-51-2 77355-54-5 77399-91-8
83178-05-6 83562-97-4 83564-26-5 83564-27-6 83602-46-4
85188-33-6 86746-87-4 86746-88-5 88007-08-3
88007-09-4 88070-66-0 88070-67-1 88070-68-2 88070-70-6
88089-12-7 88089-13-8
RL: BIOL (Biological study)
(at **asparagine**-linked glycosylation sites, of human IgD WAH, structure of)

IT 70-47-3, biological studies
RL: BIOL (Biological study)
(-linked glycosylation sites, of human IgD WAH, oligosaccharide structure determination of)

RN 70-47-3 HCAPLUS

CN L-Asparagine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 66091-47-2 71246-55-4 77036-51-2
77355-54-5 77399-91-8 83178-05-6
86746-87-4 86746-88-5
RL: BIOL (Biological study)
(at **asparagine**-linked glycosylation sites, of human IgD WAH, structure of)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 77355-54-5 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 77399-91-8 HCAPLUS

CN D-Glucose, O- α -D-glucopyranosyl-(1 \rightarrow 3)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A


AcNH




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 83178-05-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 86746-87-4 HCAPLUS
 CN D-Glucose, O- α -D-glucopyranosyl-(1 \rightarrow 3)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A


AcNH




PAGE 1-B



PAGE 2-A




PAGE 2-B





RN 86746-88-5 HCAPLUS
 CN D-Glucose, O- α -D-glucopyranosyl-(1 \rightarrow 3)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L91 ANSWER 43 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:87359 HCAPLUS
 DN 98:87359
 ED Entered STN: 12 May 1984
 TI Structure and location of **asparagine**-linked oligosaccharides in
 the Fc region of a human immunoglobulin D
 AU Ishihara, Hideko; Tejima, Setsuzo; Takahashi, Noriko; Takayasu, Tatsunori;
 Shinoda, Tomotaka
 CS Fac. Pharm. Sci., Nagoya City Univ., Nagoya, 467, Japan
 SO Biochemical and Biophysical Research Communications (1983),
 110(1), 181-6
 CODEN: BBRCA9; ISSN: 0006-291X
 DT Journal
 LA English
 CC 15-3 (Immunochemistry)
 AB Seven kinds of **asparagine**-linked oligosaccharides were bound to
 the Fc region of a human IgD (NIG-65). The oligosaccharides quant.
 released from 4 species of glycopeptides by digestion with almond
 glycopeptidase were separated by Bio-Gel p-4 column chromatog. and were
 purified further by thin-layer chromatog. The sugars were identified by
 gas chromatog.-mass spectroscopy following permethylation of the resp.
 oligosaccharides. Two kinds of **high-mannose**-type
 oligosaccharides were bound to **Asn**-168. A kind of hybrid-type
 and 2 kinds of bisected complex-type oligosaccharides were attached to
Asn 159. From **Asn**-210, 4 kinds of bisected complex-type
 oligosaccharides were isolated.
 ST IgD Fc **asparagine** linked oligosaccharide
 IT Immunoglobulins
 RL: BIOL (Biological study)
 (D, Fc region of, **asparagine**-linked oligosaccharides in, of
 human, structure and location of)
 IT Oligosaccharides
 RL: PROC (Process)
 (**asparagine**-linked, of human IgD Fc region, structure and
 location of)
 IT 84632-69-9 84632-70-2 84632-71-3 84632-72-4 84632-73-5
 84632-74-6 84632-75-7 84632-76-8 84632-77-9 84632-78-0
 84632-79-1 84632-80-4 84643-40-3 84643-41-4
 84643-42-5 84643-43-6

RL: BIOL (Biological study)

(asparagine-linked, of human IgD Fc region, structure and location of)

IT 84632-69-9 84632-74-6 84643-40-3
84643-42-5


RL: BIOL (Biological study)

(asparagine-linked, of human IgD Fc region, structure and location of)


RN 84632-69-9 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 84632-74-6 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




PAGE 3-A




RN 84643-40-3 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A




RN 84643-42-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L91 ANSWER 44 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1981:456669 HCAPLUS
 DN 95:56669
 ED Entered STN: 12 May 1984
 TI Carbohydrate structures of HVJ (Sendai virus) glycoproteins
 AU Yoshima, Hideo; Nakanishi, Mahito; Okada, Yoshio; Kobata, Akira
 CS Sch. Med., Kobe Univ., Kobe, Japan
 SO Journal of Biological Chemistry (1981), 256(11), 5355-61
 CODEN: JBCHA3; ISSN: 0021-9258
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB The carbohydrate structures of 2 membrane glycoproteins (HANA protein and F protein) of HVJ were determined on materials purified from virions grown in the allantoic sac of embryonated chicken eggs. Both glycoproteins contain fucose, mannose, galactose, and glucosamine but not galactosamine, indicating that their sugar chains are exclusively of the asparagine-linked type. The radioactive oligosaccharide fractions obtained from the 2 glycoproteins by hydrazinolysis followed by NaB[3H]4 reduction gave quite distinct fractionation patterns after paper electrophoresis. More than 75% of the oligosaccharides from F protein were acidic and separated into ≥ 4 components by paper electrophoresis. Only 18% of the oligosaccharide from HANA protein was an acidic single component. These acidic oligosaccharides could not be converted to neutral oligosaccharide by sialidase digestion. Structural studies of the neutral oligosaccharide fractions from HANA and F proteins revealed that both of them are mixts. of a series of high mannose type oligosaccharides and of complex type oligosaccharides with Gal β 1 \rightarrow 4(Fuc α 1 \rightarrow 3)GlcNAc group in their outer chain moieties.
 ST glycoprotein carbohydrate structure HVJ virus
 IT Carbohydrates, biological studies
 RL: BIOL (Biological study)
 (of glycoproteins, of HVJ virus)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (of glycoproteins, of HVJ virus, structure of)
 IT Glycoproteins
 RL: BIOL (Biological study)
 (F, of HVJ virus, oligosaccharide structures of)
 IT Glycoproteins

RL: BIOL (Biological study)

(HANA, of HVJ virus, oligosaccharide structures of)

IT Virus, animal

(sendai, glycoproteins of, oligosaccharide structures of)

IT 66091-47-2 71496-53-2 78334-42-6 78334-43-7 78334-44-8
78334-45-9 78334-46-0 78334-47-1 78350-88-6 78350-89-7
78392-29-7 78392-30-0 78392-31-1 78392-81-1

RL: BIOL (Biological study)

(of glycoproteins, of HVJ virus)

IT 66091-47-2 78392-29-7 78392-30-0
78392-31-1

RL: BIOL (Biological study)


(of glycoproteins, of HVJ virus)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 78392-29-7 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, mono- α -D-mannopyranoside (9CI) (CA INDEX NAME)

CM 1


CRN 66091-47-2
 CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2

CRN 7296-15-3
 CMF C6 H12 O6

Absolute stereochemistry.



RN 78392-30-0 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, di- α -D-mannopyranoside (9CI)
(CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.




RN 78392-31-1 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L91 ANSWER 45 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1981:438086 HCAPLUS
 DN 95:38086
 ED Entered STN: 12 May 1984
 TI Comparative studies of **asparagine**-linked oligosaccharide

structures of rat liver microsomal and lysosomal β -glucuronidases

AU Mizuochi, Tsuguo; Nishimura, Yukio; Kato, Keitaro; Kobata, Akira

CS Sch. Med., Kobe Univ., Kobe, Japan

SO Archives of Biochemistry and Biophysics (1981), 209(1), 298-303

CODEN: ABBIA4; ISSN: 0003-9861

DT Journal

LA English

CC 7-5 (Enzymes)

AB The sugar chains of microsomal and lysosomal β -glucuronidases of rat liver were studied by endo- β -N-acetylglucosaminidase H digestion and by hydrazinolysis. Only a part of the oligosaccharides released from microsomal β -glucuronidase was an acidic component. The acidic component was not hydrolyzed by sialidase and by calf intestinal and Escherichia coli alkaline phosphatases, but was converted to a neutral component by phosphatase digestion after mild acid treatment, indicating the presence of a phosphodiester group. The neutral oligosaccharide portion of microsomal enzyme was a mixture of 5 **high mannose**-type sugar chains: (Man α 1 \rightarrow 2)6-4 [Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man β 1 \rightarrow 4GlcNAc β 1 \rightarrow 4GlcNAc]. In contrast, lysosomal enzyme contains only Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man β 1 \rightarrow 4GlcNAc β 1 \rightarrow 4GlcNAc. Apparently, removal of α 1 \rightarrow 2-linked mannosyl residues from (Man α 1 \rightarrow 2)4 [Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man α 1 \rightarrow 6 (Man α 1 \rightarrow 3)Man β 1 \rightarrow 4GlcNAc β 1 \rightarrow 4GlcNAc **Asn**] is already started in the endoplasmic reticulum of rat liver.

ST glucuronidase microsome lysosome oligosaccharide structure; liver glucuronidase oligosaccharide microsome lysosome

IT Oligosaccharides

RL: BIOL (Biological study)
(of β -glucuronidase, of liver lysosomes and microsomes, structure of)

IT Liver, composition
(β -glucuronidase of lysosomes and microsomes of, oligosaccharide structures of)

IT Lysosome
Microsome
(β -glucuronidase of, of liver, oligosaccharide structure of)

IT 9001-45-0
RL: BIOL (Biological study)
(of liver lysosomes and microsomes, **asparagine**-linked oligosaccharide structures of)

IT 66091-47-2
RL: BIOL (Biological study)
(of β -glucuronidase, of liver lysosomes and microsomes)

IT 71246-55-4 77036-51-2 77355-54-5
77449-92-4
RL: BIOL (Biological study)
(of β -glucuronidase, of liver microsomes)


IT 66091-47-2
RL: BIOL (Biological study)
(of β -glucuronidase, of liver lysosomes and microsomes)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




IT 71246-55-4 77036-51-2 77355-54-5
 77449-92-4
 RL: BIOL (Biological study)
 (of β -glucuronidase, of liver microsomes)
 RN 71246-55-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH

PAGE 2-A




RN 77355-54-5 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 77449-92-4 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, mono- α -D-mannopyranoside (9CI) (CA INDEX NAME)


CM 1

CRN 77355-54-5


CMF C52 H88 N2 O41

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7296-15-3

CMF C6 H12 O6

Absolute stereochemistry.



L91 ANSWER 46 OF 46 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1979:590024 HCAPLUS
 DN 91:190024
 ED Entered STN: 12 May 1984
 TI Synthesis and processing of protein-linked oligosaccharides in vivo
 AU Hubbard, S. Catherine; Robbins, Phillips W.
 CS Cent. Cancer Res., Massachusetts Inst. Technol., Cambridge, MA, 02139, USA
 SO Journal of Biological Chemistry (1979), 254(11), 4568-76
 CODEN: JBCHA3; ISSN: 0021-9258
 DT Journal
 LA English
 CC 12-2 (Nonmammalian Biochemistry)
 AB The **high-mannose** (Man) and complex **asparagine**-linked oligosaccharides of glycoproteins are believed to derive from a common precursor, a lipid-linked oligosaccharide. Pulse and pulse-chase labeling techniques, together with high-resolution gel filtration chromatog. and digestion with glycosidases, were used to examine the structure of lipid-linked oligosaccharides and their fate after transfer to proteins in vivo. The major lipid-linked oligosaccharide synthesized in secondary chick embryo fibroblasts had the composition Glc3Man3GlcNAc2, with the glucose (Glc) residues exterior to the remainder of the mol. and the N-acetylglucosamine (GlcNAc) residues at the reducing terminus. This oligosaccharide appeared to be the major or exclusive species transferred to protein and, after transfer, it underwent a series of modifications. The 1st glucose residue was removed extremely rapidly (half-time for reaction, <2 min); the 2nd, more slowly (half-time, .apprx.5 min); and the last, most slowly. Subsequent hydrolysis of a variable number of mannose residues gave rise to a family of protein-linked **high-mannose** oligosaccharides ranging from Man9GlcNAc2 to Man5GlcNAc2. Complex protein-linked oligosaccharides were not detectable until after .apprx.10 min of incubation with mannose-3H. Although these results were obtained with uninfected cells, a similar situation appears to exist in vesicular stomatitis- or Sindbis virus-infected cells, in which only 1 or 2 proteins are glycosylated.
 ST oligosaccharide metab fibroblast protein; glycoprotein formation fibroblast
 IT Glycoproteins
 RL: FORM (Formation, nonpreparative)
 (formation of, by fibroblast, precursors in)
 IT Fibroblast
 (glycoprotein formation by, lipid- and protein-linked oligosaccharides in)
 IT Oligosaccharides
 RL: BIOL (Biological study)
 (lipid and protein derivs., of fibroblast, glycoprotein formation in relation to)
 IT Lipids
 RL: BIOL (Biological study)
 (oligosaccharide derivs., of fibroblast, glycoprotein formation in relation to)

IT 66091-47-2D, protein derivs. 71066-12-1D, lipid and protein derivs. 71085-68-2D, protein derivs. 71116-95-5D, protein derivs. 71246-55-4D, protein derivs. 71267-41-9D, protein derivs.
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism of, by fibroblast, glycoprotein formation in relation to)


IT 66091-47-2D, protein derivs. 71066-12-1D, lipid and protein derivs. 71085-68-2D, protein derivs. 71116-95-5D, protein derivs. 71246-55-4D, protein derivs. 71267-41-9D, protein derivs.
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (metabolism of, by fibroblast, glycoprotein formation in relation to)

RN 66091-47-2 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 71066-12-1 HCAPLUS
 CN D-Glucose, O- α -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-glucopyranosyl-(1 \rightarrow 3)-O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B



RN 71085-68-2 HCAPLUS
 CN D-Glucose, O-D-glucopyranosyl- (1→3) -O-D-glucopyranosyl- (1→3) -
 O-α-D-mannopyranosyl- (1→2) -O-α-D-mannopyranosyl-
 (1→2) -O-α-D-mannopyranosyl- (1→3) -O- [O-α-D-

mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-
α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-
(1→6)]-α-D-mannopyranosyl-(1→6)]-O-β-D-
mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX
NAME)


PAGE 1-A




PAGE 1-B

— OH

PAGE 2-A



PAGE 3-A



RN 71116-95-5 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy-, O- α -D-mannopyranosyl deriv.
 (9CI) (CA INDEX NAME)


CM 1

CRN 66091-47-2


CMF C46 H78 N2 O36

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




CM 2

CRN 7322-31-8

CMF C6 H12 O6

Absolute stereochemistry.




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 71267-41-9 HCAPLUS

CN D-Glucose, O-D-glucopyranosyl-(1→3)-O-α-D-mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]]-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A


AcNH




PAGE 1-B



PAGE 2-A



PAGE 2-B



=> => d his

(FILE 'HOME' ENTERED AT 13:33:58 ON 07 OCT 2004)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 13:35:40 ON 07 OCT 2004

FILE 'REGISTRY' ENTERED AT 13:35:52 ON 07 OCT 2004
ACT MAIER714/A

L1 STR
L2 5778 SEA FILE=REGISTRY SSS FUL L1

ACT MAIER714A/A

L3 STR
L4 (5778) SEA FILE=REGISTRY SSS FUL L3
L5 STR
L6 1776 SEA FILE=REGISTRY SUB=L4 SSS FUL L5

ACT MAIER714B/A

L7 STR
L8 (5778) SEA FILE=REGISTRY SSS FUL L7
L9 STR
L10 (1776) SEA FILE=REGISTRY SUB=L8 SSS FUL L9
L11 STR
L12 719 SEA FILE=REGISTRY SUB=L10 CSS FUL L11

FILE 'HCAPLUS' ENTERED AT 13:36:34 ON 07 OCT 2004

L13 1128 S L6
L14 19 S L6 (L) (THU OR PAC OR PKT OR DMA)/RL
L15 15 S L6 (L) BAC/RL
L16 36 S L6 (L) USES+NT/RL
L17 47 S L14-L16
L18 33 S L17 AND (PHARMACEUT? OR PHARMACOL? OR PATHOL? OR IMMUN?)/SC,S
L19 45 S L17 NOT CHLAMYD?
L20 31 S L18 AND L19
L21 45 S L17 NOT CHLAMYD?
L22 45 S L20,L21
L23 360 S L13 AND (PHARMACEUT? OR PHARMACOL? OR PATHOL? OR IMMUN?)/SC,S
L24 218 S L13 AND HIGH MANNOS?
L25 432 S L13 AND N LINK?

FILE 'REGISTRY' ENTERED AT 13:39:49 ON 07 OCT 2004

L26 1 S CHITOBIOSE/CN
L27 2 S ASPARAGINE/CN

FILE 'HCAPLUS' ENTERED AT 13:39:56 ON 07 OCT 2004

L28 32 S L13 AND (L26 OR CHITOBIOSE?)
L29 332 S L13 AND (L27 OR ASN OR ASPARAG?)
L30 81 S L24 AND L28,L29
L31 99 S L24 AND L25
L32 9 S L28 AND L29
L33 5 S L32 AND L22-L25
L34 4 S L33 NOT CHLAMYD?
L35 4 S L32 NOT L33
L36 38 S L22 AND L23-L25
L37 3 S L22 AND L28-L31
L38 39 S L36,L37 NOT CHLAMYD?
L39 769 S L13 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)
L40 0 S L30 AND L22
L41 31 S L30 AND L23
L42 349 S L24,L25,L28,L28 AND L39
L43 23 S L41 AND L42
L44 29 S L41,L43 NOT CHLAMYD?
L45 228 S L23 AND L39
L46 225 S L45 NOT CHLAMYD?

L47 16 S L45 AND ?INFECT?
E INFECTION/CT
L48 16 S E3+OLD,NT,PFT,RT AND L39
L49 13 S L48 NOT CHLAMYD?
L50 16 S L39 AND L47
L51 13 S L50 NOT CHLAMYD?
L52 21 S L49,L51 AND L13-L25,L28-L51
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 13:49:13 ON 07 OCT 2004

L53 79 S E1-E79
L54 45 S L53 AND L12
L55 34 S L53 NOT L54

FILE 'HCAPLUS' ENTERED AT 13:49:42 ON 07 OCT 2004

L56 688 S L54
L57 478 S L56 AND (PY<=1997 OR PRY<=1997 OR AY<=1997)
L58 17 S L57 AND L52
L59 14 S L54 (L) (THU OR BAC OR PKT OR PAC OR DMA)/RL
L60 84 S L54 AND USES+NT/RL
L61 145 S L54 AND (PHARMACOL? OR PHARMACEUT? OR PATHOL? OR IMMUN?)/SX,S
L62 34 S L54 AND ?INFECT?
L63 22 S L54 AND INFECTION+OLD,NT,PFT,RT/CT
L64 102 S L57 AND L59,L50,L61,L62,L63
L65 99 S L64 NOT CHLAMYD?
L66 6 S L59 AND L65
L67 11 S L59 AND L60
L68 5 S L59 AND L62
L69 8 S L59 AND L63
L70 11 S L66-L69 NOT CHLAMYD?
L71 0 S L54 (L) COS/RL
L72 1 S L54 AND COSMETICS+OLD,NT,PFT,RT/CT
L73 1 S L72 AND L57
L74 12 S L70,L73

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:53:42 ON 07 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l74 all hitstr tot


L74 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:791637 HCAPLUS

DN 139:307071
ED Entered STN: 10 Oct 2003
TI Carbohydrates as nutraceuticals and their applications
AU Juneja, Lekh Raj; Sasaki, Ken
CS R & D Lab., Taiyo Kagaku Co., Ltd., Japan
SO Nippon Nogeï Kagaku Kaishi (2003), 77(10), 991-993
CODEN: NNKKAA; ISSN: 0002-1407
PB Nippon Nogeï Kagakkai
DT Journal; General Review
LA Japanese
CC 18-0 (Animal Nutrition)
Section cross-reference(s): 1, 33
AB A review on the preparation and structure of sialylglycopeptide (SGP) and free sialyloligosaccharide (YDS) of hen's egg yolk, preparation of tris-bipyridine ruthenium-complexes carrying YDS and its high-affinity to type A influenza virus, anti-influenza virus activity of polyacrylic type conjugates of YDS, synthesis of oligosaccharide derivs. from YDS or SGP, characteristics of partially hydrolyzed guar gum (PHGG), effects of PHGG on short-chain fatty acid production by human fecal microflora, and physiol. functions of PHGG as a dietary fiber.
ST review sialooligosaccharide egg yolk antiviral; guar gum dietary fiber review
IT Antiviral agents
Dietary fiber
Human
(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); **FFD (Food or feed use)**; **PAC (Pharmacological activity)**; **RCT (Reactant)**; **SPN (Synthetic preparation)**; **BIOL (Biological study)**; **PREP (Preparation)**; **RACT (Reactant or reagent)**; **USES (Uses)**
(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
IT **71496-55-4**
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **PRP (Properties)**; **RCT (Reactant)**; **BIOL (Biological study)**; **RACT (Reactant or reagent)**
(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
IT **71496-55-4DP, conjugates**
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **SPN (Synthetic preparation)**; **BIOL (Biological study)**; **PREP (Preparation)**
(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
IT 9000-30-0, Guar gum
RL: BSU (Biological study, unclassified); **FFD (Food or feed use)**; **PRP (Properties)**; **BIOL (Biological study)**; **USES (Uses)**
(partially hydrolyzed; antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
IT **71496-55-4**
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; **PRP (Properties)**; **RCT (Reactant)**; **BIOL (Biological study)**; **RACT (Reactant or reagent)**
(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)
RN 71496-55-4 HCAPLUS
CN D-Glucose, O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl-


(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-B



IT 71496-55-4DP, conjugates

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(antiviral activity of sialyloligosaccharide derivs. and physiol. functions of partially hydrolyzed guar gum)

RN 71496-55-4 HCAPLUS


CN D-Glucose, O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-B



L74 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:520285 HCAPLUS
 DN 139:96335
 ED Entered STN: 09 Jul 2003
 TI Galectin-9 carbohydrate recognition domain functional analysis for
 eosinophil chemoattractant activity
 IN Kasai, Kenichi; Hirabayashi, Atsushi; Nakamura, Takanori; Nishi, Nozomu;
 Hirashima, Mitsuomi
 PA Gal Pharma Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 44 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 IC ICM C12N015-09
 ICS A61K031-715; A61K039-395; A61K045-00; A61P037-02; A61P037-04;
 A61P037-06; A61P043-00; C07K014-47; C07K016-18; C07K017-10;
 C12N001-15; C12N001-19; C12N001-21; C12N005-10; C12P021-02;
 G01N033-15; G01N033-50
 CC 3-2 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003189874	A2	20030708	JP 2001-398780	20011228
PRAI JP 2001-398780		20011228		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2003189874	ICM	C12N015-09
	ICS	A61K031-715; A61K039-395; A61K045-00; A61P037-02; A61P037-04; A61P037-06; A61P043-00; C07K014-47; C07K016-18; C07K017-10; C12N001-15; C12N001-19; C12N001-21; C12N005-10; C12P021-02; G01N033-15; G01N033-50

AB A solid support having N- or C-terminal carbohydrate recognition domains (CRDs) of galectin-9 immobilized on, and its use in screening of sugar

chains recognized by galectin-9 as modulator of galectin-9 activity, are disclosed. Recombinant galectin-9 having N-terminal CRD and lacking C-terminal CRD or vice versa, encoding nucleic acid, and recombinant expression, are claimed. Antibodies against the sugar chains recognized by galectin-9 are also claimed. Human galectin-9 is a β -galactoside-binding protein consisting of two carbohydrate recognition domains (CRDs) and a linker peptide. The authors have shown that galectin-9 represents a novel class of eosinophil chemoattractants (ECAs) produced by activated T cells. A previous study demonstrated that the carbohydrate binding activity of galectin-9 is indispensable for eosinophil chemoattraction and that the N- and C-terminal CRDs exhibit comparable ECA activity, which is substantially lower than that of full-length galectin-9. In this study, the authors investigated the roles of the two CRDs in ECA activity in conjunction with the sugar-binding properties of the CRDs. In addition, to address the significance of the linker peptide structure, the authors compare the three isoforms of galectin-9, which only differ in the linker peptide region, in terms of ECA activity. Recombinant proteins consisting of two N-terminal CRDs (galectin-9NN), two C-terminal CRDs (galectin-9CC), and three isoforms of galectin-9 (galectin-9S, -9M, and -9L) were generated. All the recombinant proteins had hemagglutination activity comparable to that of the predominant wild-type galectin-9 (galectin-9M). Galectin-9NN and galectin-9CC induced eosinophil chemotaxis in a manner indistinguishable from the case of galectin-9M. Although the isoform of galectin-9 with the longest linker peptide, galectin-9L, exhibited limited solubility, the three isoforms showed comparable ECA activity over the concentration range tested.

The

interactions between N- and C-terminal CRDs and glycoprotein glycans and glycolipid glycans were examined using frontal affinity chromatog. Both CRDs exhibited high affinity for branched complex type sugar chain, especially for tri- and tetraantennary N-linked glycans with N-acetyllactosamine units, and the oligosaccharides inhibited the ECA activity at low concns. These results suggest that the N- and C-terminal CRDs of galectin-9 interact with the same or a closely related ligand on the eosinophil membrane when acting as an ECA and that ECA activity does not depend on a specific structure of the linker peptide.

ST eosinophil chemotaxis galectin 9 carbohydrate recognition domain

IT Oligosaccharides, biological studies

RL: ANT (Analyte); BSU (Biological study, unclassified); **THU** (Therapeutic use); ANST (Analytical study); BIOL (Biological study); **USES (Uses)**

(N-linked, tri- and tetraantennary, binding to galectin-9; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Oligosaccharides, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study) (acetyllactosamine-containing, inhibition of galectin-9 ECA activity by; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Chemotaxis

Hemagglutination (activity; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Protein motifs

(carbohydrate recognition; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Agglutinins and Lectins

RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); **BUU (Biological use, unclassified)**; PRP (Properties); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); **USES (Uses)** (galactose-binding, galectin-9; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Drug screening
Eosinophil
Molecular cloning
(galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Antibodies and Immunoglobulins
RL: **BUU (Biological use, unclassified); THU (Therapeutic use);** BIOL (Biological study); **USES (Uses)**
(galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Human
(galectin-9 from; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Oligosaccharides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of galectin-9 ECA activity by; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Immobilization, molecular or cellular
(of galectin-9 carbohydrate recognition domain; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT Carbohydrates, biological studies
RL: ANT (Analyte); BSU (Biological study, unclassified); **THU (Therapeutic use);** ANST (Analytical study); BIOL (Biological study); **USES (Uses)**
(recognized by galectin-9; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT 82867-73-0 82867-74-1 84813-89-8 107676-46-0
107688-07-3 107741-95-7
RL: ANT (Analyte); BSU (Biological study, unclassified); **THU (Therapeutic use);** ANST (Analytical study); BIOL (Biological study); **USES (Uses)**
(binding to galectin-9; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)


IT 556877-54-4 556877-55-5 556877-56-6 556877-57-7 556877-58-8
556877-59-9 556877-60-2 556877-61-3
RL: PRP (Properties)
(unclaimed nucleotide sequence; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)

IT 82867-73-0 82867-74-1
RL: ANT (Analyte); BSU (Biological study, unclassified); **THU (Therapeutic use);** ANST (Analytical study); BIOL (Biological study); **USES (Uses)**
(binding to galectin-9; galectin-9 carbohydrate recognition domain functional anal. for eosinophil chemoattractant activity)


RN 82867-73-0 HCAPLUS
CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-B



—CHO

RN 82867-74-1 HCAPLUS


CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



—CHO

L74 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:458435 HCAPLUS
 DN 138:117255
 ED Entered STN: 19 Jun 2002
 TI Polymeric inhibitor of influenza virus attachment protects mice from
 experimental influenza **infection**
 AU Gambaryan, A. S.; Tuzikov, A. B.; Chinarev, A. A.; Juneja, L. R.; Bovin,
 N. V.; Matrosovich, M. N.
 CS M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides, Russian
 Academy of Medical Sciences, Moscow, 142 782, Russia
 SO Antiviral Research (2002), 55(1), 201-205

CODEN: ARSRDR; ISSN: 0166-3542

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-5 (Pharmacology)

AB Synthetic sialic acid-containing macromols. inhibit influenza virus attachment to target cells and suppress the virus-mediated hemagglutination and neutralize virus **infectivity** in cell culture. To test the protective effects of attachment inhibitors in vivo, mice were **infected** with mouse-adapted influenza virus A/Aichi/2/68 (H3N2) and treated with synthetic polyacrylamide-based sialylglycopolymer PAA-YDS bearing moieties of (Neu5Ac α 2-6Gal β 1-4GlcNAc β 1-2Man α 1)2-3,6Man β 1-4GlcNAc β 1-4GlcNAc. Single intranasal inoculations with PAA-YDS 30 min before or 10 min after **infection** increased the survival of mice. Multiple treatments with aerosolized PAA-YDS on days 2-5 post **infection** also increased survival, alleviated disease symptoms, and decreased lesions in the mouse lungs. These data suggest that synthetic polyvalent inhibitors of virus attachment can be used for prevention and treatment of influenza.

ST polymeric inhibitor influenza virus **infection** treatment

IT Antiviral agents

Influenza

Influenza A virus

(polymeric inhibitor of influenza virus attachment protects mice from exptl. influenza **infection**)

IT 67391-52-0D, reaction products with sialylglycoside 71496-55-4D,

reaction products with nitrophenyl acrylate homopolymer

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(polymeric inhibitor of influenza virus attachment protects mice from exptl. influenza **infection**)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bovin, N; Glycoconj J 1993, V10, P142 HCAPLUS

(2) Bradley, D; Drug Discov Today 1999, V4, P540

(3) Chinarev, A; Tetraivalent Blockers for Influenza Virus Hemagglutinin 1999, P135

(4) Choi, S; J Am Chem Soc 1997, V119, P4103 HCAPLUS

(5) Dintzis, R; J Immunol 1989, V143, P1239 HCAPLUS

(6) Gambaryan, A; Virology 1997, V232, P345 HCAPLUS

(7) Herrler, G; Biology of the Sialic Acids 1995, P315 HCAPLUS

(8) Itoh, M; Virology 1995, V212, P340 HCAPLUS

(9) Kiessling, L; Chem Biol 1996, V3, P71 HCAPLUS

(10) Matrosovich, M; FEBS Lett 1989, V252, P1 HCAPLUS

(11) Mochalova, L; Antiviral Res 1994, V23, P179 HCAPLUS

(12) Ovcharenko, A; Antiviral Res 1994, V23, P107 HCAPLUS

(13) Paulson, J; The Receptors 1985, V2, P131 HCAPLUS

(14) Reuter, J; Bioconj Chem 1999, V10, P271 HCAPLUS

(15) Skehel, J; Annu Rev Biochem 2000, V69, P531 HCAPLUS

(16) Tuzikov, A; Antiviral Res 1997, V33, P129 HCAPLUS

(17) Tuzikov, A; J Carbohydr Chem 2000, V19, P1191 HCAPLUS

IT 71496-55-4D, reaction products with nitrophenyl acrylate homopolymer

RL: PAC (Pharmacological activity); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)

(polymeric inhibitor of influenza virus attachment protects mice from exptl. influenza **infection**)


RN 71496-55-4 HCAPLUS

CN D-Glucose, O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-


(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-B



L74 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:214941 HCAPLUS

DN 134:256860

ED Entered STN: 27 Mar 2001

TI Genetic liposomal vaccines containing oligosaccharides on the surface

IN Mizuochi, Tsugio; Kojima, Naoya; Yasuda, Atsushi

PA Tokai University, Japan; Nippon Zeon Co., Ltd.

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K039-00

ICS A61K009-127; A61K031-711; A61P037-04

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001081044	A2	20010327	JP 1999-259717	19990914
PRAI	JP 1999-259717		19990914		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2001081044	ICM	A61K039-00
	ICS	A61K009-127; A61K031-711; A61P037-04

AB This invention relates to liposomes which contain nucleic acids and oligosaccharides bonded to antigen-presenting cell derived lectin. The liposomes provide adjuvant activities and are highly efficient in inducing cell-mediated immunity when administered to a host. A liposomal vaccine was prepared containing mannopentaose/dipalmitoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine, and pCMV-βGalplasmid.

ST genetic liposome vaccine oligosaccharide lectin

IT Gene therapy

Vaccines

(genetic liposomal vaccines containing oligosaccharides on surface)

IT Agglutinins and Lectins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(genetic liposomal vaccines containing oligosaccharides on surface)

IT DNA
RL: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(genetic liposomal vaccines containing oligosaccharides on surface)

IT Nucleic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(genetic liposomal vaccines containing oligosaccharides on surface)

IT Oligosaccharides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(genetic liposomal vaccines containing oligosaccharides on surface)

IT Drug delivery systems
(liposomes; genetic liposomal vaccines containing oligosaccharides on surface)

IT Plasmids
(pCMV-βGal; genetic liposomal vaccines containing oligosaccharides on surface)


IT 57-88-5D, Cholesterol, glycolipids containing 2644-64-6D,
Dipalmitoylphosphatidylcholine, glycolipids containing 5681-36-7D,
Dipalmitoylphosphatidylethanolamine, glycolipids containing 34141-02-1D,
glycolipids containing 71246-55-4D, glycolipids containing
112828-69-0D, glycolipids containing 129583-07-9D, glycolipids containing
137056-72-5D, 3β-[N-[2-(N,N-Dimethylamino)ethyl]carbamoyl]cholesterol
, glycolipids containing 149952-31-8D, glycolipids containing
RL: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(genetic liposomal vaccines containing oligosaccharides on surface)

IT 71246-55-4D, glycolipids containing
RL: THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(genetic liposomal vaccines containing oligosaccharides on surface)


RN 71246-55-4 HCAPLUS

CN D-Glucose, O-α-D-mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-α-D-mannopyranosyl-(1→6)-O-[O-α-D-mannopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 1-A



PAGE 1-B



PAGE 2-A



L74 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:742234 HCAPLUS
 DN 133:295375
 ED Entered STN: 20 Oct 2000
 TI Method for controlling the activity of immunologically functional molecule
 IN Hanai, Nobuo; Nakamura, Kazuyasu; Shoji, Emi; Yamasaki, Motoo; Uchida, Kazuhisa; Shinkawa, Toyohide; Imabeppu, Susumu; Kanda, Yutaka; Yamane, Naoko; Anazawa, Hideharu
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM C12N015-09
 ICS C12P021-00; C12P021-08; A61K039-00; G01N033-53
 CC 15-3 (Immunochemistry)
 Section cross-reference(s): 1, 3

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061739	A1	20001019	WO 2000-JP2260	20000407
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1176195	A1	20020130	EP 2000-915403	20000407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-103158	A	19990409		
	WO 2000-JP2260	W	20000407		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000061739	ICM	C12N015-09
	ICS	C12P021-00; C12P021-08; A61K039-00; G01N033-53
EP 1176195	ECLA	C07K016/28H; C07K016/30

AB A method for controlling the activity of an immunol. functional mol. such as an antibody, a protein or a peptide; a promoter of the activity of an immunol. functional mol.; and an immunol. functional mol. having a promoted immunol. functional activity. The immunol. functional mol. contains carbohydrate moiety having reduced N-glycoside or N-acetylglucosamine terminal with/without fucose linkage. The immunol. functional mols. are useful for diagnosis and treatment of cancers, autoimmune diseases, allergies, circulation system diseases, inflammations, and viral or bacterial infections.

ST antibody glycoside cancer autoimmune disease infection

IT Animal cell line
 (ATCC CRL1662; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT Glycosides
 RL: BSU (Biological study, unclassified); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (N-; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease, allergy, circulation disease and

- viral or bacterial infection)
- IT Allergy
Allergy inhibitors
Animal virus
 Anti-inflammatory agents
 Antibacterial agents
Antitumor agents
Antiviral agents
Autoimmune disease
Immunosuppressants
Inflammation
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease)
- IT Antigens
Interleukin 5 receptors
RL: BSU (Biological study, unclassified); **THU (Therapeutic use);**
BIOL (Biological study); **USES (Uses)**
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease)
- IT Multiple myeloma
Rat
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease, allergy, circulation disease and
 viral or bacterial infection)
- IT Antibodies
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
PRP (Properties); **THU (Therapeutic use);** BIOL (Biological
study); PREP (Preparation); **USES (Uses)**
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease, allergy, circulation disease and
 viral or bacterial infection)
- IT Enzymes, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease, allergy, circulation disease and
 viral or bacterial infection)
- IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); **THU (Therapeutic use);**
BIOL (Biological study); **USES (Uses)**
 (antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease, allergy, circulation disease and
 viral or bacterial infection)
- IT Antigens
RL: BSU (Biological study, unclassified); **THU (Therapeutic use);**
BIOL (Biological study); **USES (Uses)**
 (autoantigens; antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease)
- IT Infection
 (bacterial; antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease)
- IT Diagnosis
 (cancer; antibodies or proteins containing reduced N-glycosides or
 N-acetylglucosamines with or without fucose linkage for diagnosis and
 therapy of cancer, autoimmune disease)
- IT Neoplasm

(diagnosis; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT Circulation

(disorder; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT Peptides, biological studies

Proteins, general, biological studies

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological

study); PREP (Preparation); **USES (Uses)**

(immunol. functional; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT Biochemical molecules

(immunol.; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease, allergy, circulation disease and viral or bacterial **infection**)

IT Antigens

RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**;

BIOL (Biological study); **USES (Uses)**

(tumor-associated; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT Infection

(viral; antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease)

IT 56626-18-7, Fucosyltransferase 62010-37-1, Ganglioside GD3 113670-18-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease, allergy, circulation disease and viral or bacterial **infection**)

IT 2438-80-4 7512-17-6 70858-45-6

RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**;

BIOL (Biological study); **USES (Uses)**

(antibodies or proteins containing reduced N-glycosides or N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease, allergy, circulation disease and viral or bacterial **infection**)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Behringwerke Aktinen Gesellschaft; JP 06319554 A HCAPLUS

(2) Behringwerke Aktinen Gesellschaft; CA 2122745 A HCAPLUS

(3) Behringwerke Aktinen Gesellschaft; DE 4314556 A1 HCAPLUS

(4) Behringwerke Aktinen Gesellschaft; AU 9461829 A HCAPLUS

(5) Behringwerke Aktinen Gesellschaft; EP 623352 A2 1994 HCAPLUS

(6) Biogen Inc; JP 08507680 A

(7) Biogen Inc; EP 678122 A1 HCAPLUS

(8) Biogen Inc; AU 9459936 A HCAPLUS

(9) Biogen Inc; WO 9416094 A2 1994 HCAPLUS

(10) Iain, B; Glycoconjugate Journal 1998, V15(11), P1055

(11) Kenya, S; Journal of Immunological Methods 1994, V167(1-2), P271

(12) Kyowa Hakko Kogyo Kk; JP 10257893 A HCAPLUS

(13) Kyowa Hakko Kogyo Kk; AU 9859420 A HCAPLUS

(14) Kyowa Hakko Kogyo Kk; EP 882794 A2 1998 HCAPLUS

IT 70858-45-6

RL: BSU (Biological study, unclassified); **THU (Therapeutic use)**;

BIOL (Biological study); **USES (Uses)**


(antibodies or proteins containing reduced N-glycosides or

N-acetylglucosamines with or without fucose linkage for diagnosis and therapy of cancer, autoimmune disease, allergy, circulation disease and viral or bacterial **infection**)

RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L74 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:518252 HCAPLUS

DN 131:153726

ED Entered STN: 19 Aug 1999

TI Inhibition of bacterial binding by high-mannose oligosaccharides, and method for the treatment of Gram-negative bacterial **infections**

IN Smith, Sam; Elbein, Alan D.; Pan, Y. T.

PA The Board of Trustees of the University of Arkansas, USA

SO U.S., 20 pp.

CODEN: USXXAM

DT Patent

LA English

IC ICM G01N033-554

ICS G01N033-53; C12Q001-18

NCL 435007320

CC 1-5 (Pharmacology)

Section cross-reference(s): 10

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5939279	A	19990817	US 1997-932876	19970918 <--
PRAI US 1997-932876		19970918	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 5939279	ICM	G01N033-554
	ICS	G01N033-53; C12Q001-18
	NCL	435007320

AB A method is provided for the treatment of Gram-neg. bacterial **infections** using high-mannose containing oligosaccharides.

Specifically, the invention describes the use of Man9 (GlcNAc)₂-hydrophobic glycopeptides (i.e. tyrosinamide) to block adhesion of the bacteria pili to the oligosaccharide of the host cells plasma membrane in **infections** of Enterobacter cloacae and other Enterobacter and gram-neg. species.

- ST high mannose oligosaccharide bacterial **infection** treatment; Gram neg bacterial **infection** mannose oligosaccharide; Enterobacter **infection** treatment high mannose oligosaccharide; tyrosinamide high mannose oligosaccharide antibacterial
- IT Adhesins
RL: PUR (Purification or recovery); PREP (Preparation)
(Enterobacter cloacae pili; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Pilus
(Enterobacter cloacae, adhesin from; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Soybean (Glycine max)
(agglutinin, high-mannose oligosaccharide-tyrosinamide from; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Animal cell
(bacterial binding; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Bacteria (Eubacteria)
(bacterial-cell binding; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT **Antibacterial agents**
Cell adhesion
Enterobacter cloacae
Gram-negative bacteria
Protein sequences
(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Oligosaccharides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (**Therapeutic use**); BIOL (Biological study); **USES (Uses)**
(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT Agglutinins and Lectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(soy bean, high-mannose oligosaccharide-tyrosinamide from; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT 237743-58-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (**Therapeutic use**); BIOL (Biological study); PREP (Preparation); **USES (Uses)**
(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)
- IT 617-04-9 3458-28-4, Mannose 6614-35-3 34141-02-1 69401-47-4
71246-55-4 72741-87-8, Swainsonine 79831-76-8, Castanospermine
84182-22-9 84444-90-6, Deoxymannojirimycin 109944-15-2,
Kifunensine 112828-69-0 164121-22-6 164121-23-7 164121-31-7
220696-55-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (**Therapeutic use**); BIOL (Biological study); **USES (Uses)**

(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)

IT 237743-63-4 237743-64-5 237743-65-6

RL: PRP (Properties)

(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)

IT 37211-66-8, Mannosidase 82047-77-6, Mannosidase II

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Eden; Current Topics in Microbiology 1990, V151, P167

(2) Elbein; FASEB 1991, V5, P3055 HCAPLUS

(3) Firon; Biochem Biophys Res Commun 1982, V105, P1426 HCAPLUS

(4) Jones; Proc Natl Acad Sci USA 1995, V92, P2081 HCAPLUS

(5) Wold; Infection and Immunity 1990, V58(9), P3073 HCAPLUS

IT 71246-55-4 84182-22-9 220696-55-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); **USES (Uses)**

(high-mannose oligosaccharides for inhibition of bacterial binding, and method for treatment of Gram-neg. bacterial **infections**)


RN 71246-55-4 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute ϵ




PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 84182-22-9 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

7

PAGE 1-A




PAGE 2-A




RN 220696-55-9 HCAPLUS
 CN Carbamic acid, [(1S)-2-amino-1-[[4-[[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxylphenyl]methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L74 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:352961 HCAPLUS
 DN 129:37202
 ED Entered STN: 11 Jun 1998
 TI Novel polymeric complexes for the transfection of nucleic acids, with
 residues causing the destabilization of cell membranes
 IN Midoux, Patrick; Monsigny, Michel
 PA I.D.M. Immuno-Designed Molecules, Fr.; Midoux, Patrick; Monsigny, Michel
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 IC ICM C12N015-88
 ICS A61K048-00
 CC 3-1 (Biochemical Genetics)
 Section cross-reference(s): 33, 34
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9822610	A1	19980528	WO 1997-FR2022	19971110 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				

GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

FR 2755976	A1	19980522	FR 1996-13990	19961115 <--
FR 2755976	B1	19990115		
CA 2267833	AA	19980528	CA 1997-2267833	19971110 <--
AU 9851239	A1	19980610	AU 1998-51239	19971110 <--
AU 742818	B2	20020110		
EP 946744	A1	19991006	EP 1997-945903	19971110 <--
EP 946744	B1	20040818		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

JP 2001504344	T2	20010403	JP 1998-523257	19971110 <--
US 6372499	B1	20020416	US 1999-297519	19990503 <--

PRAI FR 1996-13990 A 19961115 <--
 WO 1997-FR2022 W 19971110 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9822610	ICM	C12N015-88
	ICS	A61K048-00

OS MARPAT 129:37202

AB The invention concerns a complex between at least a (neg. charged) nucleic acid and at least a pos. charged polymeric conjugate, the bond between the nucleic acid and the polymeric conjugate being electrostatic in nature, the polymeric conjugate containing a polymer formed by monomer units bearing free NH₃⁺ functions, and being such that: the free NH₃⁺ functions of said monomer units are substituted in a ratio of ≥ 10 % by residues causing in weak acid medium destabilization of cell membranes, in particular the endocytosis vesicle membrane, and/or endosomes; said residues having further the following properties: they comprise a functional group for being fixed to said polymer, they are not active as recognition signal identified by a cell membrane receptor, they can comprise at least one free NH₃⁺ function; said uncharged residues having further the following properties: they comprise at least a hydroxyl group, they are not active as recognition signal identified by a cell membrane receptor, the hydroxyl groups of said uncharged residues being capable of being substituted by at least a mol. which constitutes a recognition signal identified by a cell membrane receptor, with reservation that the whole set of free NH₃⁺ functions is at least 30 % of the number of monomer units of the polymeric network of said polymeric conjugate.

ST gene transfection polymer complex oligosaccharide prepn

IT **Immunodeficiency**

(ADA; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (HLA-B7, gene encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

IT Lipoprotein receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (LDL, gene encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

IT Histocompatibility antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (MHC (major histocompatibility complex), gene encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

IT **Vaccines**

(antigens for; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

IT Polyelectrolytes

(cationic, nucleic acid conjugates; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

- IT Receptors
 - RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
 - (cell membrane; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Nervous system
 - (central; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Cell membrane
 - (destabilization; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Organelle
 - (endocytic vesicle; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Blood vessel
 - (endothelium; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Respiratory tract
 - (epithelium; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Muscle
 - (fiber; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Antibiotic resistance
 - (gene conferring; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Dystrophin
 - Tumor necrosis factors
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (gene encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Antisense RNA
 - RNA
 - Ribozymes
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (genes encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Liver
 - (hepatocyte; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Skin
 - (keratinocyte; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Fibronectins
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (ligands; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Enzymes, biological studies
 - RL: BSU (Biological study, unclassified); BIOL (Biological study)
 - (lysosomal, genes encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Lymphocyte
 - (natural killer cell; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Influenza virus
 - (nucleoproteins of, genes encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)

- IT Nucleoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of influenza virus, genes encoding; polymeric complexes for the
transfection of nucleic acids, with residues causing the
destabilization of cell membranes)
- IT Hormones, animal, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); PEP
(Physical, engineering or chemical process); PRP (Properties); **THU**
(**Therapeutic use**); BIOL (Biological study); PROC (Process); **USES**
(**Uses**)
(peptide; polymeric complexes for the transfection of nucleic acids,
with residues causing the destabilization of cell membranes)
- IT Acidity
Aequorea victoria
Alzheimer's disease
Cystic fibrosis
Dendritic cell
Endosome
Fibroblast
Gaucher disease
Hydroxyl group
Lymphocyte
Macrophage
Melanocyte
Molecular cloning
Neoplasm
Parkinson's disease
Phenylketonuria
Skin
Transformation, genetic
pH
(polymeric complexes for the transfection of nucleic acids, with
residues causing the destabilization of cell membranes)
- IT Nucleic acids
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(polymeric complexes for the transfection of nucleic acids, with
residues causing the destabilization of cell membranes)
- IT Annexins
Chemotactic factors
RGD peptides
RL: BPR (Biological process); BSU (Biological study, unclassified); PEP
(Physical, engineering or chemical process); PRP (Properties); **THU**
(**Therapeutic use**); BIOL (Biological study); PROC (Process); **USES**
(**Uses**)
(polymeric complexes for the transfection of nucleic acids, with
residues causing the destabilization of cell membranes)
- IT Aequorins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymeric complexes for the transfection of nucleic acids, with
residues causing the destabilization of cell membranes)
- IT CFTR (cystic fibrosis transmembrane conductance regulator)
Cytokines
Interleukins
Polyamides, biological studies
Polymers, biological studies
Quaternary ammonium compounds, biological studies
Reporter gene
RL: PEP (Physical, engineering or chemical process); **THU** (**Therapeutic**
use); BIOL (Biological study); PROC (Process); **USES** (**Uses**)
(polymeric complexes for the transfection of nucleic acids, with
residues causing the destabilization of cell membranes)
- IT Protein motifs

- (recognition signals; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Genetic element
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); **USES (Uses)**
(signal sequence; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Blood vessel
(smooth muscle; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Hematopoietic precursor cell
(stem; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT Human herpesvirus
(thymidine kinase of; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 9002-06-6, Thymidine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene encoding, of Herpes simplex virus; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 9001-28-9, Factor ix 9014-00-0, Luciferase 9025-05-2, Cytosine deaminase 9026-93-1, Adenosine deaminase 9029-73-6, Phenylalanine hydroxylase 9031-11-2, β -Galactosidase 9036-22-0, Tyrosine hydroxylase 9040-07-7, Chloramphenicol acetyl transferase 113189-02-9, Factor viii
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gene encoding; polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 58-85-5, Biotin 59-30-3, Folic acid, biological studies 135-16-0
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 58-82-2, Bradykinin 37213-49-3, α -MSH 37221-79-7, Vip 40077-57-4, Vasoactive intestinal octacosapeptide (swine) 59880-97-6 77036-51-2 82867-73-0 82867-74-1 85637-73-6, ANP 85985-42-8 91917-63-4, Atrial natriuretic peptide-28 (human reduced) 118850-72-9 140913-62-8 208337-46-6 208337-47-7 208342-23-8 208342-24-9
RL: BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); **USES (Uses)**
(polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 1404-04-2, Neomycin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 14798-03-9, Ammonium ion, processes
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(polymeric complexes for the transfection of nucleic acids, with residues causing the destabilization of cell membranes)
- IT 51-45-6, Histamine, biological studies 59-67-6, Nicotinic acid, biological studies 70-26-8, Ornithine 71-00-1, Histidine, biological studies 86-68-0, Quininic acid 89-00-9, Quinolinic acid 90-34-6, Primaquine 91-22-5D, Quinoline, derivs., biological studies 110-86-1D, Pyridine, derivs., biological studies 119-24-4, Pteric acid 288-32-4D, Imidazole, derivs. 305-84-0, Carnosine 501-75-7 526-95-4D, Gluconic acid, derivs. 644-42-8 645-65-8,

1H-Imidazole-4-acetic acid 2236-60-4D, Pterin, derivs. 2466-76-4,
 Acetyl imidazole 4298-14-0 7212-31-9 9041-92-3, α 1-Antitrypsin
 9061-61-4, Nerve growth factor 14403-45-3 16042-25-4,
 1H-Imidazole-2-carboxylic acid 25104-18-1, Polylysine 26469-60-3,
 Quinoline carboxylic acid 28095-60-5 38000-06-5, Polylysine
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
 use); BIOL (Biological study); PROC (Process); USES (Uses).

(polymeric complexes for the transfection of nucleic acids, with
 residues causing the destabilization of cell membranes)

IT 25988-63-0P, Polylysine hydrobromide

RL: PNU (Preparation, unclassified); RCT (Reactant); PREP (Preparation);
 RACT (Reactant or reagent)

(polymeric complexes for the transfection of nucleic acids, with
 residues causing the destabilization of cell membranes)

IT 104-15-4, reactions 5961-85-3, Tris-carboxyethylphosphine 7087-68-5,
 Diisopropylethylamine 20866-46-0 56602-33-6 112241-19-7
 208342-20-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(polymeric complexes for the transfection of nucleic acids, with
 residues causing the destabilization of cell membranes)

IT 25104-18-1DP, Polylysine, reaction products with 4-carbonyl- α -methyl-
 α -(2-pyridinyldithio)toluene N-hydroxysuccinimide 208342-19-2P
 208342-21-6P 208342-22-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(polymeric complexes for the transfection of nucleic acids, with
 residues causing the destabilization of cell membranes)

IT 6379-56-2, Hygromycin

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (resistance to; polymeric complexes for the transfection of nucleic
 acids, with residues causing the destabilization of cell membranes)

IT 56-87-1, L-Lysine, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ϵ -amino group of; polymeric complexes for the transfection of
 nucleic acids, with residues causing the destabilization of cell
 membranes)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Advanced Magnetics Inc; WO 9211037 A 1992 HCAPLUS
- (2) Boehringer Ingelheim Int Inc; WO 9213570 A 1992 HCAPLUS
- (3) Boehringer Ingelheim International Inc; EP 0387775 A 1990 HCAPLUS
- (4) Boehringer Ingelheim International Inc; EP 0388758 A 1990 HCAPLUS
- (5) Hoffmann-La Roche; FR 2107756 A 1972 HCAPLUS
- (6) Idm Immuno-Designed Molecules; FR 2719316 A 1995 HCAPLUS
- (7) Mezo, G; BIOPOLYMERS 1993, V33(6), P873 HCAPLUS
- (8) Midoux, P; NUCLEIC ACIDS RESEARCH 1993, V21(4), P871 HCAPLUS
- (9) Takeda Chemical Industries Ltd; EP 0350246 A 1990 HCAPLUS
- (10) Wang, C; BIOCHEMISTRY 1984, V23(19), P4409 HCAPLUS
- (11) Wu, G; US 5166320 A 1992 HCAPLUS

IT 77036-51-2 82867-73-0 82867-74-1

208337-46-6 208337-47-7 208342-24-9

RL: BPR (Biological process); BSU (Biological study, unclass:
 (Physical, engineering or chemical process); PRP (Properties)
 (Therapeutic use); BIOL (Biological study); PROC (Process); t
 (Uses)

(polymeric complexes for the transfection of nucleic acids
 residues causing the destabilization of cell membranes)


RN 77036-51-2 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-
 mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O-
 α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-
 (1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-
 mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-

(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-
2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OH


PAGE 2-A




RN 82867-73-0 HCAPLUS
 CN D-Glucose, O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-[O-β-D-galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)]-O-α-D-mannopyranosyl-(1→3)-O-[O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



CHO

RN 82867-74-1 HCAPLUS


CN D-Glucose, O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 6)]- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME),

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




— CHO


RN 208337-46-6 HCAPLUS
 CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-6-O-phosphono- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O-6-O-phosphono- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 208337-47-7 HCAPLUS


CN D-Glucose, O-2-(acetylamino)-2-deoxy-4-O-sulfo- β -D-glucopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-2-(acetylamino)-2-deoxy-4-O-sulfo- β -D-glucopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B




RN 208342-24-9 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-6-O-phosphono- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O-6-O-phosphono- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B

—OPO₃H₂

L74 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:87591 HCAPLUS
 DN 128:171946
 ED Entered STN: 14 Feb 1998
 TI Reduction of hair growth by inhibiting the formation of glycoproteins
 IN Henry, James P.; Ahluwalia, Gurpreet S.; Kaszynski, Edwin; Shander, Douglas
 PA Handelman, Joseph, H., USA; Henry, James P.; Ahluwalia, Gurpreet S.; Kaszynski, Edwin; Shander, Douglas
 SO PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K007-06
 CC 62-3 (Essential Oils and Cosmetics)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803149	A1	19980129	WO 1997-US11990	19970716 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5908867	A	19990601	US 1996-684287	19960718 <--
	AU 9735995	A1	19980210	AU 1997-35995	19970716 <--
	EP 938286	A1	19990901	EP 1997-932567	19970716 <--
	EP 938286	B1	20031105		
	R: DE, ES, FR, GB, IT				
	ES 2208928	T3	20040616	ES 1997-932567	19970716 <--
	ZA 9706348	A	19980203	ZA 1997-6348	19970717 <--
	ZA 9711008	A	19980615	ZA 1997-11008	19971208 <--
PRAI	US 1996-684287	A1	19960718	<--	
	WO 1997-US11990	W	19970716	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9803149	ICM	A61K007-06
WO 9803149	ECLA	A61K007/06C16; A61K007/06C14B; A61K007/06C26; A61K008/49F; A61K008/49H; A61K008/60; A61K008/60A; A61K008/64; A61Q007/02 <--
US 5908867	ECLA	A61K007/06C14B; A61K007/06C16; A61K007/06C22; A61K007/06C26; A61K007/06C20 <--

AB A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatol. acceptable composition containing a compound that inhibits the formation of glycoproteins, proteoglycans, or glycosaminoglycans in an amount effective to cause a reduction

in hair growth. D-Mannose was mixed at a concentration of 30 % in a vehicle containing water 68, ethanol 16, propylene glycol 5, dipropylene glycol 5, benzyl alc. 4, and propylene carbonate 2 % and when tested in the Golden Syrian hamster assay, hair growth inhibition by 77 % was observed

ST hair growth redn glycoprotein inhibitor; mannose hirsutism hair growth inhibitor

IT **Cosmetics**
(depilatories; hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

IT Hirsutism
(hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

IT Exocytosis
(of proteoglycans; hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

IT 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 9050-30-0, Heparan sulfate 9068-25-1 9073-99-8, Glucosidase II 24967-94-0, Dermatan sulfate 37247-98-6D, Pyrophosphoryl dolichol, oligosaccharide derivs. 56938-89-7, N-Acetylglucosamine pyrophosphoryldolichol 70226-44-7, Heparan **71246-55-4D**, glucopyranose derivs. 73699-12-4, Glucosidase I 82047-77-6, Mannosidase II 169799-44-4, Keratin sulfate
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

IT 59-23-4, Galactose, biological studies 90-89-1, Diethylcarbamazine 612-05-5, Methyl- β -D-xylopyranoside 1402-82-0, Amphomycin 1405-87-4, Bacitracin 2001-96-9 2438-80-4, Fucose 3416-24-8, D-Glucosamine 3458-28-4, D-Mannose 3615-37-0, D-Fucose 6734-33-4, 4-Methylumbelliferyl- β -D-xyloside 7512-17-6, N-Acetyl-D-glucosamine 10030-80-5, L-Mannose 11054-63-0, Tsushimycin 11089-65-9, Tunicamycin 11141-18-7, Diumycin 12633-72-6, Amphotericin 14948-96-0 15572-79-9, L-Galactose 16755-07-0, Showdomycin 17090-79-8, Monensin 19130-96-2, Deoxynojirimycin 38440-79-8 41355-95-7 56833-74-0, Streptovirudin 69567-10-8 79831-76-8, Castanospermine 84444-90-6, Deoxymannojirimycin 95189-02-9 101858-10-0, Mycosporidin 202843-55-8
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

IT 9031-11-2, β -Galactosidase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Golub; US 5532227 A 1996 HCAPLUS
- (2) Handelman, J; WO 9626712 A 1996 HCAPLUS
- (3) Institut Pasteur; FR 2632526 A 1989 HCAPLUS
- (4) Kao Corp; JP 860175414 A 1986
- (5) Medicis Pharmaceutical Corporation; WO 9715282 A 1997 HCAPLUS
- (6) Merrell Dow Pharm Inc; EP 0295538 A 1988 HCAPLUS
- (7) Sansho Seiyaku Kk; EP 0308919 A 1989 HCAPLUS
- (8) The Rockefeller University; WO 9313775 A 1993 HCAPLUS
- (9) The Rockefeller University; WO 9314750 A 1993 HCAPLUS
- (10) Unilever Plc; EP 0277428 A 1988 HCAPLUS
- (11) Unilever Plc; EP 0295092 A 1988 HCAPLUS


IT **71246-55-4D**, glucopyranose derivs.
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hair preps. containing glycoprotein formation inhibitors for reduction of hair growth)

RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L74 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:321020 HCAPLUS
 DN 124:333054
 ED Entered STN: 01 Jun 1996
 TI Medicinal composition containing sialic acid derivative
 IN Koketsu, Mamoru; Nishizono, Masakazu; Nitoda, Teruhiko; Enoki, Yuko;
 Kawanami, Hiroshi; Juneja, Lekh Raj
 PA Taiyo Kagaku Co., Ltd., Japan
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM A61K031-70
 ICS A61K031-725; A61K031-73; A61K038-02
 ICA C07H005-06; C07H007-02; C08B037-00; C07K002-00
 CC 1-5 (Pharmacology)
 Section cross-reference(s): 17

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9602255	A1	19960201	WO 1995-JP1415	19950714 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2171614	AA	19960201	CA 1995-2171614	19950714 <--
EP 727216	A1	19960821	EP 1995-925133	19950714 <--
EP 727216	B1	20030528		
R: BE, CH, DE, DK, FR, GB, LI, NL, SE				
US 5834423	A	19981110	US 1996-617821	19960315 <--
PRAI JP 1994-186699	A	19940715	<--	
JP 1994-186700	A	19940715	<--	
WO 1995-JP1415	W	19950714	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9602255	ICM	A61K031-70
	ICS	A61K031-725; A61K031-73; A61K038-02
	ICA	C07H005-06; C07H007-02; C08B037-00; C07K002-00

AB A medicinal composition containing sialic acid derivs. e.g. oligosaccharides as the active ingredient and usable as an antiviral agent, diarrhea remedy, antiulcer agent, antiinflammatory agent, antiallergic agent and Bifidus growth accelerator. A process for producing the derivative comprises adding almond or apricot seeds to an avian egg yolk, and can provide the target substance readily in a high yield.

ST antiviral sialate deriv oligosaccharide prepn; antidiarrheal sialate deriv oligosaccharide prepn; antiulcer sialate deriv oligosaccharide prepn; antiinflammatory sialate deriv oligosaccharide prepn; antiallergic sialate deriv oligosaccharide prepn; Bifidus growth sialate deriv oligosaccharide prepn

IT Sialic acids

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(derivs.; medicinal composition containing sialic acid derivs.)

IT Diarrhea
(inhibitors; medicinal composition containing sialic acid derivs.)

IT Allergy inhibitors
Bifidobacterium
Inflammation inhibitors
Ulcer inhibitors
Virucides and Virustats
(medicinal composition containing sialic acid derivs.)

IT Almond
Apricot
Egg yolk
RL: RCT (Reactant); RACT (Reactant or reagent)
(medicinal composition containing sialic acid derivs.)

IT Oligosaccharides
Phospholipids, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(sialyl derivs.; medicinal composition containing sialic acid derivs.)

IT 112-47-0, 1,10-Decanediol 504-63-2, 1,3-Propanediol 629-11-8,
1,6-Hexanediol 629-41-4, 1,8-Octanediol 10589-47-6 10589-48-7,
1-Stearoyl-2-palmitoyl lecithin 16655-75-7 17364-19-1, Stearoyl
lysophosphatidylcholine 17688-29-8 40811-59-4, Dilinolenoyl
phosphatidylcholine 45108-98-3, N-Acetyl nonylamine 82057-50-9,
9-O-Acetyl neuraminic acid
RL: RCT (Reactant); RACT (Reactant or reagent)
(medicinal composition containing sialic acid derivs.)

IT 71496-55-4DP, reaction product with phosphatidyl alkanols
82659-92-5DP, reaction product with phosphatidyl alkanols 119534-74-6DP,
reaction product with phosphatidyl alkanols 167013-38-9DP, conjugate
with mono and disialyl oligosaccharides 176914-09-3DP, conjugate with
mono and disialyl oligosaccharides 176914-10-6DP, conjugate with mono
and disialyl oligosaccharides 176914-11-7DP, conjugate with mono and
disialyl oligosaccharides 176914-12-8DP, conjugate with mono and
disialyl oligosaccharides
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal composition containing sialic acid derivs.)


IT 71496-55-4DP, reaction product with phosphatidyl alkanols
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(medicinal composition containing sialic acid derivs.)

RN 71496-55-4 HCAPLUS


CN D-Glucose, O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





PAGE 2-B



L74 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:733329 HCAPLUS
 DN 123:123168
 ED Entered STN: 12 Aug 1995
 TI Liposome having oligosaccharide on the surface
 IN Hatanaka, Masakazu; Mizuochi, Tsuguo; Sugimoto, Masanobu; Ohishi, Kazue
 PA Tonen Corp., Japan
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 IC ICM A61K047-36
 CC 63-6 (Pharmaceuticals)
 Section cross-reference(s): 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511704	A1	19950504	WO 1994-JP1828	19941028 <--
	W: CA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 07126185	A2	19950516	JP 1993-272693	19931029 <--
	JP 2828391	B2	19981125		
	CA 2152917	AA	19950504	CA 1994-2152917	19941028 <--
	EP 677295	A1	19951018	EP 1994-931186	19941028 <--
	R: DE, FR, GB, IT				
	US 5759572	A	19980602	US 1995-481300	19950918 <--
PRAI	JP 1993-272693	A	19931029	<--	
	WO 1994-JP1828	W	19941028	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES	
WO 9511704	ICM	A61K047-36	
WO 9511704	ECLA	A61K009/127B; A61K047/48W6D	<--
EP 677295	ECLA	A61K009/127B; A61K047/48W6D	<--
US 5759572	ECLA	A61K009/127B; A61K047/48H	<--
AB	The invention is related to a liposome as an adjuvant which is effective		

for somatic immunization and reduced in toxicity and antigenicity and can be administered to humans. The liposome comprises 2-11 saccharide residues and has on its surface an oligosaccharide which can combine with a lectin originating in an antigen-presenting cell, and a vaccine is prepared by enclosing an antigen in the liposome.

ST liposome oligosaccharide coating vaccine

IT **Vaccines**

(oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT **Antigens**

Oligosaccharides

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines

Phosphatidylserines

RL: THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT **Immunization**

(somatic; oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT **Immunostimulants**

(adjuvants, oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT **Steroids, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(hydroxy, oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT **Pharmaceutical dosage forms**

(liposomes, oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT 57-88-5, Cholesterol, biological studies 2644-64-6,
Dipalmitoylphosphatidylcholine 2706-65-2 3036-82-6,
Dipalmitoylphosphatidylserine 4537-76-2, Distearoylphosphatidylethanolamine 4539-70-2, Distearoylphosphatidylcholine 5681-36-7,
Dipalmitoylphosphatidylethanolamine 17966-25-5, Distearoylphosphatidic acid 19698-29-4, Dipalmitoylphosphatidic acid 34141-02-1 36467-68-2
38854-46-5 38864-21-0 69401-47-4 70858-45-6D, derivs.
71246-55-4 73508-66-4D, derivs. 92216-05-2 102038-83-5D, derivs. 110387-51-4D, derivs. 110402-13-6D, derivs. 112828-69-0
136036-84-5D, derivs.

RL: THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

IT 70858-45-6D, derivs. 71246-55-4

RL: THU (Therapeutic use); BIOL (Biological study); USES


(Uses)

(oligosaccharide-coated liposomes and the liposomes containing antigens as vaccines)

RN 70858-45-6 HCAPLUS

CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



L74 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:656381 HCAPLUS
 DN 123:105585
 ED Entered STN: 05 Jul 1995
 TI Structures of the N-linked oligosaccharides on human plasma vitronectin
 AU Ogawa, Haruko; Yoneda, Atsuko; Seno, Nobuko; Hayashi, Masao; Ishizuka, Ineo; Hase, Sumihiro; Matsumoto, Isamu
 CS Dep. Chem., Ochanomizu Univ., Tokyo, Japan
 SO European Journal of Biochemistry (1995), 230(3), 994-1000
 CODEN: EJBCAI; ISSN: 0014-2956
 PB Springer
 DT Journal
 LA English
 CC 6-3 (General Biochemistry)
 AB The structures of N-linked oligosaccharides present on human plasma vitronectin were elucidated. Oligosaccharides were released from the vitronectin by N-glycosidase F digestion and tagged with 2-aminopyridine; the pyridylamino-oligosaccharides were then fractionated by anion-exchange and reverse-phase HPLC. Ten major pyridylamino-oligosaccharides were isolated. The linkages and locations of sialic acid residues were determined by desialylation with *Salmonella* sialidase in combination with acid. The asialo forms were then analyzed by two-dimensional sugar mapping, component sugar anal. and 400-MHz ¹H-NMR spectroscopy. The major oligosaccharides of human vitronectin were of the diantennary N-acetylactosamine type, with a lesser amount of the tri- and a small amount of the monoantennary type, to which 1-3 mol sialic acid residues were linked, mostly through α2-6 linkages, although α2-3 linkages were also present. The possibility that several binding activities of

vitronectin can be ascribed to its glycan moiety was discussed, based on the specific features of the N-linked oligosaccharides on human vitronectin revealed here.

ST vitronectin oligosaccharide N linked structure

IT Oligosaccharides

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(N-linked, structures of N-linked oligosaccharides on human plasma vitronectin)

IT Animal growth regulators

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(vitronectins, structures of N-linked oligosaccharides on human plasma vitronectin)

IT 71496-55-4 76859-00-2 79295-70-8 80338-46-1 82659-92-5
83411-87-4 118074-20-7 118325-36-3

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(structures of N-linked oligosaccharides on human plasma vitronectin)

IT 71496-55-4 83411-87-4

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); PRP (Properties); BIOL (Biological study)


(structures of N-linked oligosaccharides on human plasma vitronectin)

RN 71496-55-4 HCAPLUS


CN D-Glucose, O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 6)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetyl-amino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetyl-amino)-2-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 2-B




RN 83411-87-4 HCAPLUS
 CN D-Glucose, O- (N-acetyl- α -neuraminosyl) - (2 \rightarrow 6) -O- β -D-galactopyranosyl- (1 \rightarrow 4) -O-2- (acetyl-amino) -2-deoxy- β -D-glucopyranosyl- (1 \rightarrow 2) -O- [O- (N-acetyl- α -neuraminosyl) - (2 \rightarrow 6) -O- β -D-galactopyranosyl- (1 \rightarrow 4) -2- (acetyl-amino) -2-deoxy- β -D-glucopyranosyl- (1 \rightarrow 4)] -O- α -D-mannopyranosyl- (1 \rightarrow 3) -O- [O- (N-acetyl- α -neuraminosyl) - (2 \rightarrow 6) -O- β -D-galactopyranosyl- (1 \rightarrow 4) -O-2- (acetyl-amino) -2-deoxy- β -D-glucopyranosyl- (1 \rightarrow 2) - α -D-mannopyranosyl- (1 \rightarrow 6)] -O- β -D-mannopyranosyl- (1 \rightarrow 4) -O-2- (acetyl-amino) -2-deoxy- β -D-glucopyranosyl- (1 \rightarrow 4) -2- (acetyl-amino) -2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



L74 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:554483 HCAPLUS

DN 122:312852

ED Entered STN: 17 May 1995

TI Oligomannose-coated liposomes as an adjuvant for the induction of cell-mediated immunity

AU Sugimoto, Masanobu; Ohishi, Kazue; Fukasawa, Masashi; Shikata, Kohdoh; Kawai, Hiromi; Itakura, Hideyo; Hatanaka, Masakazu; Sakakibara, Ryuzo; Ishiguro, Masatsune; et al.

CS Institute of Tropical Medicine, Nagasaki University, Sakamoto-machi 12-4, Nagasaki, 852, Japan

SO FEBS Letters (1995), 363(1,2), 53-6
 CODEN: FEBLAL; ISSN: 0014-5793

PB Elsevier

DT Journal

LA English

CC 15-9 (Immunochemistry)

AB The effect of the coating of ovalbumin-reconstituted liposomes with various oligosaccharides on their immunogenicity was investigated in mice. The coating of liposomes with oligomannose or yeast mannan drastically enhanced their ability to induce an ovalbumin-specific delayed-type footpad swelling response with a peak at 24 to 48 h post-challenge. Among various oligosaccharides tested, only those with mannose residue at the non-reducing termini manifested the activity when applied to liposomes. Since such oligosaccharides are ubiquitously found in the body, these results suggested the usefulness of oligomannose-coated liposomes as a safe adjuvant for the induction of cell-mediated immunity.

ST oligomannose liposome adjuvant delayed type hypersensitivity

IT Liposome
 (oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)

IT Oligosaccharides
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)

IT Immunostimulants
 (adjuvants, oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)

IT Allergy
 (delayed hypersensitivity, oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)

IT 34141-02-1 69401-47-4 71246-55-4 78392-31-1 84808-03-7
 112828-69-0
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)


IT 71246-55-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (oligomannose-coated liposomes as an adjuvant for the induction of delayed-type hypersensitivity)

RN 71246-55-4 HCAPLUS


CN D-Glucose, O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



=>